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1.0 INTRODUCTION 
 
T 
1.1. 
he lactic acid bacteria (LAB) are a group of bacteria united by a constellation of 
morphological, metabolic and physiological characteristics. Generally, LAB are 
described as Gram-positive, non-sporing, non-respiring cocci or rods, which produce lactic 
acid as a major end-product during fermentation of carbohydrates (Axelsson, 1998).  
Lactic acid bacteria in food production and human health 
Historically, LAB have long been known to be involved in the production of fermented 
foods. Presently, these products constitute one-quarter of our diet and are characterised by a 
safe history, certain beneficial health effects, and an extended shelf life when compared to 
non-fermented, fresh foods (Hammes and Tichaczek, 1994). Lactic acid producing bacterial 
starter cultures are used in the production of fermented dairy, meat and plant products and the 
fermentation results in products which have improved shelf life, flavour, aroma and texture 
(Sofos, 1993). The major food commodities fermented by LAB are listed in Table 1. 
Fermentation ensures not only the microbial safety of the food product, but may also render 
some foods more digestible. In addition, fermentation may also serve to reduce the toxicity of 
the food substrate, as occurs for example in the fermentation of cassava tubers (Manihot 
esculentum) which contains toxic cyanogens (Caplice and Fitzgerald, 1999). Another 
beneficial aspect of fermentation is that growth of spoilage and pathogenic bacteria in 
fermented foods is usually inhibited due to competition for nutrients and the presence of 
starter-derived inhibitor compounds such as lactic acid, hydrogen peroxide and bacteriocins 
(Ray and Daeschel, 1995). Bacteriocins are extracellularly released peptides that are 
bactericidal to bacteria closely related to the producer microorganisms (Tagg et al., 1976). 
Bacteriocins produced by LAB may be considered as natural preservatives or 
‘biopreservatives’, as these compounds have been produced by food-associated LAB and 
consequently have been associated with the human food supply for many years (Schillinger et 
al., 1996). LAB are generally considered as ‘food grade’ organisms. It is assumed that most 
representatives of this group do not pose any health risks to healthy humans. Most LAB are 
designated as ‘GRAS’ (generally recognised as safe) microorganisms in the USA based on a 
long history of safe use in foods. However, some species may act as opportunistic pathogens 
in rare cases (Aguire and Collins, 1993; Gasser, 1994; Holzapfel et al., 1995).  
Of all lactic fermented foods, dairy products are the most important worldwide, both by 
production volume and value (Lücke, 1996). More than 50% of the total milk in Europe is 
processed into sourmilk, sour cream, butter and cheese. All dairy fermentations include an 
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initial lactic fermentation, only in rare cases accompanied by yeasts, as in the case of kefir and 
some traditional sourmilks. Desired sensory properties of some products are contributed by 
certain LAB, propionibacteria, brevibacteria, yeasts or moulds through secondary 
fermentation (Lücke, 1996).  
Many studies have shown that fermentation with LAB improves the nutritional value of 
food products by increasing the quantity, availability, digestibility, and assimilation potential 
of nutrients. Yoghurt for example, contains higher levels of free amino acids as compared to 
milk as a result of proteolysis of the milk proteins by the yoghurt microflora (Gorbach, 1990). 
In addition, fermentation of foods with LAB can exert the following beneficial effects: (a) 
production of lactic acid and minor amounts of acetic and formic acids, which cause a drop in 
pH and thereby inhibit the growth of food spoilage or food poisoning bacteria, (b) 
detoxification by degradation of noxious compounds of plant origin such as cyanogens, (c) 
production of antimicrobial compounds (e.g. bacteriocins, hydrogen peroxide, fatty acids) 
which can also inhibit spoilage or food poisoning bacteria, and (d) probiotic effects as of LAB 
administered as live organisms in food (Hammes and Tichaczek, 1994). 
Yoghurt and particularly probiotic fermented milk products are also reported to be 
effective in the treatment of a variety of disorders, including colitis, constipation, diarrhoea, 
prevention of recolonisation of the intestine with pathogens after antibiotic treatment, 
reduction of flatulence, prevention of gastroenteritis, gingivitis, hypercholesterolaemia, 
hepatic encelopathy and tumorigenesis. In addition, the lactose intolerance of affected persons 
can be alleviated by consuming yoghurt which contains bacterial β-galactosidase produced by 
lactobacilli during fermentation (Gorbach, 1990). Pouwels et al. (1998) studied the possibility 
for use of LAB in general and strains of Lactobacillus in particular, for oral vaccination 
purposes. This was done on the presumption that these bacteria have GRAS status, have 
adjuvant properties, mucosal adhesive properties and low intrinsic immunogenicity. However, 
a number of problems will have to be solved before the first LAB vaccine can be marketed. 
One such problem, for example, is that gene expression is difficult to be measured in the gut 
(Pouwels et al., 1998).  
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Table 1: Food commodities fermented by lactic acid bacteria (LAB) or LAB in 
combination with other microorganisms (Lücke, 1996). 
 
Raw material Product Main fermentation 
agents 
Additional fermentation agents 
in some products 
 
Milk 
Milk 
 
 
Meat 
 
Doughs, grain 
mashes 
Vegetables 
Olives 
Soybeans, peanuts 
Soy mash 
(Grape) musts 
Fish 
 
 
sour milk 
cheeses 
 
 
fermented sausages 
 
sourdough, sour 
mash 
sauerkraut 
table olives 
tempeh, ontjom 
soy sauce 
wine 
lightly salted fish 
products, fish sauces
 
 
LAB 
LAB 
 
 
LAB + Staphylococcus 
or Micrococcus 
LAB + yeasts 
LAB 
LAB 
Rhizopus, LAB 
Yeasts, LAB 
Yeasts 
Fish enzymes, LAB 
 
Yeasts 
Propionibacterium, 
Brevibacterium, 
Penicilllium 
Yeasts, Penicillium 
 
 
 
 
 
 
LAB 
 
The currently recognised genera of LAB are Aerococcus, Alloiococcus, 
Carnobacterium, Dolosigranulum, Enterococcus, Globicatella, Lactobacillus, Lactococcus, 
Lactosphaera, Leuconostoc, Melissioccus, Oenococcus, Pediococcus, Streptococcus, 
Tetragenococcus, Vagococcus, and Weissella (Axelsson, 1998). This classification is largely 
based on phenotypic characteristics such as morphology, mode of glucose fermentation, 
growth at different temperatures, configuration of the lactic acid produced, ability to grow at 
high salt concentrations, and acid or alkaline tolerance (Axelsson, 1998). As a group, the LAB 
are catalase-negative, non-sporeforming with coccoid, cocco-bacilli or rod-shaped 
morphology. They have less than 55% mol% G+C content in the DNA and therefore belong 
to the Clostridium branch of Gram-positive bacteria (Stiles and Holzapfel, 1997). 
Bifidobacteria, which were in the past considered to be a member of the LAB, have a mol% 
G+C content of more than 55% and therefore belong to ‘Actinomycetes’ branch of Gram-
positive bacteria (Schleifer and Ludwig, 1995). 
 
1.2.1. Technological and functional aspects of probiotic LAB strains 
In recent years, the consumer has been increasingly confronted with functional food 
products which are claimed to promote his /her health and well-being. At the centre of these 
food products are the so-called pro- and prebiotics (Simmering and Blaut, 2001). The term 
‘probiotic’ (Greek: ‘for life’) originally referred to a phenomenon observed when two 
organisms were cultured together, in which substances produced by one organism stimulated 
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the growth of the other organism. These substances were referred to as ‘probiotics’. This term 
was subsequently used to describe living preparations of microbial cells that could be 
administered to animal and humans to promote the health of its consumer (Tannock, 1997).  
Fuller (1991) defined probiotics as ‘a live microbial feed supplement which beneficially 
affects the host animal by improving its microbial balance’. This definition was broadened by 
Reuter (1997) to ‘any viable mono- or mixed culture of microorganisms which beneficially 
affects the host on the indigenous microflora’. Marketing of probiotics for human 
consumption relies heavily on this definition. In the case of farm animals, faster weight gain 
for the same amount of feed consumed has been the primary importance for probiotic 
application (Tannock, 1997). Prebiotics are non-digestible food ingredients that beneficially 
affect the host by selectively stimulating the growth and/or activity of one or a limited number 
of bacterial species already resident in the colon (Gibson and Roberfroid, 1995; Simmering 
and Blaut, 2001). The concept of prebiotics arose from the observation that inulin and 
fructooligosaccharides (FOS) selectively stimulate the growth of bifidobacteria, which are 
considered to be beneficial for human health (Gibson and Roberfroid, 1995).   
Traditionally, LAB are the basic components of probiotics as they best fit the 
functional and safety requirements by their definitions (Reuter, 1997). However, today a wide 
number of microbial species and genera also are considered to meet the requirement for 
probiotics (Table 2).   
 
Table 2: Microorganisms used as probiotics (Holzapfel et al., 1998). 
 
Lactobacillus species Bifidobacterium 
species 
Other LAB Non LAB 
 
L. acidophilus 
L. amylovorus 
L. casei 
L. crispatus 
L. delbrueckii 
   subsp. bulgaricus 
L. gallinarum1
L. gasseri 
L. johnsonii 
L. paracasei 
L. plantarum 
L. reuteri 
L. rhamnosus 
    
 
B. adolescentis 
B. animalis 
B. bifidum 
B. breve 
B. infantis 
B. lactis3
B longum 
 
Enterococcus faecalis1
Enterococcus faecium 
Lactococcus lactis 
Leuconostoc mesenteroides 
Pediococcus acidilactici 
Sporolactobacillus inulinus1
Streptococcus thermophilus 
 
Bacillus cereus var. toyoi1,2 
Escherichia coli strain nissle 
Propionibacterium 
freudenreichii1,2
Saccharomyces cerevisiae2
Saccharomyces boulardii2
 
1Main application for animals 
2Applied mainly as pharmaceutical preparations 
3Synonymous with B. animalis 
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Probiotic bacteria may be delivered to the consumer in a food system and they then 
begin their journey to the lower intestinal tract at uptake in the mouth. Therefore, 
physiologically important properties of probiotic LAB include their resistance to enzymes 
present in the oral cavity (e.g. lysozyme), tolerance to bile acids, and that they possibly attach 
to the epithelium of the small intestine and can grow and be metabolically active in the lower 
intestinal tract as to provide health benefits (Chou and Weimer, 1999).  
Klaenhammer and Kullen (1999) compiled selection criteria for probiotic strains. 
These include: (1) appropriateness (accurate taxonomic identification, normal inhabitant of 
the host species targeted, i.e. human origin for human probiotics, nontoxic, nonpathogenic, 
GRAS status), (2) technological suitability (amenable to mass production and storage: 
adequate growth, recovery, concentration, freezing, dehydration, storage, and distribution; 
viability at high numbers; stability of desired characteristics during culture preparation, 
storage, and delivery); provides desirable organoleptic qualities (or no undesirable qualities) 
when included in foods or fermentation processes; genetic stability; (3) survival 
competitiveness and establishment (capable of survival, proliferation, and metabolic activity 
at the target site in vivo, resistant to bile, resistant to acid, able to compete with normal 
microflora, including the same or closely related species: potentially resistant to bacteriocins, 
acid, and other antimicrobials produced by the residing microflora, and adherence and 
colonisation potential preferred), (4) performance and functionality (able to exert one or more 
clinically documented health benefits, antagonistic towards pathogenic/procarcinogenic 
bacteria, production of antimicrobial substances such as bacteriocins, immunostimulatory, 
antimutagenic and anticarcinogenic activity, as well as production of bioactive compounds 
such as enzymes, vaccines or peptides). Bacteriocin production thus is considered as one of 
the performance or functional characteristics of probiotic strains and is discussed in more 
detail below. 
Because of the potential health benefit of probiotic bacteria, these organisms are 
increasingly being incorporated into dairy and other foods. Claimed health benefits include 
prevention or alleviation of diarrhoea, antimicrobial, antimutagenic and anticarcinogenic 
properties, reduction of serum cholesterol levels, and improvement of lactose tolerance (Shah, 
2000). Therapeutic properties of probiotic Lactobacillus acidophilus and bifidobacteria are 
summarised in Table 3.  
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Table 3: Therapeutic (probiotic) properties of Lactobacillus acidophilus and 
Bifidobacteria (Shah, 2000). 
 
Therapeutic (probiotic) properties Possible causes and mechanisms 
 
Colonisation of gut and inhibition 
of pathogenic microorganisms 
 
 
 
 
Improved digestibility of food 
and enhanced growth of host 
 
 
alleviation of lactose intolerance 
 
 
 
Hypocholesterolaemic effect 
 
 
 
Anticarcinogenic effect 
 
 
 
 
 
Stimulation of the host immunological 
system 
 
 
Increased vitamin availability to host 
 
Survive gastric acid, resist lysozyme, tolerate 
high bile salt concentration, adhere to 
intestinal surface and production on 
inhibitory compounds i.e. acids, H2O2 and 
bacteriocins. 
 
Partial breakdown of protein, fat, 
carbohydrate and improved bioavailability of 
nutrients. 
 
Reduced lactose in the product and further 
availability on bacterial lactase enzymes for 
lactose hydrolysis. 
 
Production of inhibitors of cholesterol 
synthesis, deconjugation of bile salt, 
assimilation of cholesterol. 
 
Inhibition of carcinogens and enzymes 
involved in converting procarcinogens to 
carcinogens, inhibition of growth of 
putrefying organisms and stimulation of host 
immune system.  
 
Enhancement of macrophage formation, 
stimulation of T supressor cells and 
production of interferon. 
 
Synthesis of group B (folate) vitamins. 
 
 
Dunne et al. (1999) defined criteria by which a microorganism may be considered as a 
probiotic. Thereby, a probiotic microorganism should: 
 
1. Be of human origin. 
2. Demonstrate non-pathogenic behaviour. 
3. Exhibit resistance to technological production processes. 
4. Prove resistance to gastric acid and bile. 
5. Adhere to gut epithelial tissue. 
6. Be able to persist, albeit for short periods, in the gastrointestinal tract. 
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7. Produce antimicrobial substances. 
8. Modulate immune responses. 
9. Have the ability to influence metabolic activities (e.g. cholesterol assimilation, lactase 
activity, vitamin production). 
 
LAB used in probiotic preparations usually are derived from human sources and include 
strains which are typical of the human gastrointestinal tract (Holzapfel et al., 2001). These are 
represented by three groups: 1) the L. acidophilus group involving strains that are recognised 
today as L. acidophilus, L. gasseri, L. crispatus and L. johnsonii 2) Lactobacillus salivarius 
and 3) Lactobacillus casei group involving strains of L. casei, L. paracasei and L. rhamnosus 
(Holzapfel et al., 2001). Some probiotic lactobacilli strains which have been utilised in 
commercial products include L. paracasei Shirota from Yakult, L. casei GG (although this 
strains was first classified as a L. casei strain, it actually is a L. rhamnosus strain) from Emmi 
and L. acidophilus LA-1 (this strain was later shown to be a L. johnsonii strain) from Nestle. 
L. paracasei Shirota and L. casei GG are marketed in yoghurt drinks, whilst L. acidophilus 
LA-1 is marketed in yoghurt –products (Table 4). 
 
Table 4:  Lactobacillus strains and their used in probiotic yoghurts or yoghurts-like 
products and levels in which they are employed (Holzapfel et al., 2001). 
Probiotic strain Type of product Identification on the basis of 
DNA-homology analysis 
Viable counts 
(Log10CFU/g) 
 
L. acidophilus LA-1 
L. acidophilus LA-7 
L. acidophilus LA-H3 
L. acidophilus 
L. acidophilus 
L. casei Actimel 
L. casei Shirota 
L. casei GG 
L. casei LC-H2 
L. casei 
L. casei 
 
Yoghurt 
Yoghurt 
Dietetic yoghurt 
Yoghurt 
Yoghurt 
Yoghurt drink 
Probiotic drink 
Yoghurt drink 
Dietetic yoghurt 
Yoghurt 
Yoghurt 
 
L. johnsonii 
L. acidophilus 
L. acidophilus 
L. crispatus 
L. acidophilus 
L. paracasei 
L. paracasei 
L. rhamnosus 
L. casei 
L. paracasei  
L. paracasei 
 
7.1-8.0 
3.9-6.1 
5.8-8.4 
6.8-8.2 
5.5-6.8 
7.4-8.4 
7.9-8.9 
8.0 
4.7-5.3 
6.2-7.8 
8.6-8.7 
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Not only lactobacilli strains have been extensively studied regarding their functional 
properties as probiotics, but a great amount of research has also been performed on 
enterococci as probiotics. One such strain, i.e. Enterococcus (E.) faecium strain SF68 in 
particular, has been studied in detail for use as a human probiotic, especially in the treatment 
of diarrhoea. The strain was originally isolated in Sweden and patented in Switzerland and 
other countries (Franz et al., 1999). Its effectiveness for treatment of intestinal disorders can 
probably be attributed to the fact that it has a short lag phase and generation time (ca. 20 min 
under optimal conditions) and thus may outcompete gastrointestinal pathogens. This strain is 
sensitive to clinically relevant antibiotics and has an inhibitory effect in vitro to the growth of 
E. coli, Salmonella spp., Shigella spp., and Enterobacter spp. It is resistant to low pH and 
insensitive to bile salts (Canganella et al., 1996) which enables the strain to survive transit 
through the stomach and the conditions encountered in the small intestine. Use of E. faecium 
SF68 for treatment of diarrhoea is considered an alternative to antibiotic treatment (Bellomo 
et al., 1980). However, some enterococcal probiotic preparations for which the strains that are 
included are not well defined are sold in ‘health food’ stores as nutrition supplements, with 
vague claims to improve the gastrointestinal balance. Such preparations containing strains of 
E. faecium are also available on the market (Franz et al., 1999).  
The functional properties of probiotic LAB strains (e.g., stimulation of immune response, 
anticarcinogenis/antimutagenic activity, cholesterol reduction, antimicrobial activity by 
bacteriocin production, and alleviation of lactose intolerance) will be discussed in more detail 
below. 
 
1.2.1.1. Immune response 
The immune system consists of a number of organs and different cell types that 
recognise foreign antigens of intruder microorganisms. The leukocytes are the most dominant 
in the immune system and they comprise two cell types, i.e. (1) phagocytes, which provide 
non-specific immunity, and (2) the lymphocytes, which provide specific immunity. It has 
been suggested that LAB might thus be responsible for immune activation and thus prevent 
and stabilise enteric infections.  
Perdigon and Alvarez (1992) studied the effect of L. acidophilus, L. casei, L. 
delbrueckii subsp. bulgaricus and yoghurt on non specific immune response (mediated by 
macrophages). They concluded that L. acidophilus, L. casei and L. delbrueckii subsp. 
bulgaricus strains could activate the cells involved in the non-specific immune response and 
that oral administration was as effective as intraperitoneal administration. L. casei was also 
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shown to stimulate the increase of the mucosal intestinal IgA levels against Salmonella 
typhimurium in mice, indicating its potential as probiotic oral adjuvant to prevent enteric 
functions (Perdigon et al., 1990; Perdigon et al., 1995). Tomioka et al. (1992) found that L. 
casei protected mice against Listeria monocytogenes infection when pre-treated with L. casei 
2 or 13 days before infection. This was due to immune stimulation of the probiotic resulting in 
higher levels of macrophage.  
 
1.2.1.2. Anticarcinogenic/antimutagenic activity 
Consumption of fermented milk products or the intake of live probiotics have been 
shown to exert anticarcinogenic and antimutagenic effects. Several studies with animals or 
humans have indicated the effect of fermented milk products or supplementation with 
Lactobacillus and Bifidobacterium strains on enzyme activity in the gastrointestinal tract 
(Mital and Garg, 1992; Kulkarni and Reddy, 1994; Rafter, 1995).  
Goldin et al. (1992) showed that Lactobacillus GG could survive and colonise the 
human gastrointestinal tract (GIT) and simultaneously lower the faecal bacterial β-
glucuronidase activity. β-Glucuronidase is one of the bacterial enzymes associated with the 
generation of mutagens, carcinogens and tumour promoters. For example, β-glucuronidase 
can release from conjugated forms a number of dietary carcinogens such as polycyclic 
aromatic hydrocarbons. Other such enzymes include β-galactosidase, nitroreductase, 
azoreductase and 7-α-hydroxy-steroid dehydrogenase (Goldin, 1990) and are involved in the 
generation of mutagens or carcinogens including N-nitroso compounds, ammonia, phenols, 
cresols and deoxycholic acid (Burns and Rowland, 2000). When healthy volunteers were fed 
fermented dairy products containing L. acidophilus and Bifidobacterium bifidum, no changes 
were detected in the levels of β-glucuronidase and azoreductase, whilst nitroreductase was 
reduced (Marteau et al., 1990). McConnell and Tannock (1991) showed that the azoreductase 
activity was 31% lower in the cecae of mice colonised with L. delbrueckii and L. fermentum 
when compared to Lactobacillus-free mice. 
LAB may also retard or prevent the initiation and promotion of tumours. Tumour 
suppression is associated with intact viable cells, intact dead cells, as well as cell wall 
fragments of lactobacilli and bifidobacteria (Fernandez and Sahani, 1990; Modler et al., 1990; 
Zhang and Ohta, 1991). Feeding fermented milk or live bacteria such as L. acidophilus and L. 
bulgaricus and/or L. casei was shown to suppress Ehrlich ascites tumour or sarcoma 180 in 
mice (Fernandez and Sahani, 1990; Goldin, 1990).  
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The antimutagenic effects of fermented milk have been widely demonstrated (Bodana 
and Rao, 1990; Nadathur et al., 1994; Abdelali et al., 1995; Hosoda et al., 1996). These were 
suggested as a result of the presence of viable LAB (Kulkarni and Reddy, 1994; Bouberki and 
Ohta, 1996). Orally administered strains of L. casei were effective in preventing recurrence of 
superficial bladder cancer (Aso et al., 1995). B. longum and lactulose exerted an 
anticarcinogenic effect against azoxymethane-induced colonic aberrant crypt foci in rats 
(Challa et al., 1997). 
The mechanisms of anticarcinogenicity and antigenotoxicity are not well understood. 
However, a large number of reports describe the adsorption or binding in vitro by LAB of  a 
variety of foodborne carcinogens including heterocyclic amines formed during cooking of 
meat, the fungal toxin aflatoxin B1, benzo(a)pyrene and the food contaminant AF2 (Burns 
and Rowland, 2000). The adsorption appears to be a physical phenomenon, mostly due to a 
cation exchange mechanism. However, the effectiveness of adsorption in vivo has been 
questioned especially since the adsorption appears to take place in vitro at pH values lower 
than encountered in the small or large intestine (Burns and Rowland, 2000). Other 
mechanisms for anticarcinogenic and antigenotoxic activity may be based on the fact that 
LAB when given as a probiotic increase in number and suppress other bacteria of the colonic 
microflora. LAB themselves do not appear to form appreciable amounts of enzymes which 
may convert procarcinogens into carcinogens. In addition, the LAB may stimulate the 
immune response and thus the anticarcinogenic activity of the human immune system 
(Perdigon et al., 1998; Burns and Rowland, 2000). 
 
1.2.1.3.  Cholesterol reduction 
Heart diseases, especially atherosclerosis, are one of the major causes of death in 
humans. Hypercholesterolaemia is considered the most common risk factor associated with 
atherosclerosis leading to cardiovascular disease in modern industrialised countries.  
Cholesterol accumulation in the wall of the arteries causes atherosclerosis, which is a 
condition resulting from plaques forming in the vessels that inhibit blood flow. This leads to 
clot formation and heart attack. Low-density lipoproteins (LDL) are usually responsible for 
plaque formation in the aetiology of atherosclerosis, whilst low levels of coronary heart 
disease may also be as a result of plaque formation by high-density lipoprotein (HDL).  
Cholesterol is usually synthesised in the liver at a rate the body requires; however, alteration 
of the diet might have a significant effect on the serum cholesterol level.  
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Zacconi et al. (1992) showed that serum cholesterol levels were lower in axenic mice 
colonised with E. faecium and L. acidophilus. Serum cholesterol levels of rabbits fed on a diet 
supplemented with yoghurt decreased significantly (Kiyosawa et al., 1984). Feeding L. 
acidophilus or a commercial probiotic preparation (consisting of a mixture of L. acidophilus, 
L. casei, B. bifidum, and Aspergillus oryzae) decreased serum cholesterol levels in chickens 
and in egg yolk (Abdulrahim et al., 1996; Mohan et al., 1996). In humans, GAIO, a fermented 
milk product containing a strain of E. faecium of human origin and two Streptococcus 
thermophilus strains, decreased serum cholesterol and LDL levels after six weeks of 
consumption in a group of 44-year old healthy men (Hølund, 1993).  
Klaver and van der Meer (1993) suggested that the assimilation of cholesterol, 
associated with the cholesterol reducing activity of probiotic bacteria, was not due to a direct 
interaction between the bacteria and cholesterol, but rather due to the co-operation of 
cholesterol with deconjugated bile salt at pH values below 6.0. This would not explain 
reduction of cholesterol in vivo, as the pH of the lower GIT is neutral to alkaline. Marshall 
and Taylor (1995) also observed co-precipitation of cholesterol with deconjugated bile salts, 
but also reported cholesterol removal in the absence of bile. They suggested a physical 
association between cholesterol and the cell surface. Cholesterol lowering effects have more 
recently been linked to bacterial bile salt hydrolase (BSH) activity. BSH activity is found 
among various Gram-positive intestinal bacteria, including members of the genera 
Enterococcus, Peptostreptococcus, Bifidobacterium, Clostridium, Bacteroides and 
Lactobacillus (Hylemon 1985, Chikai et al., 1987). The conjugated BSH enzyme (E.C. 
3.5.1.24) deconjugates bile salts by liberating the glycine and/or taurine moiety from the side 
chain of the steroid core (Chikai et al., 1987). The two predominant bacterial modifications of 
bile salts include: (1) hydrolysis of glycocholic acid into cholic acid and (2) dehydroxylation 
of cholic acid into deoxycholic acid acid  (de Boever and Verstraete, 1999).  
Although BSH activity is a commonly observed phenomenon, its ecological 
significance for the bacteria is not well understood. Certain BSH-active clostridia were 
proposed to use the released taurine as an electronacceptor, which was argued to result in a 
higher growth rate. On the other hand, deconjugation might be a detoxification reaction of 
vital importance to the microbial cell (de Boever and Verstraete, 1999). It has also been 
suggested that the BSH enzyme might be a detergent shock protein that enables lactobacilli to 
survive the intestinal bile stress. As such, BSH active lactobacilli may have a competitive 
advantage over other bacteria for surviving in the small intestine (de Smet et al., 1995). 
However, Moser and Savage (2001) tested a wide spectrum of BSH+ lactobacilli for their 
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resistance against bile salt toxicity, and could not support this hypothesis. This led Moser and 
Savage (2001) to suggest that instead of protecting lactobacilli from toxicity of conjugated 
bile salts, BSH activity may rather be important for the bacteria to grow in and colonise the 
intestine. 
At hte human/animal physiological level, the conversion of glycocholic acid to cholic 
acid may contribute to lower cholesterol levels, because free bile acids may be excreted more 
likely from the gastrointestinal tract than conjugated bile salts (Chikai et al., 1987). If 
enhanced faecal loss of bile acids occurs as a result of bacterial BSH activity, it may increase 
the demand for cholesterol as a precursor for de novo synthesis of bile salts, which in turn 
may lower cholesterol levels (de Rodas et al., 1996; Driessen and de Boer, 1989). 
So far, the bsh genes from Lactobacillus (L.) plantarum (Christiaens et al., 1992), L. 
gasseri (Russell et al., 2001), L. johnsonii (Elkins and Savage, 1998), Bifidobacterium longum 
(Tanaka et al., 2000) and Clostridium perfringens (Coleman and Hudson, 1995) have been 
cloned and characterised. To our knowledge, a BSH gene from an Enterococcus strain has not 
been cloned and characterised yet.  
 
1.2.1.4. Improvement of lactose digestion 
 Lactose can not be utilised by a large part of the human population, especially of 
Asian and African origin, due to a lack of the intestinal mucosal enzyme β-galactosidase 
(lactase) or by a reduction in lactase activity caused by intestinal infection (e.g. rotaviral 
gastroenteritis). The enzyme β-galactosidase hydrolyses milk lactose to glucose and 
galactose. The symptoms of lactose maldigestion are flatulence, abdominal pain and 
diarrhoea. However, in fermented dairy products, the starter cultures degrade lactose or 
produce β-galactosidase, which is secreted in the intestinal tract (Fuller, 1991; O’Sullivan et 
al., 1992). Intracellular lactase will survive passage through the stomach and reach the small 
intestines (Daly, 1991). Thus, for aiding human lactose digestion, either the LAB culture 
degrades lactose in the milk product, or the enzyme is supplied by the microbe and delivered 
to the gastrointestinal tract of the human, where it can reduce lactose levels. 
In one study, milk fermented with L. delbrueckii subsp. bulgaricus and Streptococcus 
thermophilus was much more effective than L. acidophilus strains in improving lactose 
tolerance (Noh and Gilliland, 1993). The yoghurt starter cultures S. thermophilus and L. 
delbrueckii subsp. bulgaricus were shown to possess high levels of β-galactosidase activity. 
Both species are, however, sensitive to bile salts, which causes the microorganisms to die and 
cells to disintegrate, thus leading to the release of high levels of β-galactosidase in the 
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gastrointestinal tract (Noh and Gilliland, 1993). L. acidophilus, on the other hand, is more bile 
resistant and has lower levels of β-galactosidase than the yoghurt starter cultures. Therefore, 
strains of this species may be able to grow in the gastrointestinal tract and thus may increase 
β-galactosidase levels for longer periods (Sanders. 1993).  
 
1.2.1.5 Bacteriocin production 
A bacteriocin is defined as a proteinaceous compound (protein or peptide) that has 
bactericidal or bacteriostatic action against a limited range of organisms, which are usually 
closely related to the producer organism (Barnby-Smith, 1992). The inhibitory activity of 
these substances produced by LAB is generally confined to Gram-positive bacteria. 
Bacteriocin inhibition of Gram-negative bacteria has not been demonstrated unless chelating 
agents (e.g. EDTA) were added to the test system, which make the Gram-negative outer 
membrane leaky for these compounds (Abee et al., 1995). Bacteriocins are believed to be 
important for the ability of LAB to compete in non-fermentative ecosystems such as the 
gastrointestinal tract (Lindgren and Dobrogosz, 1990). 
The major classes of bacteriocins produced by LAB include: Class I, lantibiotics, 
which are small, heat stable, and contains unusual amino acids such as lanthionine and β-
methyllanthionine; Class II, small heat stable peptides (30-100 amino acids), which are 
further divided into the following subclasses: Subclass IIa, the pediocin-like bacteriocins that 
are characterised by anti-Listeria activity; Subclass IIb, two peptide bacteriocins for which the 
antimicrobial activity depends on the presence of two peptides; and subclass IIc, the sec-
dependent bacteriocins which are secreted via the general secretory (sec) pathway; and finally 
Class III, large (>30 kDa) heat labile proteins (Nes et al. (1996). The lantibiotic nisin is the 
only bacteriocin that is currently commercially exploited and which is used in food 
preservation in more than 40 countries. Examples of bacteriocins are shown in Table 5. 
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Table 5: Examples of bacteriocins produced by lactic acid bacteria (Barnby-Smith, 
1992) 
 
Microorganisms Bacteriocin Inhibitory spectrum 
 
Lactococcus lactis subsp. lactis 
Lactococcus lactis subsp. lactis CNRZ 
Pediococcus pentosaceus FBB61 
Pediococcus acidilactici 
Lactobacillus sake 
Leuconostoc mesenteroides UL5 
 
Nisin 
Lacticin 481 
Pediocin A 
Pediocin PA1 
Sakacin A 
Mesentericin 5 
 
Many Gram-positive bacteria 
LAB, clostridia 
LAB, clostridia, listeria, staphylococci 
 
Some LAB, listeria 
Some LAB, listeria 
Some LAB, listeria 
 
 
Bacteriocins are usually formed as prepeptides in the cell and mature bacteriocins are 
generated by processing during export (Nes et al., 1996; Garneau et al., 2002). This is 
generally accomplished by removal of a N-terminal leader peptide either by signal peptidase 
in sec-pathway secreted bacteriocins, or more often at a specific double glycine position (-2,-
1) in the prepeptide, concomitant with externalisation by a dedicated ABC-transporter protein 
and an accessory protein (Garneau et al., 2002). With the exception of disulfide bridge 
formations, posttranslational modifications are rare among the non-lantibiotic bacteriocins 
(Nes et al., 1996; Ennahar et al., 1999; Garneau et al., 2002).  
 At least four different genes are required to achieve the production of bacteriocins by 
Gram-positive bacteria: 1) a structural gene (or two structural genes in two-peptide 
bacteriocins) encoding the prepeptide; 2) dedicated immunity gene; 3) a gene encoding a 
dedicated ABC transporter; and 4) a gene encoding an accessory protein which is necessary 
for bacteriocin transport (Nes et al., 1996; Ennahar et al., 1999). Usually, the bacteriocin 
structural and immunity genes occur in an operon, as do the transport genes. For most 
nonlantibiotics, the bactericidal effect of bacteriocins occurs as a result of permeabilisation of 
the cell membrane (Nes and Holo, 2000). This pore forming ability leads to cell leakage and 
efflux of K+ ions, which in turn leads to dissipation of membrane potential and inhibition of 
amino acid uptake. Cell death is finally effected by futile cycle of ATP-driven potassium 
uptake and bacteriocin-mediated potassium release in combination with increased ATP 
hydrolysis by an ATPase (Jack et al., 1995; Garneau et al., 2002, Fig. 2). 
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Fig. 1:  Bactericidal action of bacteriocin by potassium ion efflux and increased ATP 
demand from K+ ATPase (adapted from Garneau et al., 2002) 
 
 
Mature bacteriocins are generally cationic, amphiphilic species and the environment in 
which they are found can strongly dictate their secondary structure. In cases where the 
structure has been examined, they usually exist as random coils under aqueous conditions, but 
in charged, weakly ionic solution they exist in ordered conformation (β-sheet and α-helices) 
(Garneau et al., 2002). It has been shown that upon contact with the membranes, the otherwise 
random-coiled peptides adopt ordered helical structures. The formation of such amphipathic 
helices is the critical conformational change required for pore formation by the ‘barrel-stave’ 
or ‘wormhole’ mechanism. This mechanism relies upon stabilising interactions between 
membrane phospholipids and the cationic residues of the peptide allowing for insertion of 
hydrophobic regions into the outer leaflet of the membrane. Once associated with the 
membrane surface, a number of the ordered bacteriocins can potentially aggregate and the 
complex can completely span the membrane, thereby forming a transient pore (Fig. 3) (Moll 
et al., 1996; Abee, 1995; Garneau et al., 2002). 
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Fig. 2:  Barrel-stave (wormhole) mechanism of pore formation by cationic bacteriocin 
peptides (adapted from Garneau et al., 2002). 
 
 
Intestinal LAB are known to produce bacteriocins which can inhibit pathogenic 
bacteria, for example the intestinal isolates Lactobacillus acidophilus 30SC (Oh et al., 2000), 
Lactobacillus delbrueckii subsp. lactis UO004 (Boris et al., 2001), Lactobacillus salivarius 
subsp. salivarius UCC118 (Flynn et al., 2002), as well as a vaginal isolate of Lactobacillus 
salivarius CRL 1328 (Ocana et al., 1999). L. acidophilus LF221, isolated from infant faeces 
was shown to produce at least two bacteriocins (designed as acidocin LF221 A and acidocin 
LF221 B) which exhibited activity against different bacteria including some pathogenic 
species such as Bacillus cereus, Clostridium difficile, Listeria innocua, Staphylococcus 
aureus and group D streptococci. Bogovič-Matijašić et al. (1998) proposed L. acidophilus 
LF221 as a probiotic strain on the basis of its human origin and bacteriocin-inhibition of 
pathogenic bacteria. Gusils et al. (1999) showed that Salmonella Gallinarum could be 
inhibited by Lactobacillus animalis isolated from the chicken intestine in a competition 
experiment in which 1 x 107 CFU/ml L. animalis and 106 CFU/ml Salmonella Gallinarum 
were inoculated in co-culture in vitro. The growth of the mixed culture was followed by 
measuring the OD560 and measuring the pH at different times, as well as determining total 
counts of the different strains. Moreover, Audisio et al. (2000) showed that Enterococcus 
faecium J96, isolated from a healthy free-range chicken, exhibited a protective effect on 
chicks infected with Salmonella Pullorum. In a former experiment, Audisio et al. (1999) 
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found that the protective effect exerted by L. animalis was caused by production of both lactic 
acid and bacteriocin.  
The effect in the intestinal tract of bacteriocin-producing Lactobacillus sakei MI401 
against Listeria monocytogenes EP2 was examined in vivo in 20Mol:Wistar SPF rats by 
Saadbye et al. (1999). The rats were treated with streptomycin to facilitate the introduction of 
streptomycin-resistant L. monocytogenes and L. sakei into the gastrointestinal tract. One 
group (10 rats) was orally inoculated with 109 CFU L. sakei and 7 days later orally inoculated 
with 109 CFU L. monocytogenes EP2. This group reached a maximum Listeria concentration 
of 104 CFU/g feces whereas the control group reached a maximum of 108 CFU/g feces. The 
control group did not receive L. sakei but otherwise treated identically. The numbers of L. 
monocytogenes were significantly lower (p <0.001) in the group which received L. sakei 
compared to the control group.  
Du Toit et al. (1998, 2000) showed that enterococci isolated from the faeces of 
Göttingen mini-pigs had bacteriocin activity against many enterococci species, Lactobacillus 
salivarius which is often associated with the human gastrointestinal tract, as well as 
Clostridium and Listeria spp. One of the bacteriocin, produced by E. faecalis BFE 1071, was 
characterised at the chemical and genetic level in detail in a follow-up study (Balla et al., 
2000). This bacteriocin, termed enterocin 1071A&B was shown to be a two-peptide 
bacteriocin and thus can be classified as a class IIb bacteriocin according to the bacteriocin 
classification scheme of Nes et al. (1996). This bacteriocin will be discussed in more detail, as 
the producer strain E. faecalis BFE 1071 and a bacteriocin-negative mutant were used in this 
study to determine the effect of the bacteriocin-producer on the gastrointestinal microflora of 
the rat.  
 Clearly therefore, bacteriocin production does occur also from gastrointestinal isolates 
of LAB. There are, however, little data on the in vivo effect of bacteriocin production on the 
intestinal microflora. It is thought that bacteriocin production serves to increase the 
competitiveness of bacteria in their relative ecological niche (Dykes, 1995). Thus bacteriocin 
production may change the composition of the microflora of a particular ecosystem, in that 
sensitive organisms are suppressed at the expense of the bacteriocin producer. However, such 
investigations of interaction between bacteriocin producer and the dynamics of the microflora 
of complex ecosystems have not been conducted yet. 
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1.3 The enterococci 
1.3.1 Phylogeny and taxonomy of enterococci 
Enterococci were described for the first time by Thiercelin in 1899. They were thought 
to be a new Gram-positive diplococcus and were ater included in the new genus 
Enterococcus, proposed by Thiercelin and Jouhaud in 1903, with the type species 
Enterococcus proteiformis. Andrewes and Horder (1906), however, renamed Thiercelin’s 
enterococci as Streptococcus faecalis based on their ability to form short or long chains. The 
species epithet ‘faecalis’ was suggested because of their close resemblance to strains isolated 
from the human intestine. This explains why the history of enterococci cannot be separated 
from that of the genus Streptococcus (Devriese and Pot, 1995; Franz et al., 1999).  
A serological typing system for streptococci was developed by Lancefield in 1933 in 
which those of ‘faecal origin’ possessed the group D antigen. This correlated with the 
grouping of Sherman in 1937, who proposed a new classification scheme for the genus 
Streptococcus that separated it into four divisions designated pyogenic, viridans, lactic and 
‘enterococcus’. The ‘enterococcus’ group included Streptococcus faecalis, Streptococcus 
faecium, Streptococcus bovis and Streptococcus equinus as the ‘enterococcal’ or group D 
strains.  
The genus Enterococcus was finally described by Schleifer and Kilpper-Bälz (1984), 
who used DNA:DNA hybridisation to demonstrate that Streptococcus faecalis and 
Streptococcus faecium were sufficiently distinct from other streptococci to warrant their 
transfer to a separate genus. Based on 16S rRNA cataloguing, DNA:DNA and DNA:rRNA 
hybridisation and serological studies with superoxide dismutase antisera, the streptococci 
sensu lato were subdivided into three genera: Streptococcus sensu stricto, Enterococcus and 
Lactococcus (Devriese et al., 1993).  
Enterococci belong to the clostridial subdivision of the Gram-positive bacteria, 
together with other genera of LAB (Devriese et al., 1993; Devriese and Pot, 1995). Based on 
the 16S rDNA sequence data, the enterococci form a distinct cluster within this subdivision 
with Vagococcus, Tetragenococcus, and Carnobacterium as their closest neighbours 
(Devriese and Pot, 1995). 
 
1.3.2 Phenotypic and biochemical characteristics of enterococci 
The classical taxonomy of the enterococci is vague because there are no phenotypic 
characteristics that unequivocally distinguish them from other Gram-positive, catalase-
negative, ovoid coccus-shaped bacteria (Devriese et al., 1993). However, the majority of 
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Enterococcus species can be distinguished from coccus-shaped bacteria by their group D 
antigen, grow at 10 and 45 °C, in 6.5% sodium chloride, at pH 9.6 and to survive heating at 
60 °C for 30 min (Hardie and Whiley, 1997). However, not all Enterococcus species possess 
the group D antigen. Some Streptococcus species such as S. bovis, S. suis, and S. 
alactolyticus, as well as pediococci and certain Leuconostoc strains also react with 
Lancefield’s group D antiserum. Some strains of lactococci, pediococci, aerococci and 
leuconostocs can also grow in the presence of 6.5% sodium chloride, but E. avium, E. 
cecorum and E. columbae do not (Devriese et al., 1993). On the other hand, pediococci and 
some lactococci can grow at 45°C, while most lactococci, leuconostocs and some streptococci 
grow at 10°C, but E. avium generally does not (Murray, 1990; Devriese et al., 1993). Thus, it 
can be difficult to distinguish these bacteria from other Gram-positive, catalase-negative cocci 
on the basis of phenotypic characteristics alone, without the help of genotypic methods such 
as DNA:DNA hybridisation or 16S rDNA sequencing. Nevertheless, Klein (1998) proposed a 
scheme based on phenotypic characteristics to separate enterococci from other Gram-positive 
cocci, and to presumptively identify the most common enterococcal species (Figure 1). 
 
Gram-positive, catalase-negative ovoid cocci
Serogroup D or not typable
growth at 6.5% NaCl and 10°C
no gas from glucose
growth at 45°C
other cocci
fermentation of mannitol (MAN), sorbitol (SBL),
arabinose (ARA) and raffinose (RAF)
MAN -
SBL -
ARA -
MAN +
SBL +
ARA -
50°C -
MAN +
SBL +/-
ARA +
50°C +
MAN +
SBL -
ARA -
Lactococcus spp.
E. faecium
E. faecalis
E. durans
E. hirae
RAF -
RAF +
Simple Identification Scheme
Figure 3: Simple scheme for presumptive identification of enterococci based on 
phenotypic characteristics according to Reuter (1995) and Klein (1998). 
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Schleifer and Kilpper-Bälz (1984) described certain characteristics of the genus 
Enterococcus that are valid for all described species. According to this description, the cells 
are ovoid and Gram-positive, occur singly, in pairs or in short chains. Within the chains, the 
cells are frequently arranged in pairs and are elongated in the direction of the chain. 
Endospores are absent and cells may be motile. Enterococci are facultatively anaerobic 
chemo-organotrophs with a fermentative metabolism, and a homofermentative. The 
predominant end product of glucose fermentation is L(+)-lactic acid. The peptidoglycan type 
is lysine-D-asparagine (with D-isoasparagine as cross-bridge) in all species described, except 
in E. faecalis, which has a peptidoglycan of the lysine-alanine2-3 type. The minimum 
nutritional requirements are generally complex. They are benzidine-negative and usually 
catalase-negative, but some strains may produce pseudo-catalase. 
Thus far,  more than 20 enterococcal species have been described and include E. 
faecalis, E. faecium, E. durans, E. hirae, E. mundtii, E. avium, E. pseudoavium, E. 
malodoratus, E. raffinosus, E. gallinarum, E. casseliflavus, E. flavescens, E. cecorum, E. 
columbae, E. dispar, E. sulfureus, E. saccharolyticus, E. haemoperoxidus, E. asini, E. 
moraviensis, E. villorum, and E. porcinus (Franz et al., 2003).  
 
1.3.3 Infections caused by enterococci 
Enterococci constitute an important part of the autochthonous bacteria associated with 
the mammalian gastrointestinal tract (Leclerc et al., 1996). With the exception of E. faecium 
and E. faecalis, the enterococci are rarely reported to be involved in human pathogenesis 
(Franz et al., 1999). Formerly, enterococci were indeed viewed as organisms of little clinical 
impact; however, over the last two decades enterococci, especially strains belonging to E. 
faecalis and E. faecium, have emerged as important nosocomial pathogens in 
immunocompromised patients and intensive care units. The enterococci do not possess potent 
virulence factors compared to those found in many other bacteria, but they have a number of 
other characteristics such as subtle virulence determinants and resistance to antimicrobial 
agents which may contribute to their virulence and make them effective opportunistic 
pathogens (Adams, 1999). They are considered the second most common cause of hospital-
acquired infections after Escherichia coli in the USA (Schaberg and Gaynes, 1991).  
About 90% of the human enterococcal infections are caused by E. faecalis and the 
remaining 10% by E. faecium. Enterococci cause about 5% of all urinary tract infections 
(UTI) and this incidence is even higher for patients with functional anomalies of the urinary 
tract (Morrison and Wenzel, 1986). Furthermore, enterococci constitute about 12% of 
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bacterial pathogens associated with septicaemia, and 5 to 15% of cases of bacterial 
endocarditis are caused by enterococci (Schaberg and Gaynes, 1991). 
 
1.3.4 Virulence of enterococci 
For enterococci to cause infection, they must colonise host tissue, resist host specific 
and unspecific defence mechanisms, and produce pathological changes (Franz et al., 1999). 
Virulence traits of enterococci include adherence to host tissues by a variety of adhesins, e.g. 
the ’enterococcal surface protein’ (Esp), ‘aggregation substance’ (AS), the ‘enterococcal 
endocarditis antigens’ (EfaAfm or EfaAfs from E. faecium or E. faecalis, respectively) or 
‘adhesin to collagen from E. faecalis’ (Ace) (Franz et al., 2003). Furthermore, enterococcal 
virulence is based on invasion and abscess formation, resistance to and modulation of host 
defence mechanisms, secretion of toxin such as the plasmid-encoded cytolysin, as well as 
secretion of hyaluronidase, and gelatinase (Witte et al., 1999; Franz et al., 2003). 
Some enterococci possess a plasmid collection mechanism which is based on 
production of chromosomally encoded ‘sex pheromones’. Sex pheromones are small, linear 
peptides of 7 or 8 amino acids that are excreted by Enterococcus faecalis strains which 
promote the acquisition of plasmid DNA. When pheromones bind to receptors on the cell 
surface of strains that contain plasmid DNA, this signal is transduced and leads to induction 
of the aggregation substance gene. When expressed, AS mediates the formation of cell clumps 
by binding to a complementary receptor termed ‚binding substance‘ that allows the highly 
efficient transfer of the pheromone plasmid on which the AS gene is encoded (Clewell, 1993; 
Dunny et al., 1995). The pheromones, however, not only have a role in transfer of plasmid 
DNA, they also serve as chemo-attractive substances for human neutrophils and induce 
inflammation and superoxide production (Johnson, 1994; Witte et al., 1999). 
Gelatinase is a proteolytic enzyme that acts on collagenous material present in tissues 
(Franz et al., 2002). The production of gelatinase was shown to increase pathogenicity in an 
animal model (Singh et al., 1998), which confirms its role in virulence. Enterococcal 
lipoteichoic acid from the cell wall was shown to induce production of interleukin-1β, 
interleukin-6 and TNF-α in vitro and may, therefore, contribute to local tissue damage (Witte 
et al., 1999). Hyaluronidase is a cell surface-associated enzyme which cleaves the 
mucopolysaccharide moiety of connecting tissues or cartilage. This enzyme has been 
implicated to act as ‘spreading factor’ for dissemination of some microorganisms (Witte et al., 
1999). 
Virulence of enterococci is strongly enhanced by their frequent resistance to 
commonly used antibiotics, which makes them effective opportunists in nosocomial infections 
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(Giraffa, 2002). The antibiotics against which enterococci show constitutive resistance 
include cephalosporins, β-lactams, sulphonamides, and low levels of clindamycins and 
aminoglycosides, while acquired resistances are based on acquisition of plasmids and 
transposons including resistance to chloramphenicol, erythromycin, high levels of 
clindamycin and aminoglycosides, tetracycycline, β-lactams, fluoroquinolons and 
glycopeptides (Murray, 1990; Leclercq, 1997; Franz et al., 1999).  
 
1.3.5 Bacteriocin production by enterococci. 
Many enterococcal strains produce bacteriocins. These are called enterocins, and they 
generally belong to the class II bacteriocins (Franz et al., 1999). The enterocins are generally 
active against other enterococci, as well as strains of Listeria monocytogenes (Giraffa, 1995). 
Currently, the only enterocin that can be grouped into class IIa (see above) is the enterocin A 
produced by E. faecium strains CTC492 and BFE 900 (Aymerich et al., 1996; Franz et al., 
1999). It has antimicrobial activity against Enterococcus, Lactobacillus and Listeria spp., 
including Listeria monocytogenes. Enterocin (Ent) A consists of 47 amino acids with a 
theoretical molecular weight of 4829 Da. Mundticin (Bennik et al., 1998) is a class II 
bacteriocin consisting of 43 amino acids with activity against Listeria, Enterococcus, 
Lactobacillus, Pediococcus and Pediococcus spp., as well as Clostridium botulinum. 
However, the genes for mundticin have not been cloned and it is not known whether this 
bacteriocin belongs to class IIa or to the sec-secretion-dependent class IIc enterocins. 
Enterocin P is a bacteriocin produced by E. faecium strains P13 and L50 that were isolated 
from Spanish sausages (Cintas et al., 1997; Cintas et al., 2000). It also has activity against 
other Enterococcus spp., as well as Lactobacillus and Pediococcus spp. In addition, the 
bacteriocin inactivates B. cereus, S. aureus, C. perfringens and C. botulinum (Cintas et al., 
1997). The mature bacteriocin consist of 44 amino acids and has a theoretical molecular 
weight of 4493 Da. Enterocin P is produced as a prepeptide of 71 amino acids, bearing a 
signal peptide of 27 amino acids. Secretion of enterocin P, therefore, occurs via the sec-
pathway and the bacteriocin can thus be classified as a class IIc bacteriocin (Cintas et al., 
1997). 
Some enterocins can not be readily grouped into one of the existing bacteriocin 
classes. For example, enterocin L50A and B is a two-peptide bacteriocin consisting of the 44 
amino acid EntL50A and the 43 amino acid EntL50B (Cintas et al., 1998). These peptides are 
produced without a leader peptide and thus a distinction between class IIa bacteirocins, which 
are secreted by a dedicated ABC transporter, and class IIc bacteriocins, which are secreted via 
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the sec-pathway, can not be made. Enterocin L50A and B share sequence homology to 
staphylococcal peptide toxins which include δ-lysin, SLUSH A to C and AGS1 to 3 (Cintas et 
al., 1998). The 34 amino acid bacteriocin enterocin Q also produced by E. faecium L50 also 
does not contain a N-terminal extension, i.e. it is not produced as a prepeptide (Cintas et al., 
2000). Enterocin B produced by E. faecium strains CTC 492 and BFE 900 (Casaus et al., 
1997, Franz et al., 1999) is unusual in that it does not contain a conserved YGNGV motif at 
the N-terminal end of the mature peptide. This amino acid motif is conserved in all other class 
IIb bacteriocins and was shown to be important for activity of some bacteriocins (Nes et al., 
1996). Enterocin AS-48 on the other hand is a unique bacteriocin as it is a cyclic molecule 
that results from head-tail linkage of the N-terminal methionine (M+1) with the C-terminal 
tryptophane (W+70) (Martinez-Bueno et al., 1994). AS-48 also is unique in that the bacteriocin 
has a broad range of activity, including Gram-negative bacteria (Martinez-Bueno et al., 1994)  
Enterococcus faecalis BFE 1071 isolated from the faeces of Göttingen mini-pigs 
produces a two peptide bacteriocin, designed as enterocin 1071A&B. The bacteriocin is active 
against many Gram-positive bacteria such as E. faecalis, E. faecium, E. durans, 
Bifidobacterium gallicum, Clostridium tyrobutyricum, Staphylococcus aureus, Listeria 
innocua, Leuconostoc mesenteroides subsp. cremoris, L. acidophilus, L. casei, L. fermentum, 
L. curvatus, L. helveticus, L. plantarum, L. reuteri, L. sakei, L. salivarius subsp. salivarius, 
Lactococcus lactis subsp. lactis, Propionibacterium acidipropionici, and Pediococcus 
pentosaceus (Balla et al., 2000). Thus, the activity spectrum includes strains of lactobacilli 
typical of  in the human intestine, i.e. L. acidophilus and L. salivarius. This one reason for 
using this bacteriocin-producer in this study to evaluate the effect of the strain on the 
microflora composition of the rat gastrointestinal tract. 
The bacteriocin enterocin 1071 was studied in detail both at a chemical and genetic 
level (Balla et al., 2000; Franz et al., 2002). The molecular masses of the purified bacteriocins 
were determined by electron spray mass spectrometry to be 4285 and 3899 Da for the 
enterocins 1071A and 1071B, respectively (Balla et al., 2000). The genetic determinants for 
this two-peptide bacteriocin were located on plasmid DNA (Balla et al., 2000; Franz et al., 
2002) and DNA sequencing revealed two open reading frames (ORFs) encoding the 39 and 
34 amino acid enterocin 1071A and 1071B peptides, respectively (Balla et al., 2000; Franz et 
al., 2002). These bacteriocins were encoded as prepeptides, each bearing a double-glycine-
type leader peptide of either 18 amino acids (Ent1071A) or 24 amino acids (Ent 1071B) 
(Franz et al., 2002). In addition to the bacteriocin structural genes, a gene (eni1071) encoding 
a protein of 110 amino acids with an isoelectric point of 9.278, was found downstream of 
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ent1071B. This gene was cloned and expressed in a heterologous host, where it was shown to 
confer immunity to enterocin 1071 (Franz et al., 2002). A truncated ORF (entT) was found 
upstream of the ent1071A and B genes on a 3.2-kb plasmid fragment cloned by Franz et al. 
(2002). This ORF showed homology to ABC transporter proteins of other bacteriocin 
systems, and was therefore speculated to be involved in transport of enterocin 1071 (Franz et 
al., 2002). Although an accessory gene is generally associated with bacteriocin transport, the 
fragment cloned in the study of Franz et al. (2002) did not contain a gene for this protein. 
Thus to date, this gene remains undetected , probably downstream of the ABC transporter 
gene on a region of the plasmid that was not cloned or sequenced (Franz et. al., 2002).  
 
1.3.6. Enterococci as probiotics 
Specific strains of enterococci are being used as probiotics for humans and animals. 
One of the best studied enterococci used as a human probiotic, especially in the treatment of 
diarrhoea, is Enterococcus faecium SF 68. especially in the treatment of diarrhoea. The strain 
was originally isolated in Sweden and was patented in Switzerland and other countries 
(Lewenstein et al., 1979). Its effectiveness for treatment of intestinal disorders can probably 
be attributed to the fact that it is a commensal of the intestine and that it has a short lag phase 
and generation time (ca. 20 min generation time under optimal conditions). It is moderately 
resistant to antibiotics and has an inhibitory effect in vitro to growth of E. coli, Salmonella 
spp., Shigella spp. and Enterobacter spp. In addition, this strain is resistant to low pH, 
insensitive to bile salts, and individuals show a high tolerance to it with no side effects 
(Lewenstein et al., 1979; Bellomo et al., 1980; Canganella et al., 1996). E. faecium SF 68 is 
considered as an alternative to antibiotics for treatment of diarrhoea (Lewenstein et al., 1979; 
Bellomo et al., 1980). Several controlled, ‘double blind’-type clinical studies have shown that 
treatment of enteritis with E. faecium SF68 was successful for both adults and children. It 
decreased the duration of diarrhoeal symptoms and the time for normalisation of patient’s 
stools (Bellomo et al., 1980, Bruno and Frigerio, 1981; D’Apuzzo and Salzberg, 1982).  
Another probiotic Enterococcus is the Causido® culture that consists of two strains of 
S. thermophilus and one strain of E. faecium. This probiotic has been claimed to be 
hypocholesterolaemic in the short-term (Agerholm-Larsen et al., 2000), but long-term 
reduction of LDL-cholesterol levels was not demonstrated (Richelsen et al., 1996; Sessions et 
al., 1997); hence the clinical relevance of this effect is uncertain (Lund et al., 2002). 
However, the use of enterococci as probiotics remains a controversial issue. While the 
probiotic benefits of some strains are well established, the emergence of antibiotic resistant 
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strains of enterococci and the increased association of enterococci with human disease (see 
below), has raised concern regarding their use as probiotics. Therefore, should an 
Enterococcus strain be considered as a human probiotic it should be determined whether the 
strain is antibiotic resitant and whether it contains any virulence determinants. 
 
1.4 Gastrointestinal microbiology of the human and rat 
The bacterial flora of the gastrointestinal system represents an ecosystem of the 
highest complexity and our understanding of this system and its interactions is still limited 
(Berg, 1996). The gastrointestinal tract (GIT) of an adult human is estimated to harbour about 
1014 viable bacteria, i.e. ten times the total number of eukaryotic cells in all the tissues of a 
humans’ body. The importance of these bacteria in the GIT was neglected for a long time, 
while the focus was merely placed on enteric pathogens and other factors leading to 
gastrointestinal disorders (Holzapfel et al., 1998). Both the variety and the overall sum of 
microbial numbers are determined by an array of complex factors, intrinsic to the respective 
gastrointestinal tract sections, and ‘extrinsic’ related to, for example, diet, stress and drugs. 
After the more or less neutral pH of the oral cavity, the low pH of the stomach (ranging from 
2.5 to 3.5) is destructive to most microbes. The population averages log10 3.0 bacteria g-1 and 
is dominated by Gram-positive bacteria such as streptococci and lactobacilli, and by yeast 
(Holzapfel et al., 1998). The duodenum also represents a hostile environment due to the 
aggressive intestinal fluid (e.g. bile, pancreatic juices) and the short transit time and thus 
contains relatively low numbers of microbes (Holzapfel et al. 1998). Nevertheless Reuter 
(2001) showed that lactobacilli can occur at numbers of log10 5.6-9.4 CFU/g or log10 6.0 –8.4 
CFU/g in the jejunum and ileum, respectively. Other bacteria occurring in these sites are from 
the Enterobacteriaceae, and the genera of Lactobacillus, Streptococcus, Bacteroides, 
Bifidobacterium and Fusobacterium (Simon and Gorbach, 1982).  
It is estimated that the colon of healthy adults harbours about 300-400 different 
cultivable species belonging to more than 190 genera. Among the known colonic microflora, 
only a few major groups dominate at levels around 1010-1011 g-1. They are all strict anaerobes 
such as Bacteroides, Eubacterium, Bifidobacterium, and Peptostreptococcus. Facultative 
aerobes are considered to belong to the sub-dominant flora, and are constituted of 
Enterobacteriaceae, streptococci and lactobacilli (Gedek, 1993).  
Compared to the colonic flora, the fecal flora undergoes distinct quantitative variations 
but seems to be a good qualitative indicator of the distal colonic microflora. However, it does 
not accurately reflect the intestinal flora and most definitely not those of the small intestine. 
 25
Furthermore, our knowledge on the stability of the strains, species and even genera 
relationship is still extremely limited (Gedek, 1993).  
Various species of laboratory animals are used for metabolic and toxicological studies 
and the extrapolation of results from animals to man has always taxed experimenters. 
Animals, particularly rodents and more recently pigs, have been used for gut flora studies, 
both to investigate ecological mechanisms in the gut and to study microbial metabolisms 
(Rumney and Rowland, 1992). Research has mainly concentrated on the easily accessible 
microflora of the faeces (Vaughan et al., 2000). Although animals are very convenient for 
investigating ecological mechanisms in the gut, to study microbial metabolism and enable 
monitoring of the flora in different gut regions as well as faeces, there are major differences 
between animals and humans in the microflora composition and metabolism (Rumney and 
Rowland, 1992). The differences in gut microflora between laboratory animals and man limit 
the relevance of studies on colonization resistance in animals to the human situation, but 
ethical considerations do not allow human volunteers to be challenged with live, potentially 
pathogenic organisms. An acceptable alternative for such studies is provided by human flora-
associated animals (Rumney and Rowland, 1992). Rumney and Rowland (1992) studied 
metabolism of the colon carcinogen 2-amino-3-methyl-3H-imidazo[4,5-f]quinoline (IQ) by 
suspensions of fecal organisms from rodents (rat and mouse) and humans. They found that the 
rate of the reaction was fastest in suspensions of microorganisms from rat and mouse 
compared with those from humans. In the study of dietary modification of the human gut 
microflora, Rumney and Rowland (1992) found that conventional microflora rats fed with a 
diet containing 5% pectin showed large increases in the activity of nitrate reductase, ß-
glucuronidase, and ß-glycosidase. In contrast, the feeding of pectin (18 g/d) to human 
volunteers elicits no such increase in the activity of microbial enzymes. These studies 
exemplify that direct comparisons in gastrointestinal biology between the animal model and 
the human appear not to correlate well. In our animal experiment to test the influence of a 
bacteriocin-producing potentially probiotic LAB strain on the composition of the microflora, 
we nevertheless used healthy male Sprague-Dawley rats, because human experimentation 
with enterococci would be difficult to do because of safety concerns (see above). In addition, 
it would be more difficult to control and more costly. Nevertheless the animal model can 
point towards whether a bacteriocin-producing strain can in principle modify the 
gastrointestinal flora and if such changes occur, which bacterial groups would be affected.  
Campbell et al. (1997) analysed microflora in male Sprague-Dawley rats after being 
fed with control diet containing (in g/100 g dry matter) protein (19.7), L-Cystine (0.3), 
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carbohydrate (64.75), fat (10.5), choline (0.25), vitamins (1), minerals (3.5) and gross energy 
(18.43 MJ/kg diet). It was shown that cell counts of bifidobacteria, lactobacilli, total aerobes 
and total anaerobes were (log10 CFU/g wet stool) 9.1, 7.2, 8.2, and 8.8, respectively. The cecal 
bacteria in male Wistar rats after being fed with fiber-free control diet containing (g/kg diet) 
casein (200), wheat starch (650), sunflower oil (50), mineral mixture (50), vitamin mixture 
(30), microcrystaline cellulose (20) and 16.53 MJ/kg diet gross energy, were analysed by 
Noack et al. (1998). They found that dominant cecal bacteria consisted of (log10 CFU/g dry 
cecal contents) bifidobacteria (<5.3), eubacteria (8.9), Gram-positive anaerobic cocci (8.3), 
clostridia (5.4), Bacteroides and Fusobacterium (9.4), lactobacilli (9.6), enterococci 7.5), and 
enterobacteria (7.6), with total counts of 9.9 log10 CFU/g. Henderson et al. (1997) found that 
long-term, i.e. 20 weeks, food restriction had little effect on the microflora of female Fischer 
344 rats.  
 
 
1.5 Research motivation  
Although a great deal of research has been dedicated to elucidate aspects of bacteriocin 
activity such as genetics of production, immunity and transport, as well as toxicological 
aspects and application of bacteriocins in foods, there are almost no data available on the 
effect of bacteriocins or bacteriocin-producing probiotic lactic acid bacteria on the hosts 
autochthonous flora. Because bacteriocin activity has been viewed as a functional 
characteristic of probiotic lactic acid bacteria, some research efforts have been dedicated to 
evaluate the effect of purified bacteriocins or bacteriocin producers on foodborne pathogens 
in vitro or in seldom cases also in vivo. However, no studies have yet addressed the question 
about the effect on the host autochthonous flora, which is surprising, considering that 
bacteriocins are active usually against closely related species and may thus interfere with the 
hosts established microflora. The hosts’ own microflora is considered to have an important 
function itself in protecting the gastrointestinal tract from invading pathogens. Such a 
potential interference with the protective activity of the hosts autochthonous flora has raised 
concerns on whether bacteriocin-production by probiotic bacteria is actually a desirable 
functional characteristic. This study, therefore, serves as a novel investigation, which 
addresses the question whether bacteriocin-producing, probiotic bacteria can interfere with the 
hosts own microflora, by using the rat as an experimental animal model. 
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1.6 Study objective and aims 
The objective of this study was to determine the influence of a potentially probiotic, 
bacteriocin-producing Enterococcus faecalis strain BFE 1071 and its bacteriocin-negative 
mutant on the composition of the intestinal microflora of male Sprague-Dawley rats in an in 
vivo experimental model.  
 
To reach this objective the study aimed to: 
 
1) Investigate the suitability of various enterococci strains isolated from food or 
gastrointestinal sources for use as a probiotic on the basis of their technological and 
functional properties. The technological properties included resistance to acid and 
tolerance to bile and duodenum secrete in an in vitro model. The functional, probiotic 
properties included investigations into adherance potential using a test for 
hydrophobicity and adherance to HT-29 MTX cells in vitro as well as studies for 
bacteriocin production and bile salt hydrolase activity. 
2) To study bile salt hydrolase activity of enterococci, for which no information is 
available at the genetic level, using a molecular biological approach which included 
cloning and genetic characterisation of the bile salt hydrolase gene of one of the 
enterococci strains. 
3) To evaluate and compare the probiotic potential of the selected Enterococcus strains 
using a commercial Enterococcus faecium SF68 probiotic culture, and to select a 
bacteriocin-producing strain and its bacteriocin-negative mutant for use in an in vivo 
experiment to determine their effects on the hosts autochthonous intestinal flora. 
4) To investigate the potentially probiotic enterococci strains for virulence determinants 
and antibiotic resistances in a safety evaluation for possible future probiotic research 
and application of the strain. 
5) To determine the effect of the bacteriocin and the effect of the bacteriocin producer on 
the intestinal microflora of the rat by recovering predominant gastrointestinal bacteria 
from the faeces on selective media, and specifically by phenotypic and genotypic 
identification of the lactobacilli and enterococci isolates.  
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 2.0 MATERIALS AND METHODS 
 
 
2.1 MATERIALS 
 
2.1.1. ganisms used in this study 
T 
Microor
he strains investigated for their probiotic potential in this study are listed in 
Table 4. The probiotic Enterococcus faecium strain SF68 was supplied by the 
manufacturers of this probiotic strian (Cerbios Pharma S.A., Lugano, Switzerland). 
Enterococus faecalis BFE 1071 was isolated from the faeces of Göttingen-minipigs (Du Toit 
et al., 2000). The genes associated with bacteriocin-production of this microorganism were 
cloned and characterised in a previous study (Balla et al., 2000; Franz et al., 2002) and the 
strain was shown to produce a two-component bacteriocin termend enterocin 1071A&B 
(Balla et al., 2000). The plasmid-cured, bacteriocin-negative mutant E. faecalis 1071/79(-) 
used in this study (Table 4) was also previously created (Balla et al., 2000). The other 
enterococci were obtained from the FAIR-E culture collection of the European Union (EU) 
project entitled Enterococci in Food Fermentations: Functional and Safety Aspects (FAIR-
CT97-3078) and were all isolated from food. These bacteria were selected as potentially 
probiotic candidates on the basis of limited safety investigations (gelatinase-negative, no beta-
haemolysis on blood agar, vancomycin-sensitive) and absence of plasmid DNA done in the 
FAIR-CT97-3078 study. Enterococcus faecium BFE 900 produces the bacteriocins entrocin A 
and B and the genetics of bacteriocin-production have been studied in detail (Franz et al., 
1999). This strain was isolated from Spanish olives and was used in this study as a potential 
probiotic candidate based on it’s ability to produce two chromosomally-encoded bacteriocins. 
Lactobacillus sakei Lb706 isolated from meat was included as a further potentially probiotic 
strain, for which bacteriocin-production was well studied at the genetic level (Axelsson et al., 
1993; Axelsson and Holck, 1995). This strain produces the plasmid-encoded bacteriocin 
sakacin A and a bacteriocin-negative mutant of this strain was also created previously by 
mutation with ethidium bromide (Axelsson et al., 1993). All the strains were grown 
aerobically in MRS (de Man, Rogosa and Sharpe) broth (Merck, Darmstadt, Germany) 
adjusted to pH 6.5 at 37 ºC, and stock cultures were kept in the same medium at -80 ºC with 
15% (vol./vol.) glycerol added. 
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 Table 4: Strains and relevant geno- or phenotype of potentially probiotic lactic acid 
bacteria used in this study. 
 
Strain Relative genotype/phenotype 
Enterococcus faecium SF68 Commercial probiotic strain 
Enterococcus faecalis BFE 1071 Enterocin 1071 producer. The ent1071, 
bacteriocin gene is located on a 50-kbp 
plasmid pEF1071 
Enterococcus faecalis BFE 1071 /79(-) Bacteriocin-negative, plasmid pEF1071 cured 
derivative of E. faecalis BFE 1071.  
Enterococcus faecium BFE 900 Plasmidless. Enterocin A and Enterocin B 
producer. The entA+ and entB+ bacteriocin 
genes are located on the chromosome.  
Lactobacillus sakei Lb706 Sakacin A producer. The sakA bacteriocin 
gene is located on a 60-kbp plasmid  
Enterococcus faecium FAIR-E 6 Food isolate 
Enterococcus faecium FAIR-E 9 Food isolate 
Enterococcus faecium FAIR-E 15 Food isolate 
Enterococcus faecium FAIR-E 210 Food isolate 
Enterococcus faecium FAIR-E 243 Food isolate 
Enterococcus faecium FAIR-E 345 Food isolate 
Enterococcus faecium FAIR-E 349 Food isolate 
Enterococcus faecium FAIR-E 365 Food isolate 
 
 
 
2.1.2. Media, solutions and chemicals 
 
The bacteriological media were prepared by sterilizing at 121 °C for 15 min. For the 
production of solid agar plate media, agar-agar was added at a concentration of 15 g/L. 
Bacteriological media were used to propagate potentially probiotic strains or to isolate strains 
from rat faeces in the animal experiment.  
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 2.1.2.1 MRS medium (de Man et al., 1960; Merck) (g/L): 
 D(+) Glucose    20  
 Universal peptone    10  
 Meat extract      5  
 Sodium acetate      5  
 K2HPO4.3H2O      2  
 di-Ammonium hydrogen citrate    2  
 Tween 80       1  
 MgSO4.7H2O      0.1  
 MnSO4.4H2O      0.05  
 pH        6.5 
 (pH was adjusted to pH 6.5 with 1 N NaOH). 
For MRS soft agar, 8 g/L of bacteriological agar was added to MRS broth before sterilisation.   
 
2.1.2.2 Rogosa agar (Merck, Darmstadt, Germany) (g/L): 
Peptone from casein   10.0 
Yeast extract      5.0 
D(+)-Glucose    20.0 
Potassium dihydrogen phosphate    6.0 
Ammonium citrate     2.0 
Tween 80       1.0 
Sodium acetate    15.0 
MgSO4.7H2O                   0.575 
Iron (II) sulfate         0.034 
Manganese sulfate         0.12 
Agar-agar     15.0 
Neutral red       0.03 
Crystal violet      0.002 
Agar-agar     13.0 
 
2.1.2.3 DRCM Agar (Differential Reinforced Clostridia Medium) (Merck, Darmstadt, 
Germany) (g/L): 
Peptone from casein     5.0 
Peptone from meat     5.0 
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 Meat extract      8.0 
Yeast extract      1.0 
Starch       1.0 
D(+)-Glucose      1.0 
L-cysteine chloride     0.5 
Sodium acetate      5.0 
Sodium disulfide      0.5 
Ammonium iron (III) citrate    0.5 
Resazurin sodium      0.002  
 
2.1.2.4 Azide blood agar base (Oxoid, Hampshire, England) (g/L): 
Tryptose     10.0 
‘Lab-lemco’ powder     3.0 
Sodium chloride      5.0 
Sodium azide      0.2 
Agar-agar     12.0 
 
2.1.2.5 Columbia agar (Merck, Darmstadt, Germany) (g/L): 
Special nutrient substrate   23.0 
Starch       1.0 
Sodium chloride      5.0 
Agar-agar     13.0 
     
2.1.2.6 Kanamycin aesculin azide agar (Merck, Darmstadt, Germany) (g/L): 
Peptone from casein   20.0 
Yeast extract      5.0 
Sodium chloride      5.0 
Sodium citrate      1.0 
Sodium azide      0.15 
Kanamycin sulfate      0.02 
Esculin       1.0 
Ammonium iron (III) citrate    0.5 
Agar-agar     15.0  
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 2.1.2.7 Bifidobacterium agar (g/L): 
Trypticase     10.0 
Phytone       5.0 
D(+)-Glucose      5.0 
Yeast extract      2.5 
Tween 80       1.0 ml 
Cysteine       0.5 
K2HPO4. H2O      2.0 
MgCl2. H2O        0.5 
ZnSO4. H2O      0.25 
CaCl2. H2O       0.15 
FeCl3       0.01 
Selective agent LiCl     3.0 
Agar-agar     15.0 
 
2.1.2.8 Todd-Hewitt agar (Becton and Dickinson, Heidelberg, Germany) (g/L): 
Infusion from beef heart            500.0 
Bacto neopeptone               20.0 
Bacto dextrose      2.0 
Sodium chloride      2.0 
Disodium phosphate     0.4 
Sodium carbonate      2.5 
Agar-agar     15.0 
Todd-Hewitt broth consisted of the same formulation, but without the agar-agar added. 
 
2.1.2.9 Dulbecco’s Modified Eagles medium (Life Technologies, Karlsruhe, Germany) 
(mg/L): 
CaCl2.2H2O      264.0 
Fe(NO3).9H2O          0.10 
KCl        400.0 
MgSO4.7H2O      200.0 
NaCl               6 400.0 
NaHCO3               3 700.0 
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 NaH2PO4.2H2O      141.0 
D(+)Glucose              4 500.0 
Phenol red         15.0 
Aminopterin          0.176 
Hypoxanthin        13.60 
Thymidin           3.88 
L-Arginine.HCl        84.00 
L-Cystine         48.0 
L-Glutamine      580.0 
Glycine         30.0 
L-Histidine.HCl.H2O       42.0 
L-Isoleucine      105.0 
L-Leucine       105.0 
L-Lysine.HCl      146.0 
L-Methionine        30.0 
L-Phenylalanine        66.0 
L-Serin         42.0 
L-Threonin         95.0 
L-Tryptophan        16.0 
L-Tyrosine         72.0 
L-Valine         94.0 
D-Ca-Panthothenate         4.0 
Cholinchloride          4.0 
Folic acid           4.0 
i-Inositol           7.2 
Nicotinamide          4.0 
Riboflavine          0.4 
Thiamine HCl          4.0 
Pyridoxal HCl          4.0 
      
 
2.1.2.10 Mueller-Hinton II agar (g/L) 
Beef Infusion       300.0 
Casaminoacids         17.5 
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 Starch            5 
Agar-agar          17.0 
pH              7.3 
 
2.1.2.11 Reduced Brain Heart Infusion medium (g/L): 
Infusion from calf brains      200.0 
Infusion from beef heart      250.0 
Proteose peptone         10.0 
Dextrose            2.0 
Sodium Chloride           5.0 
di-Sodium phosphate          2.5 
Cysteine monohydrochloride         1.0 
pH             7.4 
 
2.1.3 Media used for testing technological properties of potentially probiotic lactic 
acid bacteria strains 
 
2.1.3.1 Acid and bile tolerance 
MRS broth (see 2.1.2.1) adjusted to pH 3.0 was used as artificial gastric juice to test for acid 
resistance of potentially probiotic strains. MRS broth with a pH of 3.0 was prepared by 
dissolving 52.5 g MRS dry medium in 1 L destilled water and adjusting the pH to 3.0 using 5 
N HCl. An Oxgall (Difco, Detroit, USA) solution was made by dissolving 10 g of Oxgall 
powder in 100 ml volume of aqua bidest. This oxgall solution was used to simulate bile salt 
and to assess the tolerance of potentially probiotic strains. A bicarbonate buffer was used as 
artificial duodenum juice to evaluate the ability of potentially probiotic strains to tolerate 
gastric juice. This artificial duodenum juice was made by dissolving 6.4 g NaHCO3, 0.239 g 
KCL, and 1.28 g NaCl in 100 ml aqua bidest. The pH was adjusted to 7.4 with 5 N HCl.  
 
 
2.1.4 Media and solutions used for testing functional properties of potentially 
probiotic lactic acid bacteria strains 
 
2.1.4.1 Bacteriocin test 
MRS plate agar and MRS soft agar (see 2.1.2.1) were used for testing bacteriocin activity.  
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 2.1.4.2 Bile salt hydrolase activity 
Bile salt hydrolase activity was detected on MRS agar plates supplemented with 0.5% (w/v) 
sodium salt of taurodeoxycholic acid (Sigma, Deisenhofen, Germany) and 0.37 g/l of CaCl2 
(Merck, Darmstadt, Germany). 
 
2.1.4.3 Adhesion to mucus-secreting HT-29-MTX cells and Extracellular Matrix 
Proteins 
Dulbecco’s Modified Eagle’s medium (DMEM) (see 2.1.2.11) containing 2% foetal calf 
serum (Life Technologies, Karlsruhe, Germany) was used to grow test bacteria. HT-29 cells 
were cultivated in 24 well Tissue culture plates in the absence of antibiotics in glucose-free 
DMEM supplemented with 15% dialysed fetal bovine serum, 4 mmol L-glutamine/L, and 5 
mmol galactose/L.  
 
2.1.4.4  Hydrophobicity 
For hydrophobicity testing, bacteria were grown in 9 ml of MRS broth (see 2.1.2.1) and 
hydrophobicity was tested in qurter-strength Ringer‘s solution and n-hexadecane (Merck).  
 
2.1.5 Media used for testing virulence and antibiotic resistance of potentially 
probiotic enterococci strains 
 
2.1.5.1 DNAse production 
DNAse test agar (Becton Dickinson, Heidelberg, Germany) with methyl green was used for 
testing for DNAse activity, and contained (g/L): 
 Bacto tryptose   20.0 
Deoxyribonucleic acid    2.0 
Sodium chloride     5.0 
Bacto agar    15.0 
Methyl green     0.05 
 
2.1.5.2 Production of gelatinase 
Production of gelatinase was detected on Todd-Hewitt agar (see section 2.1.2.10) containing 
30 g/l gelatine (Merck, Darmstadt, Germany). 
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 2.1.5.3 Clumping assay for presence of aggregation substance 
Todd-Hewitt broth (see section 2.1.2.10) was used to test for clumping of enterococci in 
presence of pheromone. 
 
2.1.5.4 Haemolysin production 
All 4 human blood types were collected, defribinated and added (5%) to Columbia agar (see 
2.1.2.6). 
 
2.1.5.5 Mucin degradation assay  
Mucin degradation was tested using medium B of Zhou et al. (2001) in a Petri dish. Mucin 
degradation was tested three times in medium B containing either 3 or 5 g/L of purified hog 
gastric mucin and either 10 or 30 g/L of D(+) glucose. 
 
Medium B (g/L): 
Tryptone      7.5 
Casitone      7.5 
Yeast extract     3.0 
Meat extract     5.0 
NaCl      5.0 
K2HPO4.3H2O     3.0 
KH2PO4         0.5 
MgSO4.7H2O        0.5 
Cysteine HCl        0.5 
Resazurin         0.002 
D(+)-glucose   10.0 or 30.0 
Purified hog gastric mucin   3.0 or 5.0 
Agarose    15.0 
pH       7.2 
 
2.1.5.6 Staining and destaining solution for detection of mucin degradation 
The staining agent amido black was solubilized in 3.5 N acetic acid at an end concentration of 
0.1%. Acetic acid (1.2 N) was used as destaining solution.  
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 2.1.5.7 Antibiotic resistance determination 
Antibiotic resistances of potentially probiotic enterococci was tested on Mueller-Hinton agar 
(see 2.1.2.10) (Becton Dickinson, Heidelberg, Germany): 
 
2.1.5.8 Solutions used for total genomic DNA isolation of potentially probiotic 
enterococci for PCR amplification of virulence determinants 
Total genomic DNA of enterococci for PCR amplification of virulence determinants was 
isolated according to the guanidium thiocyanate method Pitcher et al. (1989). The 
composition of the TERMLS solution used for degradation of the bacterial cell wall, the GES 
solution to lyse cells and to degrade protein and the TE buffer (1 X TE solution) used to store 
DNA are given below: 
 
2.1.5.8.1 TE buffer 
TE Buffer (1 X TE solution) contains 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (pH 8.0).   
 
2.1.5.8.2 TERLMS solution 
TERLMS solution consisted of 25 µg/ml RNAse, 25 mg/ml lysozyme, 10 U/ml mutanolysin, 
and 0.2 g/ml sucrose in 1X TE solution (see 2.1.4.8.1).   
2.1.5.8.3 GES solution 
This reagent consisted of 5 M guanidium thiocyanate, 100 mM EDTA, and 0.5% Sarkosyl 
and was filter-sterilised and stored at room temperature.  
 
2.1.6 Solutions used for cloning of the bile salt hydrolase gene 
For cloning of the bile salt hydrolase gene, total genomic DNA was isolated from E. faecalis 
FAIR-E 345 according to the method of Pitcher et al. (1989) using the TE buffer, TERMLS 
and GES solutions described above (see 2.1.5.8.1, 2.1.5.8.2 and 2.1.5.8.3). In addition, small-
scale plasmid DNA was isolated by the method of van Belkum et al. (1995). Solutions for 
plasmid DNA isolation include TELS solution to degrade the bacterial cell wall and lysis 
solution to lyse cells as described below.  
 
2.1.6.1 TELMS solution 
TELMS solution consisted of 25 mM Tris, 10 mM EDTA, 20% sucrose, 20 mg/ml lysozyme 
and 1000 U/ml mutanolysin in bidest water. 
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 2.1.6.2 Lysis solution 
Lysis solution consisted of 1% SDS and 0.2 N NaOH in bidest water. 
 
 
Restriction enzymes and buffers used for cloning of the bile salt hydrolase gene were obtained 
from New England Biolabs (Frankfurt am Main, Germany). 
 
 
2.1.7 Buffers used in Southern hybridization of plasmid DNA with bile salt 
hydrolase gene probe 
Plasmid DNA was run on 1.2 % agarose gels, transferred to nylon membrane (see methods 
section below) and hybridised with a bile salt hydrolase gene probe (see methods below) 
according to Sambrook et al. (1989). 
 
2.1.7.1. Buffer 1 
Buffer 1 consisted of 100 mM Tris (pH8.0) and 150 mM NaCl in bidest water. 
 
2.1.7.2 Buffer 2 
Consisted of blocking reagent (Hering sperm DNA, commercially supplied with the DIG-
labelling and detection kit; Roche, Mannheim Germany) at a concentration of 0.5% and is 
dissolved in buffer 1 while heating at 50 to 70 °C. This buffer is kept frozen at –20 °C until 
use.  
 
2.1.7.3 Buffer 3 
Buffer 3 consisted of 100 mM Tris (pH 8.0), 100 mM NaCl and 50 mM MgCl2 in bidest 
water. The pH of buffer 3 was adjusted to pH 9.5 with 1 N NaOH.   
 
2.1.7.4 Prehybridization solution 
This solution consisted of 5X SSC (5X SSC solution was obtained by diluting 20X SSC 
solution containing 0.3 M sodium citrate, pH approximately 7.0 containing 3 M NaCl), 0.1% 
(weight/vol.) N-laurosylsacrosine, 0.02% (weight/vol.) SDS, 1% Blocking reagent (Roche) in 
bidest water. 
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 2.1.7.5 Denaturing solution 
Denaturing solution consisted of 1.5 M NaCl and 0.5 M NaOH in bidest water. 
 
2.1.7.6 Transferring solution 
Transferring solution consisted of 1 M ammonium acetate and 20 mM NaOH which were 
solubilised in bidest water.  
 
2.1.7.7 DIG-Labelling and detection 
A commercial DIG-labelling and detection kit (Roche) was obtained, containing solutions for 
labelling the bile salt hydrolase gene probe and detection of hybridization of the probe to 
plasmid DNA according to the manufacturer’s specifications. 
 
2.1.8 Animal experiments 
Thirty six male Sprague-Dawley rats (weight between 125 and 150 g) were obtained from 
Charles River Laboratories (Sulzfeld, Germany). The basal diet Altromin C 1000 (Altromin 
GmbH, Lage, Germany, see appendix A) was ordered in powder form.  
Biomass of probiotic bacteria was grown in MRS broth, collected by centrifugation, 
washed in quarter-strength Ringers’s solution (see methods below). A 10% skim milk 
solution (Merck, Darmstadt, Germany; sterilised at 120 °C for 15 min by autoclaving) was 
added to the probiotic cell biomass as protective agent during freeze-drying. 
 
2.1.8.1 Identification of the bacteria isolated from fecal samples of rats 
Rat faeces was collected and diluted ten times in reduced brain heart broth (see 2.1.2.11). 
Seven groups of bacteria were selected with selective media as described above. Rat faeces 
was serially diluted using a ten-fold dilution series in quarter-strength Ringer’s solution (see 
1.2.1.12) and plated out onto the (semi)selective media for: lactobacilli (Rogosa agar), 
enterococci (Kanamycin aesculin azide agar), Gram-positive anaerobic cocci (Bacto azide 
blood agar base), clostridia (DRCM agar), bifidobacteria (Bifidobacteria agar), and total count 
(Columbia agar).  
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 2.2 METHODS 
 
2.2.1 Investigations into technological traits of potentially probiotic enterococci 
2.2.1.1 Acid and bile tolerance 
For determinations of bile resistance and acid tolerance of potentially probiotic lactic acid 
bacteria strains (enterococci and other bacteriocin producer, i.e. L. sakei Lb706) 3 ml of MRS 
broth (pH 3.0) were seperately inoculated at a level of 2 x 108 CFU/ml. A pH of 3.0 was 
chosen to represent the pH of the stomach after swallowing a meal. The culture was placed in 
an aerobic chamber (atmosphere of 80% N2, 10% CO2, and 10% H2) in an anaerobic work 
chamber (MK3 anaerobic chamber work station, dw Scientific, Shipley, England). After one 
hour, a 1 ml sample was withdrawn under anaerobic conditions and then removed from the 
anaerobic chamber for determination of the viable cell count and, consequently acid resistance 
of the test microorganism. Aliquots of 1.2 ml of Oxgall solution (10%) and 5.1 ml bicarbonate 
buffer (artificial duodenum juice) were added after removal of the sample for cell counts, 
again under anaerobic conditions. Thus the test set up simulated conditions as bacteria would 
encounter when reaching the small intestine after a one-hour residency time in the stomach. 
Further samples were withdrawn under anaerobic conditions after one and two hours 
anaerobic incubation after addition of the Oxgall and artificial duodenum juice to determine 
the test organisms bile resistance and resistance to simulated small intestinal conditions. For 
viable count determination, samples were serially diluted using ten-fold dilution steps in 
quarter-strength Ringer’s solution and spread-plated onto MRS agar medium (pH 6.5). All 
plates were then incubated anaerobically at 37 ºC for 48 hours. The test was done in duplicate 
and duplicate counts were meaned.  The test was repeated three times in separated days.  
 
2.2.2 Investigations into probiotic properties of potentially probiotic enterococci 
 
2.2.2.1 Bacteriocin activity 
A qualitative bacteriocin test, i.e. the ‘sandwich overlay method’ of Mayr-Harting et al. 
(1972) was used to test the antimicrobial spectrum of the bacteriocin-producing, potentially 
probiotic lactic acid bacteria. Three µl of overnight culture of bacteriocin-producing strain 
was spotted onto MRS agar plates and plates were incubated at 37 °C overnight. MRS soft 
agar was inoculated with 100 µl of an overnight culture of indicator bacteria (approx. 1 x 106 
CFU/ml) and overlayered onto MRS plates onto which the bacteriocin producer was spotted. 
The plate was again incubated overnight at 37 °C. A clear zone surrounding the bacteriocin 
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 producer colony after the growth of the indicator strain was considered as bacteriocin-
positive.  
A quantitative bacteriocin test expressed in arbitrary unit (AU) of activity, developed 
by Mayr-Harting et al. (1972), was also used. For this, an overnight culture of the bacteriocin 
producing strain was centrifuged (7 500 rpm, 6 min, 4 °C) to obtain culture supernatant. This 
supernatant was heated at 95 °C for 10 min or filter-sterilized to remove or inactivate 
remaining cells. A 100 µl volume of supernatant was then diluted in a doubling dilution series 
in a microtitre plate, using sterile MRS broth as diluent (pH 6.5). Ten µl of each dilution was 
spotted onto MRS soft agar that was seeded with 1% indicator bacteria and allowed to 
solidify. Plates were incubated anaerobically at 37 °C. Arbitrary activity was determined as 
the reciprocal of the highest dilution that gave a clear inhibition zone, multiplied by a factor of 
100 to obtain AU/ ml.  
 
2.2.2.2 Bile salt hydrolase activity 
The ability of potentially probiotic enterococci (food and human isolates) and also L. sakei Lb 
706 to hydrolyse bile salt was assayed using a plate test. For this, 10 µl of an overnight culture 
was spotted onto MRS agar plates (pH 6.5) containing 0.5% Na-TDCA (taurodeoxycholic 
acid) and 0.37 g/l CaCl2  (Franz et al., 2001). Plates were incubated anaerobically at 37 ºC for 
72 hours. A strain was considered bile salt hydrolase positive if a white zone of precipitation 
occurred which surrounded the colony.  
 
2.2.2.3 Adhesion to mucus-secreting HT-29-MTX cells  
HT-29 MTX cells were cultivated according to Huet et al. (1987) in the absence of 
antibiotics in glucose-free DMEM supplemented with 15% dialysed fetal bovine serum, 4 
mmol L-glutamine/L, and 5 mmol galactose/L. HT-29 MTX enterocytes were seeded at 2 
x104 cells per well (2 cm2) in a 24-well plastic tissue culture dishes and incubated at 37 °C in 
9.5% CO2. These HT-29 cultures become confluent after 5-6 d and were used after 21-24 d 
when these enterocytes were considered polarized and differentiated. Mature HT-29 MTX 
cultures containing ~106 enterocytes per well, were >95% viable as determined 
microscopically using the vital dyes trypan blue (0.36%) and propidium iodide (20 mg/L). 
Enterococci were grown 18 hours in Dulbecco’s MOD Eagles Medium (Life 
Technologies) containing 2% foetal calf serum (FCS) and after growth, cell numbers of 
enterococci were adjusted to log 8.0 cells/ml by using a flow cytometer. One ml of this 
suspension was added to the tissue culture plate well. Plates were centrifuged and incubated at 
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 37 ºC. After 1 h incubation, the monolayers were washed 3 x with sterile phosphate buffered 
saline solution (pH 7.4). Detached bacteria were enumerated by plate counting. HT-29 MTX 
cells were lysed by adding 1% Triton X-100 solution and incubated for 10 min at 37 ºC and 
the cell count (CFU/ml) of adhering bacteria was determined in triplicate.  
 
2.2.2.4 Hydrophobicity 
For hydrophobicity testing, strains were grown in MRS broth at 37 ºC for 18 h. Cells from 5 
ml of culture were collected by centrifugation at 7500 rpm at 4ºC for 6 min. Cells were 
washed twice with quarter-strength Ringers solution, using the same centrifugation conditions 
as described above. The quarter-strength Ringer’s solution containing enterococci cells 
provided the watery suspension. One ml of this suspension was used to determine the OD580. 
In duplicate assessments, a further 1.5 ml of this suspension was added to an equal volume of 
n-hexadecane (organic phase)(Merck) and thoroughly mixed for two minutes using a vortex. 
The phases were allowed to separate at room temperature for 30 min, after which one ml of 
the watery phase was removed and the OD580 was determined. The OD580 of duplicate 
assessments was meaned and used to calculate hydrophobicity. Percentage hydrophobicity 
was calculated as follows: 
(OD580 reading 1 - OD580 reading 2 / OD580 reading 1) x 100 = % hydrophobicity.  
Hydrophobicity determinations were done in triplicate in independent experiments. 
 
2.2.3 Investigations into virulence traits of potentially probiotic enterococci 
 
2.2.3.1  DNAse production 
A loopful of an overnight Enterococcus culture was streaked out onto DNAse test agar 
containing methyl green and plates were incubated at 37 ºC for 24 hours. A clear, pinkish 
zone around the colonies after incubation was considered positive for DNAse production.  
 
2.2.3.2 Production of gelatinase 
Production of gelatinase was determined on Todd-Hewitt agar containing 30 g/l gelatine. Five 
microliter of overnight culture grown in MRS broth was spotted onto the gelatine agar. Plates 
were incubated at 37 ºC for 24 h and cooled for 5 h at 4 ºC. Appearance of a turbid halo 
around the colonies was considered positive for hydrolysis of gelatine.  
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 2.2.3.3 Clumping assay for presence of aggregation substance 
The ability of bacteria to clump in presence of pheromone was investigated. The pheromone 
producer Enterococcus faecalis JH2-2 and a plasmid-free, negative control strain 
Enterococcus faecalis OG1X were used. For the assay, 2 µl of an Enterococcus test strain 
were grown overnight at 37 ºC in Todd-Hewitt broth (THB) were used to inoculate 198 µl of 
THB in a microtiter plate (negative control). Supernatant from an overnight culture of the 
pheromone producer E. faecalis JH2-2 was prepared, autoclaved and diluted 1:5 in sterile 
THB. Two microliter of culture were inoculated into198 µl of this pheromone containing 
broth in a microtiter plate. Microtiter plates were incubated at 37 ºC and inspected for 
clumping on an hourly basis up to eight hours. 
 
2.2.3.4 Adhesion to extracellular matrix proteins 
The ability of enterococci isolates to adhere to rat collagen I and human fibrinogen and 
fibronectin extracellular matrix protein was studied using microtiter plates which were 
commercially coated with either of these proteins. Enterococci were grown 18 h in 
Dulbecco’s MOD Eagles Medium (Life Technologies) containing 2% foetal calf serum 
(FCS). After growth, cell numbers of enterococci were adjusted to log 8.0 cells/ml by using a 
flow cytometer. Microtiter plates were saturated with Dulbecco’s MOD Eagles Medium 
before addition of cells. Enterococci were incubated in coated microtiter plates at 37 ºC for 1 
h to allow binding of cells, after which the number of the adherent bacteria was established 
By removing the suspension and again counting with a flow cytometer and expressed as a 
percentage of the initial inoculum. Results shown are means of duplicate experiments. 
 
2.2.3.5 Haemolysin production 
Human blood (all 4 blood types) was collected, defribinated and added (5%) to Columbia agar 
base. Plates were pre-incubated 3 days to check for sterility. Enterococcus isolates were 
streaked out onto the blood agar, and the plates were incubated at 37 ºC for 48 h after which 
they were checked for zones of α- or β-hemolysis surrounding the colonies. 
 
2.2.3.6 Mucin degradation assay 
Partially purified hog gastric mucin (HGM) Type III (Sigma, Germany) was further 
purified according to Zhou et al., 2001. For this, 10 g of HGM were stirred for 24 h at room 
temperature in 500 ml of 0.1 M NaCl containing 0.02 M phosphate buffer (pH 7.8), and a few 
drops of toluene. The pH of this suspension was readjusted to 7.2 with 2 M NaOH after 1 
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 hour. The mucin preparation was centrifuged (10 000 x g, 4 °C) and the supernatant was 
cooled to 0 + 2 °C and pre-chilled ethanol (pre-chilled at –20 °C) was added to a final 
concentration of 60% (v/v). The resulting precipitate was dissolved in 0.1 M NaCl and 
precipitated with ethanol two more times. The final mucin precipitate pellet was washed once 
with ethanol and then dissolved in and dialysed against distilled water (4 L) for 24 h at room 
temperature with four changes. Dialysed mucin solution was then lyophilized and used as a 
source of purified mucin in all experimentation. The mucin substrate incorporated in culture 
medium was autoclaved before use. 
Purified HGM was incorporated with medium B (see section 2.1.3.13) at 
concentrations of 0.5% (w/v) with and without 3% glucose. The presence of glucose in 
medium B as carbohydrate source affect the mucinolytic activity. Ten microlitres of 24h 
viable bacterial cultures were inoculated onto the surface of the medium contained in a Petri 
dish. The plates were incubated at 37 ºC anaerobically for 72 h and subsequently stained with 
0.1% amido black in 3.5 M acetic acid for 30 min. They were then washed with 1.2 M acetic 
acid until the mucin lysis zone (discoloured halo) around the colony of positive control 
cultures (faecal flora obtained from male Fischer rat faeces) appeared. The mucin degradation 
activity was defined as the size of the mucin lysis zone.  
 
2.2.3.7 Antibiotic resistance 
Antibiotic susceptibility was tested using the E-test (Viva Diagnostika, Cologne, Germany). 
Commercial Mueller–Hinton agar (see 2.1.2.10) plates (Becton Dickinson, Heidelberg, 
Germany) For preparation of the inoculum opf the test strain, the entrococci were streaked out 
for single colonies on MRS agar plates and plates were incubated at 37°C for 48 hours. 
Individual colonies were resuspended in 5 ml quarter-strength Ringers solution to a density of 
0.5 on the McFarland scale. The Mueller-Hinton II agar plates were seeded with enterococci 
using a cotton swab. Plates were incubated at 37ºC and results were read after 48 h incubation 
according to the E-test manufacturer’s intructions. The antibiotics used included: ampicillin 
(0.016 to 256 µg/ml); benzylpenicillin (0.002 to 32 µg/ml); chloramphenicol (0.016 to 256 
µg/ml); tetracycline (0.016 to 256 µg/ml); erythromycin (0.016 to 256 µg/ml); ciprofloxacin 
(0.002 to 32 µg/ml); streptomycin (high range, 0.064 to 1024 µg/ml); and gentamicin (high 
range, 0.064 to 1024 µg/ml).  
The minimum inhibitory concentration (MIC) value determination was based on the 
reference agar dilution method described in ‘performance standards for antimicrobial 
susceptibility testing’, ninth informal supplement, National Committee for Clinical 
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 Laboratory Standards (NCCLS), Vol. 19 (10), 1999. Resistance was intrepreted according to 
the breakpoint values supplied in this document for enterococci, i.e., resistance to ampicillin, 
penicillin and tetracycline at a minimum inhibitory concentration (MIC) of ≥ 16 µg/ml; 
chloramphenicol and vancomycin, MIC of ≥ 32 µg/ml; erythromycin, MIC ≥ 8 µg/ml; 
ciprofloxacin, MIC ≥ 4 µg/ml; high level gentamicin MIC > 500 µg/ml; and high level 
streptomycin, MIC> 1000 µg/ml.  
 
2.2.3.8 PCR amplification of virulence factors 
The genetic determinants for the enterococcal virulence factors AS (aggregation substance), 
Esp (enterococcal surface protein), Ace (adhesin to collagen from E. faecalis), gel (gelatinase) 
and Cyl (cytolysin) were amplified from the DNA of the potentially probiotic enterococci 
strains by PCR using primers specific for these genes (Table 6). The PCR reactions all 
contained 10 ng template genomic DNA, 200 µM desoxyribonucleotide triphosphates 
(dNTPs), 25 pMol of each primer (Table 6), 1 x Taq polymerase buffer (Pharmacia, Freiburg, 
Germany) and 1.5 U of Taq polymerase (Pharmacia). PCR conditions and primers for 
amplification of the virulence genes are shown in Table 6. As a positive control, the DNA of 
an Enterococcus strain known to be positive for the virulence trait was used. The PCR 
products were run on 1.5% agarose gels and photographed under UV light. 
 
Table 5: Primers and amplification conditions used for PCR amplification of 
enterococcal virulence genes. 
 
Virulence 
factor 
Primer sequences  PCR amplification 
conditions (for all 35 
cycles) 
Size of 
amplification 
product 
Esp 5’-TTG CTA ATG CTA GTC CAC GAC C-3’ (forw) 
5’-GCG TCA ACA CTT GCA TTG CCG AA-3’ (reva) 
94 °C, 1 min; 61 °C, 
1 min; 72 °C, 1.5 min 
900 bp 
Ace 5’-GAA TTG AGC AAA AGT TCA ATC G-3’ (forw) 
5’-GTC TGT CTT TTC ACT TGT TTC-3’ (rev) 
94 °C, 1 min; 54 °C, 
1 min; 72 °C, 1 min 
960 
a forw = forward (sense) primer, rev = reverse (antisense) primer 
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 2.2.4 Cloning of a bile salt hydrolase gene from Enterococus faecium FAIR E-345 
Genomic DNA from Enterococus faecium FAIR E-345 was isolated according to the 
methods of Pitcher et al. (1989). For this, 5 ml of an overnight culture of E. faecium FAIR-E 
345 grown in MRS broth at 37°C was centrifuged at 13 000 x g (6 min, 4 °C). The cell pellet 
was resuspended in 1.5 ml of TE solution which contained 0.5% NaCl and the suspension was 
centrifuged again (13,000 x g, 6 min, 4 °C). The cell pellet was then resuspended in 100 µl of 
TERLMS solution and incubated at 37 °C for 1 h for lyser to occur. For removal of protein, 
500 µl GES solution was added. The tube was inverted until lysis was observed. The sample 
was cooled on ice for 5 min and after that 250 µl of cold 7.5 ammonium acetate was added. 
The sample was mixed and cooled on ice for 10 min, after which a 0.5 ml volume of 
chloroform-2-pentanol (ratio 24:1) was added. The phases were mixed thoroughly by shaking 
vigorously and the mix was centrifuged (13 000 x g, 10 min, 4 °C). The upper aqueous phase 
was transferred to a new 1.5-ml Eppendorf tube using a Pasteur pipette. Cold  (-20 °C) 2-
propanol was added (0.54 volume)  and the tube was inverted until the DNA precipitated. The 
precipitate was centrifuged (13 000 xg, 6 min, 4 °C) and the aqueous solution was aspirated. 
The DNA pellet was washed to remove salt with 500 µl of 70% ethanol. The washing step 
(centrifugation at 13 000 x g, 6 min, 4 °C) was repeated 2 times. The DNA pellet was dried in 
a vacuum concentrator for 5 to 10 min and the dried DNA pellet was then dissolved in 150 µl 
of TE solution overnight at room temperature and then stored at 4 °C.   
Genomic DNA was partially digested with Sau3AI (New England Biolabs, Frankfurt 
am Main, Germany) and subjected to electrophoresis on a 1.5% agarose gel. Following 
electrophoresis, fragments of various sizes (1.5-2.5 kb, 1.5-3.0 kb, 2.5-4.0 kb, 2.5-4.5 kb and 
4.5-6.0 kb) were extracted directly from the agarose gel using the QIAEX II gel extraction kit 
(Qiagen, Hilden, Germany). Vector pSKII+/- was digested with BamHI and dephosphorylated 
using calf intestinal phosphatase (New England Biolabs). The vector was ligated to the DNA 
fragments and ligated constructs (1.2 µl) were used for electrotransformation into 
electrocompetent E. coli TOP10 cells (Invitrogen, Groningen, the Netherlands) at 2.5 kV, 
200Ω reistance and 25 µF capacitance. Transformed cells were incubated for 1 h in SOC 
solution (Sambrook et al., 1989) and spread-plated onto Luria Bertani (LB) agar containing 
X-Gal and IPTG at standard concentrations (Sambrook et al., 1989) and 150 µg/ml ampicillin. 
Plates were incubated at 37ºC overnight. Colonies containing an insert were selected by α-
complementation and replica-plated onto LB agar and LB-based differential medium as 
described by Christians et al. (1992), to detect BSH-positive clones. The plates were 
incubated anaerobically at 37 ºC for two days and the presence of a white zone of 
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 precipitation around around the colony on differential medium was indicative of BSH activity 
(Christians et al., 1992). 
 Plasmid pAW01 isolated from a BSH-positive clone was isolated using the QIAGEN 
plasmid midi kit (Qiagen, Hilden, Germany) and used for DNA sequencing. It contained a 3-
kbp insert that was sequenced bi-directionally using M13 universal and custom made primers 
in a primer walking strategy. Sequencing was done at MWG Biotech (Ebersfeld, Germany) 
and GATC (Konstanz, Germany). The DNA sequence was analyzed using the DNASTAR 
programme. Homology searches of the amino acid sequence to known protein sequences in 
the databanks was done using the BlastX search of the National Center of Biotechnology 
Information (NCBI). BSH homology determinations were done by cluster of amino acid 
sequences contained in the GenBank databank using the DNASTAR program.  
  
 
 
2.2.5 Preparation of a BSH gene probe and determination of the genomic location of 
the bsh gene in BSH-positive enterococci 
2.2.5.1 Preparation of the gene probe and isolation of plasmid and total genomic DNA 
of BSH-positive enterococci 
The bsh gene was PCR amplified using primers Aw-01 (5‘-TAT ATC TAG AGG AGT AAT 
ATG AAC GTG GA-3‘) and primer Aw-02 (5‘- TAT AGC ATG CAA ATA ATC AAT CAC 
AAC ACA C-3‘) complementary to the 5‘ and 3‘ ends of this gene in pAW01, respectively, 
and contained XbaI and SphI restriction enzyme sites (underlined). DNA was amplified in a 
50 µl volume and the PCR mixture contained 100 ng of template DNA, 200 µM concentration 
of dNTP’s, 25 pMol of each of the respective primers, 1 U Taq DNApolymerase (Amersham 
Pharmacia, Freiburg, Germany), and 1X reaction buffer (Amersham Pharmacia). DNA 
amplification was done in 32 cycles (denaturation, 1 min at 94 °C; annealing, 1 min at 52°C, 
extension, 1 min at 72°C). The resulting PCR fragment was cloned into the XbaI and SphI 
sites of plasmid pUC19, resulting in plasmid pAW02. Plasmid pAW02 was digested with the 
restriction enzyme XbaI to linearize the plasmid and DIG labeled using the DIG dUTP 
labeling and detection kit (Roche, Mannheim, Germany) according to the manufacturer‘s 
instructions.  
Plasmid DNA was isolated from BSH-positive enterococci isolated from food (Franz 
et al., 2001) for determination of the genomic location of BSH genes among these strains. 
These food enterococcal strains investigated by Franz et al. (2001) were used, because the 
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 potentially probiotic strains subject of this study did not contain plasmid DNA. Plasmid DNA 
was isolated according to methods of van Belkum and Stiles (1995). Briefly, 5.0 ml of 
overnight culture was centrifuged at 7 500 rpm for 6 min at 4 °C to harvest the cells. The cell 
pellet was washed with 1.5 ml of TE solution containing 0.5% NaCl and this suspension was 
transfered to an Eppendorf tube and centrifuged (7,500 rpm, 5 min, 4 °C). Supernatant was 
removed and the cell pellet was resuspended with 100 µl of TELS solution. This suspension 
was incubated at 37 °C for 1 h. A 200 µl volume of fresh lysis solution  was added and mixed 
until the suspension was clear. Then 150 µl volume of 3 M potassium acetate, pH 5.0 was 
added and mixed. After incubated on ice for 12 min, the suspension was centrifuged (14 000 
rpm, 10 min, 4 °C) and the supernatant was transfered to a new sterile Eppendorf tube. For the 
phenol/chloforom purification, 200 µl phenol was added to supernatant. This suspension was 
mixed and 200 µl chloroform was added. The suspension was then mixed and centrifuged (15 
000 rpm, 10 min, 4 °C). The supernatant was removed to a new Eppendorf tube, after which 
200 µl chloroform:isoamyl alcohol (24:1) was added. The suspension was centrifuged (15,000 
rpm, 6 min, 4 °C) and the supernatant was removed. A 1/10 volume of 3 M sodium acetate 
and 2x volume of 95% ethanol were added to the supernatant to precipitate the DNA at –20 
°C overnight. The sample was then centrifuged (15 000 rpm, 8 min, 4 °C) and the DNA pellet 
was washed with 70% ethanol and dried for 5 to 10 min in a vacuum drier and resuspended in 
10 µl TE containing RNAse (20 µg/ml). The suspension was gently mixed and finally 
incubated at 37 °C for 20 to 30 min.  
Total genomic DNA was isolated using the methods of Pitcher et al. (1989) as 
described above. Total genomic DNA was digested with XbaI and HindIII and subjected to 
electrophoresis using a 1.4% agarose gel. Plasmid DNA was subjected to electrophoresis on 
these agarose gels without restriction enzyme cutting. DNA was transferred to Hybond N+ 
membrane by Southern blotting according to standard techniques (Sambrook et al. 1989) and 
the DIG-dUTP-labeled probe was used to detect the location of the bsh gene according to the 
DIG dUTP manufacturer‘s (Roche) instructions. Prehybridization was done at 65°C for 4 
hours, while hybridization was done at 60-70 °C overnight (methods see below).  
 
2.2.5.2 Southern hybridization 
The isolated plasmid and total genomic DNA was separated on a 1% agarose gel in 
TBE buffer (Sambrook et al. 81989) at 100 V for 3 h. The position of the gel pockets and the 
plasmid bands on the gel was marked by placing cellophane paper over the gel, inspecting the 
gel under UV light, and marking these positions with a marker before the gel was soaked in 
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 0.25 M HCl for 5 min. The gel was then washed with bidest water and soaked in denaturing 
solution for 30 min. After this, the gel was soaked in transferring solution for 30 min. The 
dimension of the gel was measured and a piece of nylon blotting paper and two pieces of 
Whatman paper were cut according to it’s size. DNA was transferred using a transfer box 
containing transferring solution overnight at room temperatureas as described in Sambrook et 
al. (1989). After transferring and removal of the gel, the gel pocket and the corners of gels 
were marked on the nylon membrane. The membrane was rinsed in 2x SSC and dried at room 
temperature and baked in oven at 80 °C for 2 h.  
For prehybridization, the membrane was placed in plastic bag and prehybridization 
solution was added and then sealed. Prehybridization was conducted at 65 °C for 4 h in 
hybridization chamber (Amersham Pharmacia Biotech, Freiburg, Germany). For 
hybridization, the DNA probe was boiled for 5 to 10 min and immediately cooled in ice slush. 
Prehybridization solution from the bag was poured off and the membrane in the bag was put 
on ice. The probe was added and the bag was quickly sealed. Hybridization was done in 
hybridization chamber at 60-70 °C overnight. After prehybridization, a corner of the bag was 
cut and probe was removed for reuse with Pasteur pipette. The membrane was washed 2 times 
(each time 5 min at room temperature) with washing buffer 1 (see 2.1.7.1) and 2 times (each 
time 15 min at 68 °C) with washing buffer 2 (see 2.1.7.2). The membrane was then dried 
before being equilibrated in buffer 1 for 1min. Subsequently, blocking was done for 30 min in 
buffer 2 at room temperature and the membrane was slowly shaken on shaking platform. The 
membrane was then washed for 1 min in buffer 1 and anti-DIG antibody-conjugate was 
added. Incubation was at room temperature for 30 min. The membrane was then washed 2 
times in buffer 1, each time for 15 min before being equilibrated 2 min with buffer 3 (see 
2.1.7.3). The colour solution (200 µl NTB/BCIP in 10 ml volume of buffer 3) was added and 
the bag was sealed before being put in the dark to allow to develop. After the signals were 
detected, the reaction was stopped by washing the membrane with distilled water.  
 
2.2.6 Animal experiment 
2.2.6.1 Experimental rats 
Thirty six male Sprague-Dawley rats were weighed and acclimatized for 1 week. Two rats 
were housed per cage with wooden granulate bedding and received tap water ad libitum, with 
light and dark periods for 12 hours, and fed once a day with Basal Diet Altromin C 1000. 
After this period, rats were housed individually and divided into 4 groups: 
 
 50
 • Group A (Control 1, n = 6, Diet Altromin C1000) 
•  Group B (Control 2, n = 6, Diet Altromin C1000 + heat inactivated 1% Enterococcus 
faecalis BFE 1071 Biomass) 
•  Group C (n = 12, Diet Altromin C1000 + 1% Enterococcus faecalis BFE 1071 
Biomass) 
•  Group D (n = 12,  Diet Altromin C1000 + 1% Enterococcus faecalis BFE 1071/79 (-) 
Biomass). 
Diet treatments were given to rats once a day at 20 g at 9:00 a.m. Faecal samples were 
collected 4 hours after feeding time and pre-diluted 10 times with reduced Brain Heart 
Infusion Broth (see 2.1.2.11), homogenised with stomacher for 1 min, and stored at -20 °C. 
The experiment was conducted for 8 days and after that all the rat groups were fed with basal 
diet.  
 In the first week of the animal experiment (Day1 to 7) no animals were sacrificed. At 
certain intervals, the rats were sacrificed after day 7 and their organs (caecum, small and large 
intestines) were removed and stored at –80°C for future use (see Table 4). Analysis of the 
microflora of the organs was, however, not subject of this study. The intervals in which rats 
from which groups were sacrificed is given in Table 4 below. The number of rats in the 
different groups were minimized by the animal welfare expert to minimize the number of 
animals which had to be put to death. Permission for the animal experiments was obtained 
from the local ethics committee and the animal experiments were done under the guidance, 
supervision and participation of an experienced animal expert and animal caretaker. 
 
Table 6: Time plan for sacrifice of animals in probiotic feeding experiment. 
 
Experimental animal group (see above) No. of animals/ 
sacrificed animals group A group B group C group D 
total no. of live animals 
at start of experiment 
(day 1) to day 7 of 
experiment 
6 6 12 12 
No. of animals 
sacrificed on day 8 
2 6 0 0 
No. of animals 
sacrificed on day 9 
0 0 6 8 
No. of animals 
sacrificed on day 10 
0 0 6 4 
No. of sacrificed 
animals on day 11 (end 
of experiment) 
0* 0 0 0 
*Animals were kept for other experimental purposes  which were not part of this study. 
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 2.2.6.2  Preparation of feed 
Biomass from Enterococcus faecalis BFE 1071 and Enterococcus faecalis BFE 1071/79(-) 
were prepared as follows: The culture was prepared by inoculating 1% overnight culture in 1L 
MRS broth (pH 6.5) and incubated overnight in shaking incubator (37 °C, 100 rpm). Cells 
were harvested by centrifugation (7 500 rpm, 6 min, 4 °C) and resuspended with 10 % skim 
milk solution (20 ml/L culture). This suspension was then frozen at -80 °C and freeze-dried 
for 3 days. This freeze-dried biomass was stored at –20 °C. Average cell counts for 
Enterococcus faecalis BFE 1071 and Enterococcus faecalis BFE 1071/79 (-) were 3.6 x 1011 
and 1.9 x 1011 CFU/g, respectively with end cell counts after being mixed with diet Altromin 
C100 (each 1%) were 3.6 x 109 and 1.9 x 109 CFU/g, respectively. 
 
2.2.6.3 Isolation of bacteria isolated from rat faecal samples 
Faecal samples were diluted 10 times with reduced brain heart broth and homogenized with a 
stomacher for 1 min before being stored at -20°C. Samples were subjected to a serial ten-fold 
dilution series (10-1 to 10-8) in quarter-strength Ringer’s solution and plated onto selective 
media using the drop plate method using a µl volume.  
Eight bacterial groups were isolated from faecal samples with selective media. Gram-
positive anaerobic cocci were isolated on Bacto Azide agar base supplemented with 5% sheep 
blood clostridia on DRCM agar, Bacteroides and Fusobacteria on Schaedler agar 
supplemented with 5% horse blood, lactobacilli on Rogosa Agar, enterococci on Kanamycin 
Aesculin Azide Agar (see section 2.1.3.7.), Enterobacteriaceae on VRBD agar, bifidobacteria 
with Bifidobacteria agar (see section 2.1.3.9.), and a total count was assessed on Columbia 
agar supplemented with 5% sheep blood. All plates were incubated anaerobically at 37 °C for 
3 to 5 days. All counts were done in duplicate.  
 
2.2.6.4 Presumptive identification of lactobacilli and enterococci from rat faeces by 
phenotypic tests 
Two dominant colonies from the Rogosa and Kanamycin Aesculin Azide Agar plates of the 
highest dilution factor were picked and streaked out onto MRS agar plates (pH 6.5) several 
times until the single, pure colonies were obtained. This was done from plates for using cell 
counts from faecal samples of all the animals in each of the four experimental groups. These 
isolates were kept in cryo vials containing 15% glycerol at –80 °C for further identification. 
Phenotypic tests for the presumptive identification of strains belonging to the genus 
Enterococcus, included determinations of cell morphology by phase contrast microscopy, 
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 catalase test, gas production from glucose, growth in 6.5% NaCl, growth at pH 9.6, and 
growth at 45 °C. In addition fermentation of the sugars raffinose, mannitol, arabinose and 
sorbitol was tested to presumptively identify the enterococci to species level. Phenotypic tests 
for the presumptive identification of strains belonging to the genus Lactobacillus, isolates 
included determination of cell morphology by phase contrast microscopy, catalase test, gas 
production from glucose, growth at 15 and 45 °C, determination of meso-diaminopimelic acid 
in the cell wall and determination of the enantiomer of lactic acid produced.  
 
 
2.2.6.5 Genotypic identification 
2.2.6.5.1 Random Amplified Polymorphic DNA (RAPD)-PCR fingerprinting 
Total genomic DNA from enterococci and lactobacilli were isolated using method from 
Pitcher et al. (1993). The concentration of this genomic DNA was adjusted to 100 ng/µl in 
bidest water for use as template in amplification with RAPD-PCR. DNA was amplified in 50 
µl volumes containing 100 ng template DNA, 200 µM dNTPs, 50 pM of primer M13, 2.5 U 
Taq DNA polymerase (Amersham Pharmacia, Freiburg, Germany ) and 1 x Taq polymerase 
buffer. The concentration of MgCl2 in this buffer was adjusted to 3 mM. The primer sequence 
and PCR conditions used were: M13 (5’-GAG GGT GGC GGT TCT-3’) (Huey and Hall, 
1989); 35 cycles of: 94°C for 1 min, 40°C for 20 sec, ramp to 72°C at 0.6°C s-1, 72°C for 2 
min. 
PCR products were separated by electrophoresis on a 1.8% (w/v) agarose gel at 48 V for 
16 h using 1 x TBE buffer (Sambrook et al., 1989). The gels were stained in ethidium 
bromide and photographed on an UV transilluminator. Photo-positives were digitalized by 
scanning and scanned images were normalised and subsequently analysed using the 
Bionumerics (version 2.5) software (Applied Maths, Kortrijk, Belgium). Groupings of the 
RAPD-PCR fingerprints was performed by means of the Pearson product moment correlation 
coefficient and the unweighted pair group with mathematical average (UPGMA) clustering 
algorithm.  
 
 
2.2.6.5.2 Species-specific PCR 
Lactobacillus isolates which were presumptively identified as belonging to the L. 
acidophilus group (catalase-negative, homofermentative, growing at 45 but not at 15°C 
producing DL-lactate) were subjected to group-specific PCR according to the methods of Roy 
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 et al. (2001) to confirm this presumptive identification. The group specific PCR utilises 
primers that target variable regions of the 16SrDNA which are specific for the L. acidophilus 
group. The L. acidophilus group consists of the closely related species L. acidophilus, L. 
crispatus, L. johnsonii, L. gasseri, L. gallinarum and L. amylovorus. The primers used in this 
study targeted the whole group and individual species can not be discerned. Thus, using 
primer combination LBL R1 and Lho the species L. acidophilus, L. gallinarum, L. crispatus 
and L. amylovorus were amplified. these primers do not amplify the 16S rDNA region of L. 
gasseri and L. johnsonii. For specific amplification of the L. gasseri/johnsonii species, the 
primers Lgj/LBL R1 were used. the DNA sequence of these primers is shown below: 
 
Primer LBL R1:  5’ - CCA TGC ACC ACC TGT C-3’ 
Primer Lgj:  5’- ACA CTA GAC GCA TGT CTA-3’ 
Primer Lho:  5’- CTG GGA TAC CAC TT-3’ 
 
The PCR reaction mixture consisted of 100 ng of total genomic DNA of the test strain as 
template, 200 µM dNTPs, 25 pMol of each primer, 1 x Taq polymerase buffer and 1 U of Taq 
polymerase (Amersham Pharmacia). PCR amplification was done for 35 cycles at the 
following conditions: 94 °C for1 min, 50 °C for 1 min and 72 °C for 1.5 min for both 
reactions, i.e with primer LBL R1/Lgj or LBL R1/Lho. PCR products were subjected to 
electrophoresis in 1.0% agarose gels for 2 hours at 100V in TBE buffer (Sambrook et al., 
1989). Thus all strains that were presumptively identified as belonging to the L. acidophilus 
group were subjected to group-specific PCR twice, i.e., once with each different primer 
combination.  
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3.0 RESULTS AND DISCUSSION 
 
3.1 Technological and functional properties of potentially probiotic lactic acid 
bacteria 
3.1.1 Technological properties 
3.1.1.1 Acid and bile tolerance 
Studies on acid resistance and bile tolerance were done in vitro to assess the ability of 
potential probiotic lactic acid bacteria to survive transit the stomach and conditions 
encountered in the small intestine. These studies were done using fifty-five enterococci strains 
isolated from food as well as the bacteriocin-producing strains Enterococcus faecalis BFE 
1071 (produces enterocin 1071), it’s mutant Enterococcus faecalis BFE 1071/79(-), the 
enterocin A and B producer Enterococcus faecium BFE 900 and the sakacin A producer L. 
sakei Lb706 in the investigation. Thus a large amount of bacteria, mostly enterococci, were 
tested, in order to compare their acid resistance and bile tolerances relative to the bacteriocin-
producing strains, and thus obtain a measure for the latter’s ability to survive acid and bile 
stress. The capability of bacteria to survive acid conditions in the in vitro gastrointestinal 
model of this study were arbitrarily defined as not resistant (survival of <50% of cells), 
weakly resistant (survival of 50-75% of cells), moderately resistant (survival of 75-90% of 
cells), and strongly resistant (>90% survival of cells). 
 With the exception of E. faecalis FAIR-E 115 and E. malodoratus FAIR-E 169, all 
strains survived at a level of more than 50% of the initial inoculum in MRS broth at pH 3.0 
and may thus be considered acid resistant (Table 7). For E. faecium 48,8% (21 of 43 strains), 
while for E. faecalis 46,5% (20 of 43 strains) were strongly resistant to this low pH, 
respectively. Thus, for just under half of the strains of these two species, more than 90% of 
cells survived more than one hour’s exposure to this low pH. This exemplifies that 
enterococci are actually quite acid resistant. This feature, together with the heat resistance and 
salt tolerance of enterococci, is well known for these bacteria and is one of the reasons often 
cited for the robust nature of these bacteria (Franz et al., 1999; Giraffa et al., 2003). This 
resistance of low pH was also expected for enterococci, as these bacteria naturally occur in 
the gastrointestinal tract, or can be transmitted from environmental sources or food sources to 
the human gastrointestinal tract (Van den Bogaard et al., 1997; Berchieri, 1999; Stobberingh 
et al., 1999; Gelsomino et al., 2003).  
The non-bacteriocin producing, probiotic enterococci candidates from food (see 
Materials and Methods Table 4) all exhibited either strong (FAIR-E 6, 9, 243, 345, 349, 365) 
or moderate (FAIR-E 15, 210) acid resistance (Table 7). As future potential probiotic 
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candidates, these acid resistance point towards the fact that these strains would probably 
survive stomach passage. In addition, a probiotic control strain E. faecium SF68 (deposited in 
the FAIR-E culture collection as FAIR-E 24) also showed strong acid resistance. 
Interestingly, the bacteriocin-producers E. faecalis BFE 1071 and L. sakei Lb706 showed a 
weak resistance to low pH, while E. faecium BFE 900 and the E. faecalis BFE 1071/79(-) 
showed a strong resistance to low pH (Table 7). Nevertheless, this means that these 
bacteriocin-producing strains could all be expected to survive the low pH conditions of the 
stomach to some extent in an animal feeding experiment. It is unclear why the E. faecalis 
mutant was more acid resistance than the wild-type strain. Speculatively, loss of the plasmid 
in the mutant may be energetically favourable for the mutant, in that it does not need to spend 
energy in plasmid replication functions and bacteriocin production which require ATP. This 
may mean, that the strain is more capable to withstand adverse conditions and can spend 
energy in protection of the cell by increased production of acid shock proteins involved in the 
stress response (Abee and Wouters, 1999). 
 
Table 7: Survival of enterococci strains in presence of hydrochloric acid at pH 3.0. 
 
Acid tolerance Strains 
not resistant weak resistance Moderate resistance strong resistance
E. durans - FAIR-E140, 357 FAIR-E1, 231, 251, 
364 
FAIR-E2, 326, 
332, 373 
E. faecium - FAIR-E41, 118, 
119, 121, 128, 
131, 132, 133, 
401, 402, 403  
FAIR-E13, 14, 15, 
80, 129, 130, 189, 
210, 396, E398, 
399  
FAIR-E3, 6, 9, 
24, 38, 40, 83, 
120, 134, 135, 
137, 171, 243, 
345, 349, 365, 
394, 395, 397, 
400,  
BFE 900 
E. faecalis FAIR-E115 FAIR-E82, 109, 
111, 112, 116, 
183, 186, 188, 
193, 224, 235, 
236,  
BFE 1071  
FAIR-E39, 69, 124, 
125, 185, 191, 302, 
307, 313  
FAIR-E71, 88, 
108, 113, 114, 
117, 122, 123, 
184, 190, 192, 
237, 279, 292, 
315, 339, 363, 
385, 404,  
BFE 1071/79(-) 
Others E. malodoratus 
FAIR-E169 
L. sakei Lb 706 E. casseliflavus 
FAIR-E230 
- 
 
 56
The bile tolerance and tolerance to duodenum secrete of enterococci is shown in Table 8. This 
tolerance was assessed by viable counts after 2 hours of anaerobic incubation following bile 
and duodenum secrete addition. A strong bile and duodenum secrete tolerance in this study 
was arbitrarily defined as survival of more than 5% of cells of the initial inoculum, while a 
moderate tolerance was defined as 2.5 to 5 % survival of cells. A weak tolerance was defined 
as survival of 1-2.5% of cells of the initial inoculum and a negative result implied failure to 
grow after bile and duodenum juice treatment. In contrast to acid resistance (Table 7), only 1 
E. durans strain, 28 E. faecium strains, and 2 E. faecalis strains, including the bacteriocin 
producing E. faecalis BFE 1071, were weakly, moderately or strongly tolerant against 
physiological bile salt and duodenum juice concentrations as used in this study (Table 8). 
Therefore, E. faecium strains seem to be more tolerant to bile and duodenum juice than E. 
faecalis strains.  
 
Table 8: Survival of enterococci strains in presence of physiological concentrations of 
bile and artificial duodenum secrete in an intestinal tract model. 
 
Bile and duodenum secrete tolerance Strains 
negative weak Moderate strong 
E. durans FAIR-E 1, 2, 140, 231, 251, 
326, 332, 357, 373 
FAIR-E 364 - - 
E. faecium FAIR-E 3, 24, 40, 41, 83, 
121, 130, 131, 132, 134, 135, 
137, 189, 400, BFE 900 
FAIR-E 38, 
129, 133, 396, 
401, 402, 403, 
FAIR-E 9, 13, 
80, 118, 119, 
128, 210, 243, 
349, 395, 399,  
FAIR-E 6, 
14, 15, 120, 
171, 345, 
365, 394, 
397, 398,  
E. faecalis FAIR-E 39, 69, 71, 82, 88, 
108, 109, 111, 112, 113, 114, 
115, 116, 117, 122, 123, 124, 
125, 183, 184, 186, 188, 190, 
191, 192, 193, 224, 235, 236, 
237, 279, 292, 302, 307, 313, 
315, 339, 363, 385, 404, BFE 
1071/79(-) 
FAIR-E185,  
BFE 1071 
- - 
Others E. malodoratus FAIR-E169,  
E. casseliflavus FAIR-E230, 
Lactobacillus sakei Lb 706 
- - - 
 
Bile and small intestine secrete tolerance: 
> 5% survival : +++ (strong) 
2.5-5% survival : ++   (moderate 
1-2.5% survival : +     (weak) 
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Thus 23.3% of E. faecium strains in this study showed a strong tolerance to bile and 
duodenum secrete at the conditions used in this study. These strains, including the two weakly 
tolerant E. faecalis strains BFE 1071 and FAIR-E 185 thus have desirable properties for 
probiotics from a technical point of view. The other potential future E. faecium probiotic 
candidates, which do not produce bacteriocin (see Table 4), all showed either a moderate 
(FAIR-E 9, 210, 243, 349) or strong (FAIR-E 6, 15, 345, 365) tolerance to bile and duodenum 
secrete (Table 8). This implies, that these strains are probably well suited to survive 
conditions in the small intestinal tract.  
Once bacteria reach the small intestinal tract, their ability to survive depends on their 
resistance to bile (Gilliland, 1987). Bile entering the duodenal section of the small intestine 
was found to reduce survival of bacteria. This is probably due to the fact that all bacteria have 
cell membranes consisting of lipids and fatty acids which are very susceptible to destruction 
by bile salts which have detergent characteristics. Hence, the success of a probiotic also 
depends on the selected strain possessing bile-resistance qualities (Jin et al., 1998).  
However, the bile concentration used in this study was very high, i.e. 10%. Although 
this was a physiological concentration, bile in the gastrointestinal tract is usually secreted 
following a meal and then concentrations decrease, as the bile is re-absorbed from the small 
intestine. In other words, the bile concentration in the small intestine does not remain at the 
constant high concentration as used in this experimental model. Consequently, moderately 
and highly tolerant enterococci, including the bacteriocin-producer E. faecalis BFE 1071 in 
this study, can be considered to be very tolerant to bile and duodenum secrete and probably 
would be well equipped to survive actual bile and duodenal secrete stress in the 
gastrointestinal tract. The failure of other enterococci and bacteriocin-producing strains to 
survive the bile and duodenum secrete in this study, however, does not imply that these 
organisms could not survive actual bile and duodenum secrete stress in vivo, as the conditions 
used in the in vitro study probably underestimated in vivo tolerance. To demonstrate this 
point, the successful probiotic for human and animal use, E. faecium SF 68 (FAIR-E 24), was 
not resistant to conditions of bile and duodenal secrete used in this study (Table 8). 
Nevertheless, it is well known that this strain survives gastrointestinal passage and is 
metabolically active in the gastrointestinal tract of the pig (Havenaar and Huis in ‘t Veld, 
1993). 
Enterococci are well known to be commensals of the gastrointestinal tract of human 
and animals, and in this ecological niche, these bacteria come into contact and interact with 
bile salts. Thus, it is not surprising when enterococci are resistant to bile acid (Franz et al., 
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2001). However, probiotic bacteria vary considerably in their levels of bile tolerance. The 
mechanism of tolerance is not understood and the minimum acceptable level of bile tolerance 
for a candidate probiotic remains unknown (Klaenhammer and Kullen, 1999). The fact that 
relatively many enterococci strains were bile tolerant in this study, showed that these strains 
probably have a high chance to survive in gastrointestinal tract.  
 
3.1.2 Functional properties of potentially probiotic lactic acid bacteria 
3.1.2.1 Bacteriocin production  
Bacteriocin production of probiotic strains was suggested to be one of the functional traits of 
probiotics. As this investigation concerned the influence of a bacteriocin-producing strain on 
the microflora of the rat gastrointestinal tract, we investigated the activity spectra of three 
potentially probiotic bacteriocin-producing strains against indicator bacteria which typically 
are associated with this environment.  
Activity spectra of bacteriocins produced by E. faecalis BFE 1071, it’s bacteriocin-
negative E. faecalis BFE 1071/79(-) (used as negative control), L. sakei Lb706 and E. faecium 
BFE 900 are presented in Table 9. E. faecalis BFE 1071 showed bacteriocin activity against 
six Lactobacillus acidophilus strains, two strains of L. crispatus (20584 and NCFB CHN-1-4) 
and L. gallinarum DSM 10532 and NCFB 2235, as well as L. gasseri P79 and L. fermentum 
DSM 20852 (Table 9). As expected, the bacteriocin-negative mutant Enterococcus faecalis 
BFE 1071/79(-) showed no bacteriocin towards any of the indicators. Enterococcus faecium 
BFE 900 showed antimicrobial activity only against L. gallinarum NCFB 2235, while L. sakei 
Lb706 inhibited L. acidophilus NCFB 1417 and NCFB 104 (Table 9).   
Enterocococus faecalis BFE 1071 produces 2 antimicrobial peptides called enterocin 
1071A and enterocin 1071B. These peptides are heat resistant (100 °C, 60 min), remain active 
after 30 min of incubation at pH 3 to 12, and are sensitive to treatment with proteolytic 
enzymes, namely to α-chymotrypsin, papain, pepsin, pronase, proteinase K, and trypsin 
(Balla et al., 2000). In this study E. faecalis BFE 1071 inhibited lactobacilli that are typically 
associated with the gastrointesinal tract, i.e. L. acidophilus, L. crispatus, L. gasseri, L. 
gallinarum, and Lactobacillus fermentum strains (Reuter, 2001). In addition, Balla et al. 
(2000) showed that E. faecalis BFE 1071 inhibited the growth of selected Enterococcus spp., 
Lactobacillus salivarius subsp. salivarius, and a few other Gram-positive bacteria such as, 
,Peptostreptococcus aerogenes, Streptococcus agalactiae, Listeria innocua and Clostridium 
tyrobutyricum.  
 
 59
Table 9: Activity spectra of bacteriocins from E. faecalis BFE 1071, L. sakei Lb 706, 
and E. faecium BFE 900. The bac- negative mutant E. faecalis BFE 1071/79(-) 
served as negative control, and showed no bacteriocin antagonism against any 
of the indicator strains. 
 
Diameter of inhibition zone (mm) produced by bacteriocin-
producing strain 
Indicator bacteria 
E. faecalisBFE 1071 E. faecium BFE 900 L. sakei Lb706 
L. acidophilus DSM 20242 
L. acidophilus NCFB 1360 
L. acidophilus NCFB 1417 
L. acidophilus NCFB 2261 
L. acidophilus NCFB 2658 
Lb. acidophilus NCFB 2660 
Lb. acidophilus NCFB 2662 
Lb. acidophilus NCFB 2663 
Lb. acidophilus NCFB 2473 
Lb. acidophilus NCFB 2745 
Lb. acidophilus NCFB 2471 
Lb. acidophilus NCFB 104 
- 
5 
5 
- 
- 
4 
- 
- 
4 
- 
3 
7 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
3 
- 
- 
- 
- 
- 
- 
- 
- 
7 
Lb. rhamnosus DSM 20245 
Lb. rhamnosus DSM 20711 
Lb. rhamnosus DSM 8745 
Lb. rhamnosus DSM 20247 
Lb. reuteri DSM 20053 
Lb. reuteri DSM 20016 
Lb. reuteri DSM 20015 
Lb. crispatus NCFB 2752 
Lb. crispatus  20584 
Lb. crispatus NCFB CHN-1-4 
- 
- 
- 
- 
- 
- 
- 
- 
- 
6 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Lb. gasseri DSM 28077 
Lb. gasseri P79 
Lb. gallinarum T50 
Lb. gallinarum DSM 10532 
Lb. gallinarum NCFB 2235 
Lb. amylovorus NRRLB 4540 
Lb. fermentum DSM 20852 
Lb. salivarius NCFB 15555 
- 
3 
- 
7 
7 
- 
6 
- 
- 
- 
- 
- 
6 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
Enterococcus faecium BFE 900, which produces enterocins A and B, suppressed only the 
growth of Lactobacillus gallinarum (Table 9). However, in the study of Franz et al. (1999) E. 
faecium BFE 900 was antagonistic towards L. sakei, Clostridium butyricum, enterococci and 
Listeria spp. including Listeria monocytogenes. The sakacin A producer L. sakei Lb706 in 
this study inhibited the growth of only two L. acidophilus strains. Thus the antimicrobial 
activity spectra of L. sakei Lb706 and E. faecium BFE 900 were very narrow towards the 
selected indicator strains that can be regarded as typical of the intestinal flora. In contrast, the 
enterocin 1071 producer E. faecalis BFE 1071 showed antimicrobial activity against a wider 
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range of indicator bacteria. This may be a reflection of the fact that E. faecalis BFE 1071 was 
isolated from an intestinal environment, while E. faecium BFE 900 and L. sakei Lb706 were 
isolated from food sources (Axelsson and Holck, 1995; Franz et al., 1999; Balla et al., 2000). 
Because E. faecalis BFE 1071 showed a relatively wide antimicrobial activity spectrum 
against lactobacilli strains typical of the gastrointestinal tract this bacteriocin-producer would 
probably be more suitable for studies regarding the influence of bacteriocin-activity on the 
gastrointestinal microflora in an animal model. 
 
3.1.2.2 Bile salt hydrolase activity 
3.1.2.2.1 Detection of BSH activity among probiotic candidates as well as food and 
clinical enterococci strains 
When the potentially probiotic strains and other enterococci strains from food and clinical 
sources were spotted onto MRS agar plates supplemented with the sodium salt of 
taurodeoxycholic acid and CaCl2, a white zone of precipitation occurred when these strains 
were BSH-positive (Figure 4).  
 
 A B 
Zone of precipitation 
 
 
 
 
 
 
 
Figure 4: Example of bile salt hydrolase activity showed by BSH-positive E. faecium 
FAIR-E 189 (A) and negative control E. faecium E 179 (B).  
 
Using this plate screening assay, 43 E. faecalis, 43 E. faecium and 10 E. durans strains and 
one each strain of E. malodoratus and E. casseliflavus from food, human faeces and clinical 
sources were screened for BSH activity, in addition to the potentially probiotic and 
bacteriocin-producing strains E. faecalis BFE 1071, E. faecium BFE 900 and L. sakei Lb706 
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(Table 10). This wide selection of strains was chosen to determine the incidence of BSH 
activity among enterococci. 
 
Table 10: Detection of bile salt hydrolase (BSH) activity among enterococci strains. 
 
Bile salt hydrolase activitya 
Strain positive negative 
Enterococcus durans FAIR-E1, 140, 231, 326, 332, FAIR-E2, 251, 357, 364, 373 
Enterococcus faecalis FAIR-E69, 71, 82, 88, 111, 
115, 117, 123, 124, 125, 186, 
190, 191, 192, 193, 224, 235, 
236, 237, 279, 292, 302, 307, 
313, 315, 339, 363, 385, 404  
FAIR-E39, 108, 109, 112, 
113, 114, 116, 122, 183, 184, 
185, 188, BFE 1071, BFE 
1071/79(-),  
Enterococcus faecium FAIR-E3, 6, 14, 15, 24, 38, 
120, 128, 129, 134, 137, 171, 
189, 345, 394, 395, 396, 397, 
398, 399, 400, 401, 402, 403, 
BFE 900 
FAIR-E9, 13, 40, 41, 80, 83, 
118, 119, 121, 130, 131, 132, 
133, 135, 210, 243, 349, 365 
Others - E. malodoratus FAIR-E169, 
E. casseliflavus FAIR-E230, 
L. sakei Lb 706 
a strains in bold typeface are human faecal isolates, strains in bold typeface and cursive are 
clinical strains, other strains of enterococci were food isolates 
 
Strains of the enterococcal species (E. faecalis, E. faecium and E. durans) in this study 
showed BSH activity, which was not surprising, since enterococci are well known to be 
commensals of the gastrointestinal tract of humans and animals. In this ecological niche, 
enterococci come into contact and interact with bile salts (Franz et al., 2001). Among the 43 
E. faecalis strains, 29 (67.4%) were BSH positive, whereas of the 43 E. faecium strains, 25 
(58.1%) exhibited BSH activity (Table 10). Five of the 10 E. durans strains (50%) were BSH 
positive. The only E. malodoratus, E. casseliflavus, and Lactobacillus sakei (strains Lb 706) 
strains tested were BSH negative. From the non-bacteriocin-producing, potential future 
probiotic candidate enterococci, some were BSH-positive (FAIR-E 6, 15, 345) while others 
were negative (FAIR-E 9, 210, 243, 349, 365). The control probiotic strain E. faecium SF68 
(FAIR-E 24) was BSH-positive. Interestingly, of the bacteriocin-producing, potentially 
probiotic strains investigated in this study, only the E. faecium BFE 900 strain isolated from 
black olives was BSH-positive (Table 10). This may be explained by the fact that this strain 
may have originally stemmed from a gastrointestinal source and occurred in the olives as a 
 62
contaminant. The food enterococcal strains in this study are mainly isolated from cheese. The 
fact that many of these strains exhibited BSH activity (see Table 10) may be explained by the 
fact that cheese enterococci isolates are known to originate as faecal contaminants in the dairy 
environment as result of poor hygienic practices (Litopoulou-Tzanetaki, 1990; López-Diaz et 
al., 1995). 
In contrast, the E. faecalis BFE 1071 strain isolated from the faeces of Göttingen mini-
pigs was BSH-negative. However, our extended investigation on incidence of BSH activity 
among human faecal and clinical isolates (see Table 10) showed that BSH-negative 
enterococci can be isolated from intestinal sources and thus BSH activity probably is not a 
prerequisite for intestinal survival. The ecological significance of bacterial BSH activity has 
also been subject to debate. De Smet et al. (1995), suggested that it serves as a detoxification 
reaction for lactobacilli. However, Moser and Savage (2001) tested a wide spectrum of BSH+ 
lactobacilli for their resistance towards bile salt toxicity, and could not support this 
hypothesis. This led Moser and Savage [13] to suggest that instead of protecting lactobacilli 
from toxicity of conjugated bile salts, BSH activity may rather be important for the bacteria to 
grow in and colonise the intestine. 
 
3.1.2.2.2 Hydrophobicity 
Testing for the hydrophobicity of bacterial cell surfaces was done to assess their potential for 
adhesion to intestinal epithelial cells. Based on results from acid and bile salt tolerance, some 
selected E. faecium (28 strains) and E. faecalis (25 strains) from food and human faecal 
sources as well as the bacteriocin-producing probiotic candidates of this study were subjected 
to hydrophobicity testing using the partitioning test in a watery suspension and n-hexadecane. 
Tests were done in triplicate and standard deviation of these tests generally was less than 
10%, usually around 5%. Hydrophobicity of selected enterococcal strains was arbitrarily 
defined as weak (0-30% hydrophobicity), moderate (31-60% hydrophobicity), and strong (61-
100% hydrophobicity). Most of E. faecium strains, including the bacteriocin-producer E. 
faecium BFE 900, showed weak hydrophobicities (26 strains), while one strain each showed a 
moderate (FAIR-E 41) and strong hydrophobicity (E 118) (Table 11). Among the E. faecalis 
strains, five strains exhibited moderate hydrophobicity, including the bacteriocin producing E. 
faecalis BFE 1071, E. faecalis BFE 1071/79(-), FAIR-E113, 184, 185, and 191. The other 
strains exhibited only weak hydrophobicities. The non-bacteriocin producing, potential 
probiotic enterococci candidates mostly were weakly hydrophobic (FAIR-E 6, 9, 15, 349) 
while some strains possessed moderate (FAIR-E 243, 345, 365) or strong (FAIR-E 210) 
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hydrophobicity (Table 11). The bacteriocin-producer L. sakei Lb706 strain was also shown to 
have moderate hydrophobicity value (Table 11). 
 
Table 11: Hydrophobicity of selected enterococcal strains. 
 
Hydrophobicity  
Strains weak (0-30%) moderate (31-
60%) 
strong (61-100%) 
E. faecium FAIR-E 6, 9, 15, 24, 38, 40, 119, 
120, 121, 128, 129, 130, 131, 132, 
133, 134, 135, 137, 189, 349, 394, 
395, 396, 397, 398, 399, 400, 401, 
402, 403, BFE 900 
FAIR-E 41, 243, 
345, 365  
FAIR-E 118, 210 
E. faecalis FAIR-E 39, 108, 109, 111, 114, 115, 
116, 117, 122, 123, 124, 125, 183, 
185, 186, 188, 190, 192, 193    
FAIR-E 113, 184, 
191, BFE 1071, 
BFE 1071/79(-) 
- 
Others - L. sakei Lb 706 - 
 
a strains in bold typeface are human faecal isolates, strains in bold typeface and cursive are 
clinical strains, other strains of enterococci were food isolates 
 
Bacterial adhesion has been interpreted in terms of hydrophobicity. Some authors have 
also indicated an influence of the electrical charges of bacteria and solid surface on adhesion 
(van Loosdrecht et al., 1987). Hydrophobicity is directly related to concentration of carbon in 
hydrocarbon form and inversely related to oxygen concentration or to the nitrogen/phosphate 
ratio (Mozes et al., 1988). Greater hydrophobicity of cells is postulated in greater attractive 
forces and higher levels of adhesion (Marin et al., 1997).  
The hydrophobicity of bacteria can be determined with contact angle method (van 
Loosdrecht et al., 1987), partitioning bacteria between two aqueous phases (between 
polyethylene glycol and a dextran phase), or by partitioning bacteria into either the aqueous or 
organic phase. For example using a aqueous and n-hexadecane solution in hydrophobicity 
testing bacteria would adhere to droplets of organic solvents (n-hexadecane) if their surface is 
hydrophobic (Rosenberg, 1984). Similar to our study, a hexadecane adherence assay was 
applied by Greene at al. (1992) to measure hydrophobicity of Staphylococcus intermedius and 
S. hyicus isolates, Ding and Lammler (1992) to study hydrophobicity of Actinomyces 
pyogenes strains and Del Re et al. (2000) who studied adhesion, autoaggregation and 
hydrophobicity of 13 probiotic strains of Bifidobacterium longum.  
Twenty six of the twenty eight Enterococcus faecium strains in this study (92.9%) 
exhibit only weak hydrophobicity, as well as 19 of 24 strains of Enterococcus faecalis 
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(79.2%). This indicated, that enterococci in general do not have a high hydrophobicity and 
may indicate , that based on this characteristic, they may not have high adhesion capacity. 
Nevertheless, 5 of 24 strains of E. faecalis (20.8%) exhibited moderate hydrophobicity (Table 
11). In contrast Del Re et al. (2000) found a high hydrophobicity potential among 13 strains 
of Bifidobacterium longum and thus this genus may have a higher capacity to adhere to 
gastrointestinal cells when compared to enterococci.. Similarly, among 42 Actinomyces 
pyogenes strains, Ding and Lämmler (1992) found that 60% of cells were strongly 
hydrophobic, while 40% showed a weak or moderate hydrophobicity as defined using their 
criteria. 
The bacteriocin-producing probiotic candidates E. faecalis BFE 1071 and L. sakei 
Lb706 showed a moderate hydrophobicity value in this study which may indicate that these 
bacteria would be better suited for adhesion to intestinal cells in vivo than the bacteriocin-
producer E. faecium BFE 900. A high cell surface hydrophobicity is considered an advantage 
in the colonisation of mucosal surfaces Ljungh and Wadstöm (1982). However, specific 
surface structures called adhesins may also play an important role in adhesion of bacteria to 
epithelial cells. Such adhesins for enterococci, for instance, include surface proteins such as 
aggregation substance, enterococcal surface protein, endocarditis antigen and adhesin to 
collagen from E. faecalis, which are also known virulence traits (Franz et al., 1999). In 
addition enterococci were shown to contain ligands involved in binding that contain D-glucose 
and D-mannose (Guzmàn et al., 1991). For this reason, hydrophobicity testing was only 
considered as an indication of binding capacity, and the probiotic candidates were also 
investigated for their binding capability in tissue culture, using the polarised, mucus-secreting 
and enterocyte-like HT-29 MTX cell line. This cell line is the closest mimick of 
gastrointestinal enterocytes currently employed in tissue culture experimentation. 
 
3.1.2.2.3 Adhesion to HT29 MTX-cell line 
Adherence of probiotic bacteria to enterocytes could confer a competitive advantage in 
the gut ecosystem (Holzapfel et al. 1998). This may also be an important technological 
property of these bacteria, as it may increase their residence time in the gastrointestinal tract. 
In this study, we used the human intestinal epithelial, mucus-secreting cell line HT29-MTX. 
The use of this cell line is thought to represent the in vivo situation closely (Holzapfel et al., 
1998). 
Adherance to HT29-MTX cells was studied only for selected enterococci probiotic 
candidates, including the bacteriocin-producers E. faecium BFE 900 and E. faecalis BFE 
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1071. The bacteriocin-producer L. sakei Lb706 was not included as at this stage of the study, 
as it was unlikely that this strain would be chosen as a probiotic candidate for animal 
experiments or future development, because the strain was from non-intestinal origin, is not 
usually associated with the gastrointestinal tract, was not bile tolerant, was BSH-negative and 
did not show a broad range of bacteriocin-activity against lactobacilli typical of the 
gastrointestinal tract. The other enterococci tested included non-bacteriocin producing food 
isolates (see Table 4) which in a previous EU study showed non-virulent characteristics like 
absence of plasmid DNA, absence of vancomycin resistance and gelatinase activity in a plate 
screening assay,a s well as a probiotic control strain E. faecium SF68 (FAIR-E 24). The 
enterococci were capable of adhering to HT29-MTX cells, however at a low level of generally 
less than 30% (Fig. 5). Bacteriocin-producing Enterococcus faecium BFE 900 had the lowest 
level of adherence (3%) whilst E. faecium FAIR-E 15 the highest (31%). E. faecium FAIR-
E6, E 210 and E 243 exhibited moderate adherence values (27%, 26%, and 28%, respectively. 
The Enterocin 1071-producing strain E. faecalis BFE 1071 also exhibited a moderate to high 
adherence of 17% when compared to the other enterococci cells. The probiotic control strain 
E. faecium SF68 did not show high (<15%) adherence to HT29 MTX cells. 
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Fig. 5: Percentage adherence of enterococci probiotic candidates to HT29-
MTX-cells in tissue culture 
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It is generally believed that adherence to mucosal surfaces contributes to the efficacy of a 
probiotic strain, since adherent strains could confer a competitive advantage, which is 
important for bacterial maintenance in the gastrointestinal tract. By blocking the atachment 
sites, probiotics might contribute to the prevention of infection by pathogenic microorganisms 
(Holzapfel et al., 1998).  
Adhesion of probiotic candidate enterococci to HT29 MTX-cell line was shown to be at 
low level (between 3 and 31% adherence values). By contrast, it was shown that L. 
acidophilus and L. rhamnosus strains adhere in relatively high numbers and are able to 
prevent attachment pathogenic microorganisms such as Salmonella typhimurium, Yersinia 
enterocolitica, and enteropathogenic E. coli (Coconnier et al., 1993; Bernet et al., 1994; 
Hudault et al., 1997). However, other probiotic strains such as E. faecium SF68 are known not 
to adhere strongly in the gastrointestinal tract, and were shown in animal experiments and 
with human volunteers to be washed out after 1 to 2 weeks after cessation of probiotic 
treatment (Havenaar and Huis in’t Veld, 1993; Vael and Goossens, 2002). This, however, 
does not imply that the cells are not metabolically active and it is thought that the probiotic 
activity is still sustained even though the strain cannot adhere effectively (Havenaar and Huis 
in ‘t Veld, 1993). Although adherence to such cell line may indicate the possibility of a strain 
to adhere in vivo, it does not always mean that these enterococci could not have long 
residence time in the gastrointestinal tract even when they do not adhere effectively. Havenaar 
and Huis in ‘Ät Veld (1993) and Vael and Goossens (2002) showed that E. faecium SF68 
could still be detected in the faeces at least one week after stopping probiotic treatment. It is 
important to note that results from such studies may not be predictive of the actual in vivo 
situation.  
 
The studies on technological and functional probiotic candidates are summarised in Table 12. 
All of the non-bacteriocin producing enterofcocci probiotic candidates appear to be suited for 
development of probiotics, as they have good technological characteristics (mostly resistant to 
acid and tolerant to bile and duodenum secrete). The adhesion capability as judged by their 
hydrpophobicity and adhesion to HT-29 cells differs somewhat (see Table 12) but strong 
adherance to gastrointestinal cells may not necessarily be considered as a absolutely required 
characteristic for a probiotic strain. Some strains were bile salt hydrolase positive, although 
this characteristic is considered to be a probiotic trait the potential risks associated with BSH 
activity, i.e. conversion of primary to secondary bile salt in the intestine, which are 
procarcinogenic (Marteau et al., 1995), should be kept in mind. Among the bacteriocin-
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producers, E. faecalis BFE 1071 showed the greatest promise for use as a probiotic candidate, 
also for studying the effects of this strain on the autochthonous flora of an experimental 
animal. This is because the strain is probably well adapted to survive gastrointestinal 
conditions, as it was isolated from faeces. Furthermore, the findings of this study show that 
this strain indeed was relatively acid resistant and tolerant to bile and duodenum secrete. 
Furthermore, this strain showed bacteriocin-activity against a broad range of typical 
gastrointestinal lactobacilli. As for the enterococci isolates the strain did, however, not show a 
high adherence capability. Nevertheless this strain appeared to be most suited for studying the 
effect of a bacteriocin-producer on the microflora of rats in a model study and was chosen for 
this purpose (see below). 
  
Table 12: Summary of technological and probiotic properties of candidate probiotic 
strains investigated in this study. 
 
Strain Acid 
resistance 
Tolerance 
to bile and 
duodenum 
secrete 
Bile salt 
hydrolase 
activity 
hydro-
phobicity 
Adherence 
(%) to HT29 
MTX cells 
(average of 3 
trials) 
 
Bacteriocin 
activity 
spectrum 
against typical 
intestinal 
lactobacilli 
Non-bacteriocin 
producing probiotic 
enterococci candidates 
      
FAIR-E 6 strong strong + weak 28 - 
FAIR-E 9 strong moderate - weak 20 - 
FAIR-E 15 moderate strong + weak 31 - 
FAIR-E 210 moderate moderate - strong 27 - 
FAIR-E 243 strong moderate - medium 29 - 
FAIR-E 345 strong strong + medium 13 - 
FAIR-E 349 strong moderate - weak 17 - 
FAIR E 365 strong strong - medium 6 - 
Bacteriocin-producing 
probiotic candidates 
      
E. faecalis BFE 1071 weak weak - moderate 19 broad 
E. faecium BFE 900 strong negative + weak 3 narrow 
L. sakei Lb706 weak negative - moderate n.d. narrow 
n.d. = not determined 
 
 
Because of the asociation of enterococci with human disease, it was considered important to 
investigate the safety of the non-bacteriocin producing enterococci candidates and strain E. 
faecalis BFE 1071. In addition, it was considered necessary to investigate the virulence 
potential of E. faecalis BFE 1071 before use in an animal experiments. 
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3.2 Investigation into the safety of potentially probiotic enterococci 
3.2.1 Antibiotic resistance 
The antibiotic resistance of non-bacteriocin producing, potentially probiotic E. faecium 
strains, as well as the bacteriocin-producing E. faecalis BFE 1071 was investigated using the 
E-test (Viva Diagnostika, Cologne, Germany). The results of antibiotic resistance tests are 
shown in Table 13. 
 
Table 13: Minimum inhibitory concentrations for inhibition of probiotic enterococci 
candidates with antibiotics ampicillin (Amp), benzylpenicillin (Bpen), 
Chloramphenicol (Chloram), Tetracycline (Tet), Erythromycin (Eryth), 
Ciprofloxacin (Cipro), Streptomycin (Strep) and Gentamicin (Gent). 
Resistancesa are indicated by shaded boxes. 
 
Strain Amp Bpen Chloram Tet Eryth Cipro Strep Gent 
FAIR-E 6 0.125 0.5 8.0 0.75 4.0 6.0 48.0 24.0 
FAIR-E 9 0.5 >32.0 6.0 0.25 3.0 0.25 192.0 32.0 
FAIR-E 15 1.0 16.0 16.0 1.5 6.0 2.0 64.0 8.0 
FAIR-E 210 1.5 16.0 24.0 1.0 32.0 0.5 48.0 24.0 
FAIR-E 243 0.125 4.0 6.0 0.75 1.0 6.0 64.0 32.0 
FAIR-E 345 0.190 0.38 8.0 0.5 >256.0 6.0 32.0 24.0 
FAIR-E 349 0.5 0.75 12.0 0.5 24.0 1.5 32.0 8.0 
FAIR-E 365 2.0 >32.0 8.0 0.75 4.0 0.38 128.0 8.0 
E. faecalis BFE 1071 0.5 2.0 6.0 0.75 0.75 0.5 192 12.0 
 
a Resistance interpreted on the basis of minimum inhibitory concentration values for 
enterococci supplied in ‘Performance standards for antimicrobial susceptibility testing’, ninth 
informal supplement, National Committee for Clinical laboratory standards (NCCLS) Vol. 19 
(1) from 1999. Minimum inhibitory concentration values for ampicillin, ≥16 µg/ml; penicillin, 
≥16 µg/ml; chloramphenicol ≥32 µg/ml; tetracycline, ≥16 µg/ml; erythromycin ≥8 µg/ml; 
ciprofloxacin ≥4 µg/ml; highlevel streptomycin >1000 µg/ml and high level gentamycin >500 
µg/ml. 
 
All of the strains, except the bacteriocin-producer E. faecalis BFE 1071 exhibited resistance 
to at least one of the antibiotics tested (Table 13). E. faecium strains E 210 and E 345 even 
contained resistance towards two antibiotics, i.e. penicillin and erythromycin, and 
erythromycin and ciprofloxacin, respectively. However, multiple antibiotic resistances among 
enterococci are quite common and can be explained by the fact that enterococci are naturally 
(intrinsically) resistant towards a variety of antibiotics (Murray, 1990, Franz et al., 1999). The 
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EU Scientific Committee on Animal Nutrition (SCAN) has been called by the EU to provide 
guidelines to regulate bacteria used in feeds (i.e. probiotic bacteria, starter bacteria) and 
according to the SCAN guidelines, these should not contain any acquired antibiotic 
resistances (SCAN, 2002). Such strains can, however, possess intrinsic resistances, when it 
can be shown that these are not transferable. For the enterococci, resistance to ampicillin, 
streptomycin, gentamicin, chloramphenicol, tetracycline, and erythromycin are considered to 
be acquired resistances. Thus the strains above (FAIR-E 9, 15, 210, 345, 349 and 365) 
containing resistances to some of these antibiotics (Table 13) would be difficult to develop as 
an animal probiotic strain. Although the EU has not yet established similar guidelines for 
human probiotics, this is expected to follow soon. Thus realistically, the only strains with a 
potential for future probiotic development that are considered safe from an antibiotic 
resistance point of view, would be the bacteriocin-producer E. faecalis BFE 1071 and the 
non-bacteriocin-producing E. faecium strains FAIR-E 6 and FAIR-E 243 (Table 13). 
Although the latter strains exhibit ciprofloxacin resistance, this trait is considered to be 
intrinsic to some enterococci strains.  
 
3.2.2 Physiological investigation of virulence potential 
The non-bacteriocin producing E. faecium probiotic candidates and bacteriocin-producing 
strains E. faecalis BFE 1071 were investigated using physiological tests for their virulence 
potential. This included investigations for production of DNAse, haemolysin, gelatinase and 
mucin degradation activity, as determined on agar plates, as well as testing for production of 
aggregation substance, as determined using a clumping assay. In addition, the strain were 
assessed for their ability to bind extracellular matrix proteins. The results for testing of these 
virulence determinants are shown in Table 14 and 15. 
 
Table 14: Physiological testing for virulence of probiotic enterococci candidates. 
 
Enterococci strains DNAse Gelatinase Aggregation substance Hemolysin Mucin Degradation 
FAIR-E6 
FAIR-E-9 
FAIR-E-15 
FAIR-E-210 
FAIR-E-243 
FAIR-E-345 
FAIR-E-349 
FAIR-E-365 
E. faecalis BFE 1071 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
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None of the nine strains produced DNAse, gelatinase, aggregation substance and 
hemolysin, which are important virulence traits of enterococci associated with human 
infection. Only one strain, E. faecium FAIR-E 210 hydrolysed mucin, which can be 
considered as a potential safety concern. In addition, this strain also was resistant to penicillin 
and erythromycin (Table 13) and would thus probably not be suitable for further development 
as probiotic strain.  
 
 
Table 15: Binding of potential probiotic enterococci to extracellular matrix proteins. 
 
strains Rat collagen I 
(%) 
Human fibrinogen 
(%) 
Human fibronectin 
(%) 
 
FAIR-E 6 
FAIR E 9 
FAIR E 15 
FAIR E 210 
FAIR E 243 
FAIR E 345 
FAIR E 349 
FAIR E 365 
 
 
25  
21  
25  
18  
65  
84  
88  
84  
 
0  
27  
16  
48  
59  
28  
46  
4  
 
 
32  
31  
0  
14  
57  
35  
35  
48  
 
All eight non-bacteriocin producing enterococci strains did not bind well to extracellular 
matrix (ECM) proteins, as binding to these was generally lower than 50% (Table 15). 
However, some strains bound well to specific ECM proteins (especially rat collagen I), 
indicating that this may be a potential virulence trait, should enterococci be able to reach the 
ECM. The extracellular matrix (ECM) is a stable macromolecular structure underlying 
epithelial and endothelial cells and surrounding connective tissue cells (Westerlund and 
Korhonen, 1993). The ECM underlying the cells comprises several collagens, fibronectin, 
laminin, vitronectin, thrombospondin and a number of glycosaminoglycans. Bacteria may 
come into contact with the ECM if this is exposed, as occurs in wounds, or if the bacteria 
have tissue-invasive capability or produce toxins or proteases (Ljungh and Wadström, 1996). 
Specific binding to an ECM component may lead to colonisation and possibly the 
development of an infection. Thus the relative importance of binding of enterococci probiotic 
candidates to ECM proteins should be seen in connection of presence of their other virulence 
factors such as invasins, proteases or toxins, as it would not be expected that binding of ECM 
proteins would play a role if such factors are not present. For this reason, the presence of 
virulence genes for production of the adhesins enterococcal surface protein (Esp) and the 
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adhesin to collagen from E. faecalis (Ace) and invasins (aggregation substancewas also 
investigated on the molecular biological level. 
 
3.2.3 Molecular biological investigation into potentially probiotic enterococci 
virulence factors 
The presence of genes for the virulence factor enterococcal surface protein (Esp) and adhesin 
to collagen from E. faecalis (Ace) was investigated by PCR amplification of these genes. The 
results for the PCR amplification for Ace and Esp are shown in Fig. 6. 
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Fig. 6:  PCR amplification of Ace (A) and Esp (B). Lane 1, faecium E 6, Lane 2, E 9, 
lane 3, E 15, lane 4, E 210, lane 5, E 243, lane 6, E 345, lane 7, E 349, lane 8, 
E 365, lane 9, BFE 1071, lane 10 BFE 1071/79(-), lane 11, positive conrol E. 
faecalis E 69 (A) or E. faecalis V594 (B). M: 500 bp marker (Biorad). 
 
None of the strains produced either Ace or Esp. The gene could however, be amplified at 
correct size from the DNA of control strains (see Fig. 6).. 
 
In general, the strains of potential probiotic enterococci appeared to be clear of virulence 
determinants. Production of virulence determinants appears to be common among enterococci 
from clinical and food sources, especially in E. faeclis strains. Franz et al., 2001 investigated 
47 E. faecalis strains from food and showed that 78.7% of food isolates produced one or more 
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virulence determinants (AS, Cyl, Esp or gelatinase). Many of the E. faecalis strains tested 
produced multiple virulence determinants. In contrast, only 10.4% of the food E. faecium 
strains produced one or more of these virulence determinants. Eaton and Gasson (2001) also 
reported a much higher incidence of virulence determinants from food enterococcal strains for 
E. faecalis strains, when compared to E. faecium strains. Eaton and Gasson (2001) reported 
the incidence of virulence factors (aggregation substance, Esp, Ace, gelatinase) to be highest 
among clinical isolates, followed by food isolates and then probiotic isolates. The absence of 
virulence factors of enterococci in this study was comparable to that reported for other 
probiotic strains (Eaton and Gasson, 2001) and is considered as an advantage and prequisite 
for the development of these strains as future probiotics. 
 
Based on the ability of E. faecalis BFE 1071 to resist acid and tolerate bile salt and duodenum 
secrete, it’s gastrointestinal origin, it’s ability to produce bacteriocin with activity against 
lactobacilli which are typically associated with the gastrointestinal tract, the strain was chosen 
as the probiotic candidate for use in animal experiments. E. faecalis BFE 1071 did not possess 
BSH activity, which may be a positive characteristic when considering that there is some 
debate about the value of bile salt hydrolase activity of a probiotic strain. This controversy is 
based on the fact that the primary bile salt which is produced in the deconjugation reaction by 
BSH-positive bacteria, can be further hydrolysed to secondary bile salts by other intestinal 
bacteria, and these secondary bile salts may be procarcinogenic. 
 
 Nevertheless, it was considered important to study the genetic basis of bile salt 
hydrolase activity of BSH-positive probiotic enterococci candidates. To date, the BSH gene 
has never been cloned from an Enterococcus strain and the production has not been 
investigated on a molecular biological level. For this reason, the genetic basis for BSH 
activity of one of the potentially probiotic enterococci strains, i.e. E. faecium FAIR-E 345, 
was elucidated. One aim of this study was also to determine, whether the gene for BSH 
activity is plasmid located among BSH-positive enterococci, and can thus be transferrred to 
other enterococci strains.  
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3.3 Bile Salt Hydrolase  
3.3.1 Cloning of bsh gene, nucleotide sequence and amino acid homology  
One of approximately 4000 colonies screened after transformation of E. coli TOP10 with 
chromosomal DNA fragments of 2.5-4.0 kbp length expressed the BSH gene, as was 
demonstrated by the presence of a large zone of precipitation around the colony growing on 
LB-based differential agar (Fig. 7). 
 
 
Fig. 7: Photograph showing the appearance of BSH-positive E. coli TOP 10 colony on 
the LB-based differential agar plate. A large zone of precipitation around the 
colony was evident of BSH activity, while BSH-negative colonies did not 
show a zone of precipitation. 
 
The insert in the plasmid pAW01 contained by this clone was completely sequenced in both 
directions. Analysis of the DNA sequence revealed the presence of one open reading frame 
(ORF) encoding a protein of 324 amino acids with an isoelectric point of 4.877 (Fig. 8). A 
presumptive ribosome binding site (GGAGGAA) was located 8 bases upstream of the ATG 
start codon for this ORF. Presumptive –10 (TATAGT) and –35 (TTGATA) promoter 
sequences were located upstream of this RBS (Fig. 8). A possible terminator with dyad 
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symmetry occurred 164 bp downstream of the TGA stop codon of this ORF. A databank 
search indicated that the amino acid sequence deduced from this ORF showed highest 
homology to that of the BSH protein from Listeria monocytogenes, Lactobacillus (L.) 
plantarum (68.5 % identity), while lower homologies to BSH proteins reported previously for 
L. johnsonii (52.8 % identity), L. gasseri (49.2 % identity), Clostridium perfringens (42.2 % 
identity), Bifidobacterium longum (38.2 % identity) and L. acidophilus (34.8 % identity) were 
found (Christiaens et al., 1992; Coleman and Hudson, 1995; Elkins and Savage, 1998; Tanaka 
et al., 2000; Russell and Klaenhammer, 2001). In addition, The BSH protein from E. faecium 
FAIR-E 345 also showed homology to the penicillin V acylase (PVA) of Bacillus sphaericus 
(32.7 % identity) (Suresh et al., 1999). 
 
1 TTGCAGTCTGACGACTCAAAAATGAGTCGTATAAATCAATTATAGTAATAAGTCATTGATTTCTTTAAATTCTTTATCAAGTTCTTTTTC 
 
                                                                               IR1L        
91 TCATATTTTTCATATTTATCAGCTTCATGAAGAACTTTTTTAATTTCATGAATAGCCTTTCGTTCAACTAACCATTTTTTTAGGTTATG A
                         DR1L                  DR1R                                                                          IR1R                                                       
181 TTTTTTTTCTGGATTTTCAGATAACGTATCAAGTTCGTCTAACTCTTTATCCAGTTTATTGACAACAGAAACAATTTTGTTTACAACTTT 
271 TTCTTCTTTGTTTTCTAAATTTGACATTTATCTTCACGTCCTTTTTATTTGATAATTTAAGTATAGAACTTTGATATAGTTTATACAAAT 
                                                 -35                       -10             
361 AAAAACGCTTCTTTGTGTATTCTGTGCTTTTCTTTTGGAATGAGGAAAACTTTGGAGTAATATGAACGTGGACAGAAAAATATTTAGGAG 
                                                                                       RBS 
451 GAATAAACTATGTGTACGTCTATTACTTATGTAACAAGTGATCATTATTTTGGAAGGAATTTTGATTATGAAATATCTTACAATGAAGTA 
         M  C  T  S  I  T  Y  V  T  S  D  H  Y  F  G  R  N  F  D  Y  E  I  S  Y  N  E  V   
541 GTCACTATTACTCCAAGAAATTATAAGTTGAATTTTCGAAAGGTAAATGATTTGGATACTCATTATGCAATGATTGGTATTGCCGCTGGT 
V  T  I  T  P  R  N  Y  K  L  N  F  R  K  V  N  D  L  D  T  H  Y  A  M  I  G  I  A  A  G   
631 ATAGCTGACTACCCTCTTTATTACGATGCGACAAATGAAAAAGGATTGAGTATGGCTGGACTAAATTTTTCTGGGTATGCTGATTATAAA 
I  A  D  Y  P  L  Y  Y  D  A  T  N  E  K  G  L  S  M  A  G  L  N  F  S  G  Y  A  D  Y  K   
721 GAAATACAAGAAGGGAAAGACAATGTATCTCCTTTTGAATTTATTCCTTGGATTTTAGGACAATGCTCAACAGTAGGAGAAGCTAAAAAA 
E  I  Q  E  G  K  D  N  V  S  P  F  E  F  I  P  W  I  L  G  Q  C  S  T  V  G  E  A  K  K   
811 TTGTTAAAAAATATCAATTTAGCAAATATAAATTATAGTGACGAACTTCCTTTATCCCCTTTACATTGGCTATTAGCTGATAAAGAAAAA 
L  L  K  N  I  N  L  A  N  I  N  Y  S  D  E  L  P  L  S  P  L  H  W  L  L  A  D  K  E  K   
901 TCAATTGTCATTGAAAGTATGAAAGATGGACTTCATATATATGATAACCCTGTGGGCGTTCTTACCAATAATCCTTCATTTGACTATCAA 
S  I  V  I  E  S  M  K  D  G  L  H  I  Y  D  N  P  V  G  V  L  T  N  N  P  S  F  D  Y  Q   
991 TTATTTAATTTAAACAATTATCGTGTCTTATCGAGTGAAACTCCTAAAAATAATTTTTCAAATCAAATAAGTTTGAATGCCTATAGCCGC 
L  F  N  L  N  N  Y  R  V  L  S  S  E  T  P  K  N  N  F  S  N  Q  I  S  L  N  A  Y  S  R   
1081 GGTATGGGAGGGATAGGCTTGCCTGGAGATTTATCCTCAGTATCTCGTTTTGTTAAAGCGACTTTTACGAAGCTGAATTCTGTATCTGGA 
G  M  G  G  I  G  L  P  G  D  L  S  S  V  S  R  F  V  K  A  T  F  T  K  L  N  S  V  S  G   
1171 GATTCAGAGTCAGAAAGTATTAGTCAATTTTTCCATATCTTAGGTTCAGTAGAACAACAAAAAGGTTTGTGTGATGTTGGTGATGGAAAA 
D  S  E  S  E  S  I  S  Q  F  F  H  I  L  G  S  V  E  Q  Q  K  G  L  C  D  V  G  D  G  K   
1261 TATGAATATACAATTTATTCTTCTTGTTGCAATGTTGATAAAGGAATCTATTATTATCGAACATATGAAGACAGTCAAATTACTGCAATT 
Y  E  Y  T  I  Y  S  S  C  C  N  V  D  K  G  I  Y  Y  Y  R  T  Y  E  D  S  Q  I  T  A  I   
1351 GATATGAATAAAGAAGACTTAGATAGTCATAAGTTAATTAGTTATCCAATTATAGAAAAACAACAAATTAAATATATAAATTAGTTAGTG 
                                                                                           
D  M  N  K  E  D  L  D  S  H  K  L  I  S  Y  P  I  I  E  K  Q  Q  I  K  Y  I  N  *         
1441 TGTTGTGATTGATTATTTAATATAGATATAATACAAAAAGGCAAAGATATTTTCAAAACATTTTTTCTTGATGTGATATCCTTGTCTTTT 
                                                                                            
1531 TTGTAATGTTTTTAACTTATTGCTTTTGCAAAATTTATTTACCTGTTTTCTGGATCAACGATAGTGTATATTATGCTATCCTTGTTTGGA 
 
 
Fig. 8: DNA sequence of bsh gene isolated from E. faecium FAIR-E 345. The ribosome 
binding site (RBS) is indicated in bold print, inverted (IR) or direct (DR) repeats 
are indicated by arrows. L=left, R= right. 
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The amino acids of the active site of PVA were determined by crystal structure analysis 
(Suresh et al., 1999) to be Cys-1, Asp-20, Tyr-82, Asn-175 and Arg 228. As pointed out by 
Tanaka et al. (2000), all of the BSH proteins characterised so far also have these conserved 
amino acids at these positions, with the exception of Tyr-82, which is replaced by Asn-81 in the 
BSH proteins. This was also the case for the amino acid sequence for the BSH protein of E. 
faecium FAIR-E 345 as deduced from the nucleotide sequence of the bsh gene in this study (Fig. 
9). Tanaka et al. (2000) purified the BSH protein and determined that the N-terminal amino acid 
sequence for purified BSH did not include a Met residue. The authors suggested that the 
formylmethionine was processed and that the Cys was the first amino acid of the mature protein. 
This finding was also obtained with PVA, in which Cys-1 plays a central role in the active site 
(Suresh et al., 1999; Tanaka et al., 2000).  
Using site-directed mutagenesis, Tanaka et al. (2000) furthermore showed that replacing 
Cys-1 with Ala completely abolished BSH activity. The highly conserved Cys residue in all BSH 
proteins (Fig. 9) confirms the importance of the cysteine in the active site and may imply, that 
for all the BSH proteins shown aligned in Fig. 9, the formylmethionine is processed and Cys is 
the first amino acid of the mature BSH protein. If this is the case, the BSH protein from E. 
faecium FAIR-E 345 would consist of 324 amino acids and the protein would have a pI of 4.877. 
Multiple alignment of the BSH amino acid sequences (Fig. 9) also showed that there was 
a considerable degree of heterogeneity among BSH proteins and that long stretches of conserved 
regions, which may have aided development of PCR primers for detection of BSH genes, did not 
occur. For this reason, the strategy to use the cloned BSH gene itself as a gene probe to detect the 
genomic location of BSH genes among enterococci was adopted. 
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BSH Ef 1 MCTSITYVTSD--HYFGRNFDYEISYNEVVTITPRNYKLNFRKVND–LDTHYAMIGIAAGIADYPL 
BSH Lm 1 MCTSITYTTKD—-HYFGRNFDYELSYKEVVVVTPKNYPFHFRKVED-IEKHYALIGIAAVMENYPL 
BSH Bl 1 MCTGVRFSDDEGNTYFGRNLDWSFSYGETILVTPRGYHYDTVFGAGGKAKPNAVIGVGVVMADRPM 
BSH Cp 1 MCTGLALETKDGLHLFGRNMDIEYSFNQSIIFIPRNFKCVNKSNKKELTTKYAVLGMGTIFDDYPT 
BSH La 1 MCTGLRFTDDQGNLYFGRNLDVGQDYGEGVIITPRNYPLPYKFLDNTTTK-KAVIGMGIVVDGYPS 
BSH Lg 1 MCTSILYSPKD—-HYFGRNLDYEIAYGQKVVITPKNYEFEFTDLPA-EKSHYAMIGVAAVADNTPL 
BSH Lp 1 MCTAITYQSYN—-NYFGRNFDYEISYNEMVTITPRKYPLVFRKVEN-LDHHYAIIGITADVESYPL 
BSH Lj 1 MCTGLRFTDDQGNLYFGRNLDVGQDYGEGVIITPRNYPLPYKFLDNTTTK-KAVIGMGIVVDGYPS 
 
BSH Ef 64 YYDATNEKGLSMAGLNFSGYADYKEIQ-EGKDNVSPFEFIPWILGQCSTVGEAKKLLKNINLANIN 
BSH Lm 64 YYDATNEKGLSMAGLNFSGNADYKDFA-EGKDNVTPFEFIPWILGQCATVKEARRLLQRINLVNIS 
BSH Bl 67 YFDCANEHGLAIAGLNFPGYASFVHEPVEGTENVATFEFPLWVARNFDSVDEVEETLRNVTLVSQI 
BSH Cp 67 FADGMNEKGLGCAGLNFPVYVSYSKEDIEGKTNIPVYNFLLWVLANFSSVEEVKEALKNANIVDIP 
BSH La 66 YFDCFNEDGLGIAGLNFPHFAKFSDGPIDGKINLASYEIMLWVTQNFTKVSDVKEALKNVNLVNEA 
BSH Lg 64 YCDAINEKGLGVAGLSFAGQGKYFPNA-ADKKNIASFEFISYLLATYETVDQVKESLTNANISNVS 
BSH Lp 64 YYDAMNEKGLCIAGLNFAGYADYKKYD-ADKVNITPFELIPWLLGQFSSVREVKKNIQKLNLVNIN 
BSH Lj 66 YFDCYNEDGLGIAGLNFPHFAKFSDGPIDGKINLASYEIMLWVTQNFTHVSEVKEALKNVNLVNEA 
 
BSH Ef 129 YSDELPLSPLHWLLADKE-KSIVIESMKD-GLHIYDNPVGVLTNNPSFDYQLFNLNNYRVLSSETP 
BSH Lm 129 FSENLPLSPLHWLMADQT-ESIVVECVKD-GLHIYDNPVGVLTNNPTFDYQLFNLNNYRVLSSETP 
BSH Bl 133 VPGQ-QESLLHWFIGD-GKRSIVVEQMAD-GMHVHHDDVDVLTNQPTFDFHMENLRNYMCVSNEMA 
BSH Cp 133 ISENIPNTTLHWMISDITGKSIVVEQTKE-KLNVFDNNIGVLTNSPTFDWHVANLNQYVGLRYNQV 
BSH La 132 INSSFAVAPLHWIISD-KDEAIIVEISKQYGMKVFDDRLGVLTNSPDFNWHLTNLGNYTGLDPHDA 
BSH Lg 129 FAKNTPASELHWLVGDKTGKSIVVESDEK-GLHVYNNPVNALTNAPLFPEQLTNLANYASVVPGEP 
BSH Lp 129 FSEQLPLSPLHWLVADKQ-ESIVIESVKE-GLKIYDNPVGVLTNNPNFDYQLFNLNNYRALSNSTP 
BSH Lj 132 INTSFAVAPLHWIISD-SDEAIIVEVSKQYGMKVFDDKVGVLTNSPDFNWHLTNLGNYTGLNPHDA 
 
BSH Ef 193 KNNFSNQISLNAYSRGMGGIGLPGDLSSVSRFVKATFTKLNSVSGDSESESISQFFHILGSVEQQK 
BSH Lm 193 ENNFSKEIDLDAYSRGMGGIGLPGDLSSMSRFVKATFTKLNSVSGDSESESISQFFHILGSVEQQK 
BSH Bl 196 EPTSWGKASLTAWGAGVGMHGIPGDVSSPSRFVRVAYTNAHYPQQNDEAANVSRLFHTLGSVQMVD 
BSH Cp 198 PEFKLGDQSLTALGQGTGLVGLPGDFTPASRFIRVAFLRDAMIKNDKDSIDLIEFFHILNNVAMVR 
BSH La 197 TAQSWNGQKVAPWGVGTGSLGLPGDSIPADRFVKAAYLNVNYPTVKGKKANVAKFFNILKSVAMIK 
BSH Lg 194 DNNFLPGVNLKLYSRSLGTHHLPGGMDSESRFVKVCFALNHAPKDSDEVENVTNFFHILESVEQAK 
BSH Lp 193 QNSFSEKVDLDSYSRGMGGLGLPGDLSSMSRFVRAAFTKLNSLPMQTESGSVSQFFHILGSVEQQK 
BSH Lj 197 TAQSWNGQKVAPWGVGTGSLGLPGDSIPADRFVKAAYLNANYPTVKGEKANVAKFFNILKSVAMIK 
 
BSH Ef 259 GLCDVGDGKYEYTIYSSCCNVDKGIYYYRTYEDSQITAIDMNKEDLDSHKLISYPIIEKQQIKYIN 
BSH Lm 259 GLCDVGGGKYEHTIYSSCCNIDKGIYYYRTYGNSQITGVDMHQEDLESKELAIYPLVNEQRLNIVNK 
BSH Bl 262 GMAKMGDGQFERTLFTSGYSSKTNTYYMNTYDDPAIRSYAMADYDMDSSELISV----------A-R 
BSH Cp 264 GSTRTVEEKSDLTQYTSCMCLEKGIYYYNTYENNQINAIDMNKENLDGNEIKTYKYNKTLSINHV-N 
BSH La 263 GSVVNKQGSNEYTVYTACYSAATKTYYCNFENDFELSAVDMNKEDLDSSDLVVYDLFKKQDISFI-N 
BSH Lg 264 GMDQIGPNSFEYTMYTSCMNLEKGILYFNCYDDSRISAVDMNKEDLDSSDLVVYDLFKKQDISFI-N 
BSH Lp 259 GLCEVTDGKYEYTIYSSCCDMDKGVYYYRTYDNSQINSVNLNHEHLDTTELISYPLRSEAQY-YAVN 
BSH Lj 263 GSVVNDQGSDEYTVYTACYSSGSKTYYCNFEDDFELKTYKLDDHTMNSTSLVTY 
 
Fig. 9: Alignment of the BSH protein sequences from Enterococcus faecium FAIR-E 345 
(BSH Ef), Listeria monocytogenes (BSH Lm), Bifidobacterium longum (BSH Bl), 
Clostridium perfringens (BSH Cp), Lactobacillus acidophilus (BSH La), L. gasseri 
(BSH Lg), L. plantarum (BSH Lp), and L. johnsonii (BSH Lj) by Lipman-Pearson 
alignment. Identical amino acids are indicated in black and grey boxes, amino acids 
hypothesised to be part of the active site are indicated in black boxes.  
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3.3.2 Genomic localisation of the bsh gene among Enterocococus strains 
Use of the BSH probe gave good hybridisation signals when probing the genomic DNA of 
some of the strains (Fig 10).  
 
 
1     2       3      4      5      6     7      1      2     3     4    5    6     7 BA  
 
 
 
 
 
 
 
 
 
 
Fig. 10: Photograph of agarose gel with total genomic DNA from enterococci strains 
that was cut with the restriction enzymes XbaI and HindIII (a) and nylon 
membrane after Southern blotting of the agarose gels and probing with the 
BSH probe (b). Lane 1, 1 kb DNA ladder; lane 2, Enterococcus (E.) faecium 
FAIR-E 6; lane 3, E. faecium FAIR-E 14; lane 4, E. faecium FAIR-E 15; lane 
5, E. faecium FAIR-E 20; lane 6, E. faecium FAIR-E 25; lane 7, E. faecium 
FAIR-E 34 
 
When the BSH gene probe was hybridised to the genomic DNA of the negative control strains 
E. faecalis FAIR-E 29 and E. faecium FAIR-E 80, only a very weak signal could be observed 
(result not shown). This signal was noticeably weaker and could be well distinguished from 
positive signals obtained with most of the BSH positive strains (Fig. 10). The probe 
hybridised well to and positive signals were obtained with the genomic DNA of 22 
enterococci strains (Table 16). Although ten of these strains harboured plasmid DNA, the 
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probe was found to hybridise only to the total genomic DNA and not to the plasmid DNA 
isolation of these strains (Table 16).  
 
Table 16: Occurence of bsh gene among Enterococcus strains based on hybridisation 
using a BSH gene probe and the DIG-dUTP labeling and detection kit 
 
 
Plasmid Encoded bsh gene Strains 
detected not detected plasmid chromosome not both 
Enterococcus 
durans 
FAIR-E1, 
231, 261, 389 
FAIR-E326, 
332 
- FAIR-E1, 326, 
332,  
FAIR-E 231, 
261, 389 
Enteroococcus 
faecium 
FAIR-E3, 6, 
20, 24, 25, 
84, 243 
FAIR-E14, 
15, 34, 154, 
170, 171, 
217, 225, 
227, 254, 
263, 345, 
349 
- FAIR-E3, 6, 14, 
15, 20, 24, 25, 
34, 84, 154, 170, 
171, 217, 225, 
227, 243, 254, 
263, 345, 349 
- 
Enterococcus 
faecalis 
FAIR-E63, 
69, 71, 85, 
88, 229, 237, 
255, 259, 
279, 313, 
339, 342, 
351, 363, 404 
FAIR-E82, 
176, 224, 
226, 235  
- FAIR-E69, 71, 
82, 85, 176, 224, 
229, 237, 313 
FAIR-E63, 88, 
226, 235, 255, 
259, 279, 339, 
342, 351, 363, 
404 
 
 
For twelve other enterococci strains that contained plasmids, weak signals were obtained only 
when probing the total genomic DNA. These weak signals could represent hybridisation 
signals to the BSH genes, but which could not be unequivocally differentiated from the 
negative control. This may indicate that there is a certain degree of heterogeneity among the 
nucleotide sequences of BSH genes of enterococci, which did not allow the probe to bind 
equally well in all cases and result in signals of the same intensities. Nevertheless, in this 
study hybridisation signals could not be detected from plasmid DNA preparations of any of 
the strains tested. Therefore, our results indicated that the probe could in many cases 
specifically detect the bsh gene, and that this gene is probably located on the chromosome in 
enterococci strains. Such a chromosomal location of the BSH gene would be consistent with 
all previous reports on the cloning of these genes from Listeria monocytogenes, lactobacilli, 
Bifidobacterium longum and Clostridium perfringens.  
Should BSH activity be regarded as an important functional property of probiotic 
enterococci strains, the apparent chromosomal location of BSH genes would imply, that this 
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trait is likely to be stable in such BSH+ probiotic enterococci and most likely not subject to 
plasmid loss. Furthermore, this would imply that if BSH activity is considered as a 
colonisation factor which favours intestinal growth, as suggested by Moser and Savage 
(2001), it may be viewed as a possible virulence factor for enterococci strains which carry 
additional virulence determinants. Thus, it is considered as unlikely that this trait is 
transferable by conjugation from BSH+ food strains or probiotic strains which carry no 
virulence determinants, to such food strains which do harbour virulence determinants and 
which could have, as a consequence of BSH activity, been better equipped for intestinal 
survival. 
 
 
 
 
3.4 Animal Experiment 
Bacteriocin production has been described as a functional trait of probiotic bacteria, and 
probiotic strains that produce bacteriocins have found application for human consumption. To 
date, however, data on the influence of bacteriocin production by probiotic strains on the 
autochthonous flora of the host are scarce. In this study, the bacteriocin-producing E. faecalis 
BFE 1071, which has probiotic potential, was used in an animal study to determine its 
influence on the gut flora of healthy male Sprague-Dawley rats. The animal experiment 
consisted of four groups, i.e. (1) group A fed control diet; (2) group B fed control diet and 
heat inactivated, non-viable biomass of the bacterioicin producer E. faecalis BFE 1071; (3) 
group C fed control diet and viable bacteriocin-producer E. faecalis BFE 1071 and (4) group 
D fed control diet and bacteriocin-negative mutant E. faecalis BFE 1071/79(-). Bacterial 
counts done on faeces of animals of group A were done in quadruplicate before the begin of 
experimentation, at the end of the animal acclimatisation stage. Counts were done in 
quadruplicate and after this, during the duration of the experiment, faeces from animals of 
group A were not further analysed, as it was not expected that the faecal counts and 
composition of the microflora of the faeces of the control group of animals would change 
during the experiment.  
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3.4.1 Bacterial counts of faeces of rats in the animal experiment 
3.4.1.1 Total anaerobic count 
Total anaerobic cell counts from faeces of animals belonging to experiment group B, 
C and D were compared (Fig. 11). The mean anaerobic total count on day 1 from faeces of 
animals belonging to groups B, C, and D were 8.2, 8.6, and 8.6 log CFU/g, respectively.  
After day 1, there were a general increase in total anaerobic cell count of the faeces of animals 
belonging to group B, C and D. Total anaerobic cell counts of group C tended to increase until 
the last day of treatment (day 7). The difference in total anaerobic cell counts between group 
C and control group B at the different sampling times ranged from about 0.5 to 1.5 log 
CFU/g, which is explained by the influence of feeding of the bacteriocin-producing strain E. 
faecalis BFE 1071 on the total count of bacteria. 
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Fig. 11: Comparison of total anaerobic cell count from faeces of animals belonging to 
groups B (control diet and heat inactivated E. faecalis BFE 1071), C (control 
diet containing viable bacteriocin producer E. faecalis BFE 1071), and D 
(control diet containing non-bacteriocin producer E. faecalis BFE 1071/79(-). 
 
3.4.1.2 Enterococcus counts 
Counts of enterococci from experiment groups B, C and D were compared (Fig. 12). 
On day 1, faeces of animals from groups B, C, and D had enterococcal counts of 8.15, 8.11, 
and 8.5 log CFU/g, respectively. At day 1, there were a slight increase in cell count in group 
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B, C and D. The enterococci counts, however, decreased on day 2 from 0.5 to 1.0 log CFU/g.  
Cell count of group C tended to increase until the last day of treatment (day 7). The difference 
in cell count between group C and control group B was up to 1.5 log CFU/g.    
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Fig. 12: Comparison of enterococci cell counts in faeces of animals from treatment 
groups B (control diet and heat inactivated E. faecalis BFE 1071), C (control 
diet containing viable bacteriocin producer E. faecalis BFE 1071), and D 
(control diet containing non-bacteriocin producer E. faecalis BFE 1071/79(-). 
 
 
3.4.1.3  Lactobacillus counts 
Counts of lactobacilli from rat faeces belonging to experiment groups B, C and D were 
compared (Fig. 13). On day 1, groups B, C, and D had cell counts of 8.2, 8.6, and 8.6 log 
CFU/g, respectively. Cell count on the next days increased until the last day of treatment (day 
7). The difference in cell counts between group C and control group B was at a maximum of 
about 1.25 log CFU/g. At day 8 and 9 (group C and D) at which the treatment was no longer 
applied, there were decrease in cell count from ca. 0.3 log CFU/g. 
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Fig. 13: Comparison of lactobacilli cell count in rat faeces of animals groups B (control 
diet and heat inactivated E. faecalis BFE 1071), C (control diet containing 
viable bacteriocin producer E. faecalis BFE 1071), and D (control diet 
containing non-bacteriocin producer E. faecalis BFE 1071/79(-). 
 
3.4.1.4  Bifidobacterium counts 
Counts of bifidobacteria from rat faeces of experiment groups B, C and D are shown 
in Fig. 14. On day 1, the day treatment was applied, groups B, C, and D had cell counts of 8.2, 
8.9, and 8.7 log CFU/g, respectively. Bifidobacteria counts of the next days increased until the 
last day of treatment (day 7), especially in group C, showing the effect of bacteriocin-
producing E. faecalis BFE 1071 which supported the growth of bifidobacteria. The difference 
in cell count between group C and control group B ranged from 0.8 to 1.8 log CFU/g. At day 
8 and 9 (group C and D) at which the treatment was no longer applied, there were decreases in 
bifidobacterial counts from ca. 0.3 to 1.0 log CFU/g. 
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Fig. 14: Comparison of bifidobacteria cell counts in rat faeces of groups B 
(control diet and heat inactivated E. faecalis BFE 1071), C (control diet containing 
viable bacteriocin producer E. faecalis BFE 1071), and D (control diet containing non-
bacteriocin producer E. faecalis BFE 1071/79(-). 
 
3.4.1.5  Clostridium counts 
Cell counts of clostridia from rat faeces of experiment groups B, C and D were 
compared as shown in Fig. 15. On day 1, faeces from animals of groups B, C, and D had cell 
counts of 8.4, 9.4, and 9.0 log CFU/g, respectively. Cell counts of all treatment groups 
decreased during the next days until the day 5, especially in rat faeces of group C, showing 
the effect of bacteriocin-producing E. faecalis BFE 1071 which may have inhibited the 
growth of clostridia. At group C the decrease reached a maximum of 2.0 log CFU/g. At day 6 
and 7, however, the clostridial counts were shown to increase again.  
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Fig. 15: Comparison of clostridia cell count in rat faeces of animals belonging to 
treatment groups B (control diet and heat inactivated E. faecalis BFE 1071), C 
(control diet containing viable bacteriocin producer E. faecalis BFE 1071), and 
D (control diet containing non-bacteriocin producer E. faecalis BFE 1071/79(-). 
 
3.4.1.6  Eubacterium count 
Cell counts of eubacteria from rat faeces of experiment groups B, C and D were compared as 
shown in Fig. 16. On day 1 counts of eubacteria in the rat faeces of animals of group B, C, 
and D were 7.7, 8.5, and 8.5 log CFU/g, respectively. Cell counts on the next days increased 
and decreased only slightly without noticeable effect, showing that the bacteriocin-producing 
E. faecalis BFE 1071 had no or relatively very little effect on eubacteria.  
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Fig. 16: Comparison of eubacteria cell count of rat faeces belonging to animals of 
groups B (control diet and heat inactivated E. faecalis BFE 1071), C (control 
diet containing viable bacteriocin producer E. faecalis BFE 1071), and D 
(control diet containing non-bacteriocin producer E. faecalis BFE 1071/79(-). 
 
3.4.1.7  Gram-positive anaerobic cocci 
Cell counts of anaerobic cocci from rat faeces of animals from experiment groups B, C 
and D were compared as shown in Fig. 17. On day 1, the day treatment was applied, 
anaerobic cocci counts rat faeces from groups B, C, and D were 8.4, 9.2, and 8.9 log CFU/g, 
respectively. Cell counts on the next days decreased and increased again slightly in groups B 
and C until day 5. The difference in cell count between group C and control group B was 
between 0.3 to 1.6 log CFU/g.   
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Fig. 17: Comparison of Gram-positive anaerobic cocci cell count in rat faeces from 
animals belonging to groups B (control diet and heat inactivated E. faecalis 
BFE 1071), C (control diet containing viable bacteriocin producer E. faecalis 
BFE 1071), and D (control diet containing non-bacteriocin producer E. faecalis 
BFE 1071/79(-). 
 
Overall, there was no large effect of feeding the enterococci on the numbers of bacteria in the 
rat faeces. As expected, it appeared that feeding of enterococci increased the numbers of these 
bacteria in the rat faeces. This was especially obvious for the rat treatment group C in which 
rats were fed viable bacteriocin-producing E. faecalis BFE 1071 and for which there was a 
noticeable increased in enterococci counts from day 1 to day 7. Also, a slight increase in 
lactobacilli was noticed in the rat faeces of animals belonging to treatment groups C and D. 
Vahjen et al. (2002), who studied the effect of probiotic E. faecium SF 68 on the lactobacilli 
microflora in the small intestine of growing poultry poults, also noticed an increase in 
lactobacilli numbers in the intestine after administration of probiotic. They concluded that the 
enterococci lowered the pH of the gastrointestinal tract and thus stimulated lactobacilli growth 
by creating a suitable environment for lactobacilli proliferation (Vahjen et al., 2002). 
Similarly, the increase in lactobacilli numbers noted in this study may be as a stimulatory 
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effect of the bacteirocin-producing enterococci strain. However, the bacterial counts could not 
give any information on the composition of the enterococci and lactobacilli microflora; for 
this reason predominant isolates were isolated and identified using phenotypic and genotypic 
methods (see below). Administration of enterococci also led to a slight decrease in numbers of 
clostridia in faeces from animals treated with the bacteriocin-producer from day 1 of 
treatment till day 5, which may be explained by the antimicrobial activity of the bacteriocin 
produced by E. faecalis BFE 1071. However, after day 5 clostridial counts increased again, 
which may imply that clostridia became resistant to the bacteriocin. Otherwise, treatment of 
either bacteriocin-producing E. faecalis BFE 1071 or its bacteriocin-negative mutant was not 
deemed to have any effect on counts of the other bacterial groups, i.e. eubacteria, Gram-
positive anaerobic cocci and bifidobacteria. 
 
3.4.2 Phenotypical characterisation 
3.4.2.1  Enterococcus isolates 
One hundred and thirty-nine enterococci isolates from the animal experiment were 
phenotypically characterised by determining whether they possessed coccoid morphology, 
production of CO2 from glucose, ability to grow at 45 °C, and ability to grow in MRS broth 
medium containing 6.5% NaCl and in MRS broth at a pH of 9.6. The ability to ferment key 
sugars, i.e. mannitol, sorbitol, arabinose and raffinose allowed the presumptive identification 
of enterococcal species (see Fig. 3). According to these phenotypic tests the isolates from rat 
faeces were dominated by Enterococcus faecalis (121 isolates) strains could ferment mannitol 
and sorbitol but not arabinose. There were also 12 isolates which could be presumptivly 
identified as Enterococcus faecium based on their ability to utilise mannitol and arabinose. 
Some strains of E. faecium can ferment sorbitol, while others do not, therefore sorbitol 
fermentation alone is not a useful fermentation characteristic for identification of E. faecium. 
Four presumptive Enterococcus durans strains could not utilise mannitol, sorbitol, arabinose 
and raffinose. Two presumptive Lactococcus spp. or unidentifiable enterococci were isolated 
from faecal samples and characterised by their ability to ferment mannitol but not sorbitol and 
arabinose (Fig. 18). 
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Fig. 18: A dendrogram showing phenotypical comparison of enterococci strains. The 
black small boxes showed positive results for the tests as given in the box at the 
right top of the figure. 
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When every single treatment group of the animal experiment was compared with one another, 
we could see that group A isolates consisted of E. faecalis (12 strains), E. faecium (1 strain), 
and E. durans (2 strains); group B isolates consisted of E. faecalis (25 isolates), E. faecium (4 
strains), E. durans (1 strain) and Lactococcus (1 strain); group C consisted of E. faecalis (41 
isolates), E. faecium (7 strains), and E. durans (1 strain); and group D consisted of E. faecalis 
(43 isolates) and Lactococcus (1 strain).   
Groups C and D had relatively more E. faecalis isolates than group A and B. This 
could be explained by the fact that animals in these groups were fed with diet containing 
lyophilized biomass of E. faecalis BFE 1071 and its mutant. E. faecalis BFE 1071 could 
probably survive and support other E. faecalis strains. Hence, E. faecalis dominated the 
population.   
E. faecium strains were isolated much less than E. faecalis. The possibility that growth 
of autochthonous E. faecium strains was inhibited by bacteriocin-producing E. faecalis BFE 
1071 seemed to be not relevant, since only low numbers of isolates of E. faecium strains could 
be shown also on group A and B which acted as control groups.   
 
3.4.2.2  Lactobacilli isolates 
One hundred lactobacilli isolates were characterised phenotypically to determine whether they 
were rod-shaped, catalase-negative, produced or CO2 from glucose, and their ability to grow 
at the temperatures of 15, 45 and 19 °C (for presumptive L. reuteri isolates only). In addition, 
it was investigated which lactic acid enantiomer was produced. This allowed preliminary 
identification of the Lactobacillus group or species. Six isolates were presumptively identified 
as Lactobacillus reuteri, fifty isolates were presumptively identified as members of the 
Lactobacillus acidophilus group and forty-four isolates were presumptively identified as to be 
Lactobacillus murinus group. The latter group consists of L. murinus, L. salivarius and L. 
agilis (Fig. 19). 
 
Although phenotypic identification could in many cases presumptively identify the 
enterococci and lactobacilli to species level, in some cases (especially for the lactobacilli), the 
presumptive identification was only to group level, e.g., the L. acidophilus or L. murinus 
groups. Thus, for accurate identification of the isolates, and to follow the bacteriocin-producer 
isolate in the faeces of the rat, genotypic methods such as RAPD-PCR strain typing or group-
specific PCR were used . 
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Fig. 19: Dendrogram showing the phenotypical comparison of lactobacilli. Black boxes 
showed positive results for the tests: morphology (cocci or rods), growth at 
15°C or 45°C, production of gas from glucose, and enantiomer of lactate 
produced (D, L or DL). 
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 Strains that could presumptively be identified as L. reuteri or L. fermentum by phenotypic 
tests produced DL-lactate and were heterofermentative. After testing their ability to grow at 19 
°C, however, it was shown that these strains failed to grow, confirming that these strains 
could be presumptively identified as L. reuteri. Strains belonging to the L. acidophilus group 
also produced DL-lactate but in contrast to the L. reuteri strains these were homofermentative. 
Similar to L. reuteri and L. acidophilus strains, L. murinus group-strains could also grow at 45 
°C. One strain could even grow at 15 °C. These strains belonging to the L. murinus group 
produced L-lactate. The peptidoglycan type of this group was Lys-DAsp. Based on this result, 
L. agilis could be excluded from the presumptive identification of these strains, as L. agilis 
posesses meso-diaminopimelic acid in the cell wall. 
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Fig. 20: Comparison of dendrograms obtained by clustering of phenotypic properties of 
lactobacilli species from experiment  group A (control diet)  B (control diet and 
heat inactivated E. faecalis BFE 1071), C (control diet containing viable 
bacteriocin producer E. faecalis BFE 1071), and D (control diet containing 
non-bacteriocin producer E. faecalis BFE 1071/79(-) 
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 When the distribution of lactobacilli strains from the different experimental groups are 
compared, it was interesting to note that groups A and B (control groups) only consisted of L. 
acidophilus and L. murinus group strains, where strains from the L. murinus group dominated 
the population. In contrast, for group C and D treatment groups, the population were 
dominated by L. acidophilus group strains and strains belonging to the L. murinus group made 
up only a minor proportion of the population . In addition, in the groups and D treatment 
groups all of a sudden also L. reuteri strains were isolated, albeit at a low incidence and these 
made up the smallest proportion of the strains of these treatment groups (Fig. 20). When every 
single group of experiment was compared with one-another, it was evident that both groups A 
and B had relatively the same composition of lactobacilli consisting of L. acidophilus group 
and L. murinus group strains (Fig. 21). Group C had a higher proportion of presumptive L. 
reuteri strains(5 strains) than group D (1 strain). The strains belonging to the L. murinus 
group were more numerous in faeces from animals treated in group D (8 strains) than in group 
C (2 strains), while both groups C and D had almost the same number of strains belonging to 
the L. acidophilus group (5 and 8 isolates, respectively) (Fig 21). 
 
A bacteriocin test with nine indicator strains (Enterococcus faecium FAIR E 29, 
Lactobacillus sakei DSM 20017, Lactobacillus acidophilus AC2, Lactobacillus BFE 6339, 
Lactobacillus BFE 6383, Lactobacillus BFE 6379, Lactobacillus BFE 6364, Lactobacillus 
BFE 6402, and Lactobacillus BFE 6370 showed, that all lactobacilli strains isolated from rat 
faeces did not produce bacteriocin.   
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Fig. 21: Comparison of dendrograms obtained by clustering of phenotypic properties of 
lactobacilli species from experiment group A (control diet) B (control diet and 
heat inactivated E. faecalis BFE 1071), C (control diet containing viable 
bacteriocin producer E. faecalis BFE 1071), and D (control diet containing 
non-bacteriocin producer E. faecalis BFE 1071/79(-). 
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3.4.3 Genotypical characterisation 
3.4.3.1  Enterococci group 
By analysis of the RAPD-PCR fingerprints of isolates together with enterococci type 
strains, it was found that enterococci strains of rat samples consisted of Enterococcus 
casseliflavus (4 strains), Enterococcus gallinarum (7 strains), and mostly Enterococcus 
faecalis (111 strains). In addition, one cluster revealed enterococci that did not group together 
with one of the reference strains used in this study. However, not all the reference strains were 
used, and new enterococci have been described such as E. ratti, E. haemoperoxidus and E. 
moraviensis (Teixeira et al., 2001; Svec et al., 2001) which were not used in this study. Thus 
these isolates may belong to these species, or may consist of new Enterococcus species which 
have not been described so far. Although phenotypic characterisation previously indicated 12 
E. faecium species, this could not be confirmed by genotypic identification and this serves to 
illustrate that phenotypic characterisation by comparisons of sugar fermentation patterns is not 
very reliable.  
The bacteriocin-producing E. faecalis BFE 1071 could survive in the rat 
gastrointestinal tract and dominate among enterococi from the faecal flora. This was, because 
the fingerprint of the E. faecalis bacteriocin-producer and its mutants were very characteristic, 
and this fingerprint was almost identical from many of the E. faecalis isolates that were 
recovered from groups C and D and clustered together in cluster A (see Fig. 22). The E. 
faecalis BFE 1071 bacteriocin producer and its non-bacteirocin producing mutant fingerprints 
were virtually identical. All isolates from rat faeces that had a fingerprint close to the 
bacteirocin-producer or its mutant are shown in Fig. 22 and they clustered very closely at r = 
85.47 %, indicating that these are the same strain. Thus the enterococci used as probiotic in 
this study could be selectively detected among enterococci from rat faeces. 
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Fig. 22:  Dendrogram of RAPD-PCR fingerprints of enterococci from rat faeces obtained 
from animals group A (control diet), B (control diet with heat inactivated, E. 
faecalis BFE 1071), group C (control diet with viable bacteriocin-producing E. 
faecalis BFE 1071) and D (control diet with viable non-bacteriocin-producing E. 
faecalis BFE 1071/79(-). 
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 3.4.3.2 Lactobacilli group 
Comparing the RAPD PCR along with suitable type strains, it was found that 
lactobacilli strains of rat faeces consisted of Lactobacillus reuteri (5 strains), Lactobacillus 
salivarius (45 strains), while strains from the Lactobacillus acidophilus group consisted of 2 
species, i.e. Lactobacillus johnsonii (32 strains), and Lactobacillus gasseri (16 strains) (Fig. 
23). The strains were identified to species level using group-specific PCR (result not shown). 
Thus, all strains that reacted with the L. gasseri/L. johnsonii group primers and not with the L. 
acidophilus group primers (reacting with L. acidophilus, L. crispatus; L. gallinarum, L. 
amylovorus) could be identified as either L. gasseri or L. johnsonii. Grouping of the isolates 
with a reference strain in RAPD PCR fingerprinting enabled identification of the isolate to 
species level. One isolate each had RAPD-PCR fingerprints which were similar to L. cripatus 
and L. murinus, respectively, and thus could be tentatively identified as such.  
 
 Our results thus confirmed the phenotypic identification of lactobacilli isolated from 
rat faeces. This study gives new insight on the autochthonous lactobacilli flora of the rat 
gastrointestinal tract. It appears that L. salivarius strains predominate in the normal rat and 
this is followed by L. johnsonii and L. gasseri strains (Fig. 24 groups A, B). Clearly, 
administration witht he probiotic could shift the microflora contained in the rat faeces from 
one that predominantly contains L. salivarius, to one in which members of the L. acidophilus 
groups predominate (Fig. 24 groups C, D). This ‘Enterococcus effect’ particularly appeared to 
stimulate L. johnsonii, a strain which is often used as am probiotic and thus considered to be 
valuable in gut health (Holzapfel et al., 1998). 
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Fig. 23: Dendrogram of RAPD-PCR fingerprints of enterococci from rat faeces obtained 
from animals group A (control diet), B (control diet with heat inactivated, E. 
faecalis BFE 1071), group C (control diet with viable bacteriocin-producing E. 
faecalis BFE 1071) and D (control diet with viable non-bacteriocin-producing E. 
faecalis BFE 1071/79(-). 
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RAPD-PCR is one of the most popular genotypic techniques. It was developed to 
reveal intra- and interspecific differences in bacterial genomes  and can differentiate at the 
strain level (Welsh and McClelland, 1990; Williams et al., 1990). This technique has been 
used for the classification of a variety of food-borne microorganisms, including 
Saccharomyces spp. (Molnál et al., 1995), Bacillus spp. (Stephan et al., 1994), Lactococcus 
spp. (Tailliez et al., 1998), Lactobacillus spp. (Berthier and Ehrlich, 1999; Du Plessis and 
Dicks, 1995), Penicillium spp. (Dupont et al., 1999), and Streptococcus and Enterococcus 
(Moschetti et al., 1998). Spano et al. (2001) showed that use of species-specific PCR test for 
preliminary screening and then RAPD-PCR may be considered the most reliable method in 
order to perform a rapid and correct typing of Lactobacillus plantarum from wine must.  
Lactobacillus acidophilus is a natural inhabitant of mammalian gastrointestinal 
systems. This species is of considerable industrial and medical interest, because L. 
acidophilus is believed to play an important role in human health and nutrition by its 
influence on the intestinal flora (Roy et al., 2000). The L. acidophilus complex strains were 
divided into six species including L. acidophilus, L. crispatus, L. amylovorus, L. gallinarum, 
L. gasseri, and L. johnsonii and strains of L. johnsonii, L. gasseri and L. acidophilus are 
successfully being used as probiotics (Holzapfel et al., 1998). 
Our results show that feeding bacteriocin-producing enterococci shift the 
Lactobacillus flora towards the L. acidophilus group in the rat gastrointestinal tract, i.e. 
towards L. johnsonii and L. gasseri strains. However, because the same trend is observed 
between the animal treatment groups C and D, i.e., the groups that received the bacteriocin-
producing strain and the bacteriocin-negative mutant, it appears that this effect is not due to 
bacteriocin production, but rather a result of the enterococci present, whether they produce 
bacteriocin or not. Thus overall, a net ‘enterococci effect’ was observed, which shifts the 
lactobacilli flora of the rat gastrointestinal tract towards the L. acidophilus group, while no 
’bacteriocin effect’ could be noticed, apart from the fact that in the rat group D treated with 
the bacteriocin producer, the incidence of the heterofermentative L. reuteri strains increased 
slightly. Whether this ‘Enterococcus effect’ is a result of better competition of enterococci 
and suppression of the L. salivarius group, or whether it is a result of stimulation of the 
growth of the L. acidophilus group with consequent replacement of the L. salivarius group, is 
unknown.  
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4.0 GENERAL DISCUSSION AND CONCLUSION 
 
 
The lactic acid bacteria (LAB) are a group of bacteria united by a constellation of 
morphological, metabolic and physiological characteristics. Generally, LAB are described as 
Gram-positive, non-sporing, non-respiring cocci or rods, which produce lactic acid as a major 
end-product during fermentation of carbohydrates (Axelsson, 1998). LAB are generally 
considered as ‘food grade’ organisms. It is assumed that most representatives of this group do 
not pose any health risks to healthy humans. Most LAB are designated as ‘GRAS’ (generally 
recognised as safe) microorganisms in the USA based on a long history of safe use in foods. 
However, some species may act as opportunistic pathogens in rare cases (Aguire and Collins, 
1993; Gasser, 1994; Holzapfel et al., 1995).  
LAB have long been known to be involved in the production of fermented foods. 
Presently, these products constitute one-quarter of our diet and are characterised by a safe 
history, certain beneficial health effects, and an extended shelf life when compared to non-
fermented, fresh foods (Hammes and Tichaczek, 1994). 
In recent years, the consumer has been increasingly confronted with functional food 
products which are claimed to promote his /her health and well-being. At the centre of these 
food products are the so-called pro- and prebiotics (Simmering and Blaut, 2001). 
Traditionally, LAB are the basic components of probiotics as they best fit the functional and 
safety requirements by their definitions (Reuter, 1997). Today, a wide number of microbial 
species and genera also are considered to meet the requirement for probiotics. Claimed health 
benefits exerted by probiotic include prevention or alleviation of diarrhoea, antimicrobial 
activity by bacteriocin production, antimutagenic and anticarcinogenic properties, reduction 
of serum cholesterol levels, and improvement of lactose tolerance (Shah, 2000). 
Enterococci are LAB that have also been used to advantage in the food industry. 
Enterococcal strains are used for the production of certain types of cheeses in Southern 
European countries. Specific strains of enterococci are being used as probiotics for humans 
and animals. One of the best studied enterococci used as a human probiotic, especially in the 
treatment of diarrhoea, is Enterococcus faecium SF 68. The strain was originally isolated in 
Sweden and was patented in Switzerland and other countries (Lewenstein et al., 1979).  
Intestinal LAB are known to produce bacteriocins which can inhibit pathogenic 
bacteria, for example the intestinal isolates Lactobacillus acidophilus 30SC (Oh et al., 2000), 
Lactobacillus delbrueckii subsp. lactis UO004 (Boris et al., 2001), Lactobacillus salivarius 
subsp. salivarius UCC118 (Flynn et al., 2002), as well as a vaginal isolate of Lactobacillus 
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salivarius CRL 1328 (Ocana et al., 1999). L. acidophilus LF221, isolated from infant faeces 
was shown to produce at least two bacteriocins (designed as acidocin LF221 A and acidocin 
LF221 B) which exhibited activity against different bacteria including some pathogenic 
species such as Bacillus cereus, Clostridium difficile, Listeria innocua, Staphylococcus 
aureus and group D streptococci. Du Toit et al. (1998. 2000) showed that enterococci isolated 
from the faeces of Göttingen mini-pigs had bacteriocin activity against many enterococci 
species, Lactobacillus salivarius which is often associated with the human gastrointestinal 
tract, as well as Clostridium and Listeria spp. One of the enterococcal bacteriocin, produced 
by E. faecalis BFE 1071, was characterised at the chemical and genetic level in detail in a 
follow-up study (Balla et al., 2000). This bacteriocin, termed enterocin 1071A&B was shown 
to be a two-peptide bacteriocin and thus can be classified as a class IIb bacteriocin according 
to the bacteriocin classification scheme of Nes et al. (1996).  
Although a great deal of research has been dedicated to elucidate aspects of bacteriocin 
activity such as genetics of production, immunity and transport, as well as toxicological 
aspects and application of bacteriocins in foods, there are almost no data available on the 
effect of bacteriocins or bacteriocin-producing probiotic lactic acid bacteria on the hosts 
autochthonous flora. Because bacteriocin activity has been viewed as a functional 
characteristic of probiotic lactic acid bacteria, some research efforts have been dedicated to 
evaluate the effect of purified bacteriocins or bacteriocin producers on foodborne pathogens 
in vitro or in seldom cases also in vivo. However, no studies have yet addressed the question 
about the effect on the host autochthonous flora, which is surprising, considering that 
bacteriocins are active usually against closely related species and may thus interfere with the 
hosts established microflora. The hosts’ own microflora is considered to have an important 
function itself in protecting the gastrointestinal tract from invading pathogens. Such a 
potential interference with the protective activity of the hosts autochthonous flora has raised 
concerns on whether bacteriocin-production by probiotic bacteria is actually a desirable 
functional characteristic. This study was motivated to determine the influence of a potentially 
probiotic, bacteriocin-producing Enterococcus faecalis strain BFE 1071 and its bacteriocin-
negative mutant on the composition of the intestinal microflora of male Sprague-Dawley rats 
in an in vivo experimental model. To reach this objective the study aimed to: (1) investigate 
the suitability of various enterococci strains isolated from food or gastrointestinal sources for 
use as a probiotic on the basis of their technological and functional properties. To study bile 
salt hydrolase activity of enterococci, for which no information is available at the genetic 
level, using a molecular biological approach which included cloning and genetic 
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characterisation of the bile salt hydrolase gene of one of the enterococci strains. (2) to 
evaluate and compare the probiotic potential of the selected Enterococcus strains using a 
commercial Enterococcus faecium SF68 probiotic culture, and to select a bacteriocin-
producing strain and its bacteriocin-negative mutant for use in an in vivo experiment to 
determine their effects on the hosts autochthonous intestinal flora, to investigate the 
potentially probiotic enterococci strains for virulence determinants and antibiotic resistances 
in a safety evaluation, (3) to determine the effect of the bacteriocin and the effect of the 
bacteriocin producer on the intestinal microflora of the rat by recovering predominant 
gastrointestinal bacteria from the faeces on selective media, and specifically by phenotypic 
and genotypic identification of the lactobacilli and enterococci isolates  
For technological properties of potentially probiotic LAB investigated in this study, E. 
faecium strains (48.8%) and E. faecalis (46.5%) were considered to be acid resistant, 
including the bacteriocin producer E. faecalis BFE 1071 and E. faecium BFE 900. However, 
E. faecium strains were considered more resistant against bile and duodenum secrete (65%) 
than E. faecalis (5%), including the bacteriocin producer E. faecalis BFE 1071.   
The bacteriocin producer E. faecalis BFE 1071 showed a relatively wide antimicrobial 
activity spectrum against lactobacilli strains typical of the gastrointestinal tract, compared to 
other bacteriocin producers E. faecium BFE 900 and L. sakei Lb706.  
Twenty-nine E. faecalis strains (67.4%) and 25 E. faecium strains (58.1%) were found to 
posses bile salt hydrolase (BSH) activity. However, the bacteriocin producer E. faecalis BFE 
1071 as well as the sakacin A producer L. sakei Lb 706 showed no BSH activity. In contrast, 
the other bacteriocin producer used in this study,  E. faecium BFE 900, showed BSH activity.  
Most of E.faecium strains, including the acteriocin producer E. faecium BFE 900, showed 
weak hydrophobicity (60.5%). Among the E. faecalis strains, five strains exhibited moderate 
hydrophobicity, including the bacteriocin-producing E. faecalis BFE 1071. The other E. 
faecalis strains exhibited only weak hydrophobicities.  
The selected enterococci were capable of adhering to HT29-MTX cells, however at a low 
level of generally less than 30%. Bacteriocin-producing E. faecium BFE 900 had the lowest 
level of adherence (3%) whilst E. faecium FAIR-E 15 the highest (31%). The enterocin 1071- 
producing strain E. faecalis BFE 1071 also exhibited a moderate to high adherence of 17% 
when compared to the other enterococci cells. The probiotic control strain E. faecium SF68 
did not show high (<15%) adherence to HT29-MTX cells.  
Upon physiological testing for virulence of probiotic enterococci candidates (DNAse 
production, gelatinase, aggregation substance, haemolysin and mucin degradation, the 
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enterocin 1071- producing strain E. faecalis BFE 1071 showed no positive results along with 
other E. faecium probiotic candidate strains, except E. faecium FAIR-E 210 which is capable 
of degrading the mucin. These results were confirmed with PCR amplification of enterococcal 
surface protein (Esp) and adhesin to collagen from E. faecalis (Ace) of these genes, which 
showed that all probiotic enterococci candidates posses no such genes.  
Cloning of bsh genes from BSH-positive E. faecium FAIR-E 345 and DNA sequencing of 
this gene showed that the bsh gene encodes a protein of 324 with an isoelectric point of 4.877. 
Amino acid sequence deducted from bsh revealed highest homology to that of the BSH 
protein from Listeria monocytogenes, Lactobacillus (L.) plantarum (68.5% identity), while 
lower homologies to BSH proteins reported previously for L. johnsonii (52.8% identity), L. 
gasseri (49.2% identity), Clostridium perfringens (42.2% identity), Bifidobacterium longum 
(38.2% identity), and L. acidophilus (34.8% identity) (Christiaens et al., 1992; Coleman and 
Hudson, 1995; Elkins and Savage, 1998; Tanaka et al., 2000; Russell and Klaenhammer, 
2001).  Furthermore, the BSH protein from E. faecium FAIR-E 345 showed homology to the 
penicillin V acylase (PVA) of Bacillus sphaericus (32.7% identity) (Suresh et al., 1999). 
Based on hybridisation using a BSH gene probe and the DIG-dUTP labeling and detection kit, 
it was found that bsh gene of enterococci located in the chromosome. This would imply that 
this trait is likely to be stable i such BSH+ probiotic enterococci and most likely not subject to 
plasmid lost. It is considered as unlikely that this trait is transferable by conjugation from 
BSH+ food strains or probiotic strains which carry no virulence determinants, to such food 
strains which do harbour virulence determinants and which could have, as a consequence of 
BSH activity, been better equipped for intestinal survival.  
Overall, there was no large effect of feeding the enterococci on the numbers of bacteria in 
the rat feaces. As expected, it appeared that feeding of enterococci increased the numbers of 
these bacteria in the rat faeces. This was especially obvious for the rat treatment group C in 
which rats were fed viable bacteriocin producing E.faecalis BFE 1071 and for which there 
was a noticeable increase in enterococci counts from day 1 to day 7. A slight increase in 
lactobacilli was noticed belonging to treatment groups C and D, which may be as a 
stimulatory effect of the bacteriocin-producing E. faecalis BFE 1071. A slight decrease in 
numbers of clostridia treated with bacteriocin producing E.faecalis BFE 1071 strain was 
noticed from day 1 of treatment up to day 5, which may be explained by the antimicrobial 
activity of the bacteriocin produced by E.faecalis BFE 1071. However, after day 5 clostridial 
counts increased again, which may imply that clostridia became resistant to the bacteriocin. 
Otherwise, treatment of either bacteriocin producing E.faecalis BFE 1071 or its bacteriocin-
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negative mutant was not deemed to have any effect on counts of the other bacterial groups, 
i.e. eubacteria, Gram-positive anaerobic cocci and bifidobacteria. Bcaterial counts, however, 
could not give any information on the composition of the enterococci and lactobacilli 
microflora; for this reason predominant isolates were isolated and identified using phenotypic 
and genotypic methods.  
One hundred and thirty-nine enterococci isolates from the animal experiment were 
phenotypically characterised, including their ability to ferment key sugars. According to 
these, enterococci isolates were dominated by presumptive E. faecalis (121 isolates), E. 
faecium (12 strains), E. durans (3 isolates) and Lactococcus spp., or unidentifiable 
enterococci (2 isolates). Group C and D had relatively more E. faecalis isolates than group A 
and B. This could be explained by the fact that the animals in these groups were fed with diet 
containing lyophilized biomass of bacteriocin producing E.faecalis BFE 1071 and its mutant. 
E.faecalis BFE 1071 could probably survive and support other E.faecalis strains. Hence, E. 
faecalis dominated the population.  
One hundered lactobacilli isolates were characterised phenotipically. It was found that 
lactobacilli isolates consisted of presumptive L. reuteri (6 isolates), strains belonging to the L. 
acidophilus group (50 isolates) and strains belonging to the L. murinus group (44 isolates). 
The latter consisted of L. murinus, L. salivarius and L. agilis. For accurate identification of 
the isolates from the enterococci and lactobacilli groups, genotypic methods such as RAPD-
PCR strain typing or group-specific PCR were used.  
By analysis of the RAPD-PCR fingerprints of isolates together with enterococci type 
strains, it was found that enterococci strains of rat faecal samples consisted of E. gallinarum 
(4 strains), E. casseliflavus (4 strains), and E. faecalis ( 111 strains). In addition, one cluster 
(consisted of 17 strains) revealed enterococci that did not group together with one of the 
reference strains used in this study. The bacteriocin-producing E. faecalis BFE 1071 could 
survive in the rat gastrointestinal tract and dominate among enterococci from the fecal flora. 
This was because the fingerprint of the bacteriocin producing E. faecalis BFE 1071 and and 
its mutant were characteristic, and this fingerprint was almost identical from many of the E . 
faecalis isolates that were recovered from groups C and D. Lactobacilli strains of faecal 
samples consisted of L. reuteri (5 strains), L. salivarius (45 strains), L. gasseri (16 strains) and 
L. johnsonii (32 strains). One isolate each had fingerprints which were similar to L. crispatus 
and L. murinus. An ‘Enterococccus effect’ was noted for bacteria isolated from faeces of rats 
from groups B and C and this ‘Enterococcus effect’ particularly appeared to stimulate L. 
johnsonii, i.e. feeding of the enterococci probiotics led to an increase in L. johnsonii.  
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The overall objective ot this thesis has been met and all of the the aims were fulfilled. 
Bacteriocin producing E.faecalis BFE 1071 has probiotic properties and showed so far no 
virulence traits. Bacteriocin producing E.faecalis BFE 1071 could survive in the 
gastrointestinal tract of rats and showed a possible bacteriocin activity as evidenced by 
decreases in numbers of clostridia as well as an 'Enterococcus effect’, that the supports the 
growth of particular groups of bacteria (L. johnsonii and L. gasseri) in faeces. Although an 
Enterococcus probiotic was previously described to stimulate lactobacilli growth (Vahjen et 
al., 2002) it was not shown whether a shift in predominance of the Lactobacillus species takes 
place as isolates were not characterised to species level. In this study, it was shown that the 
effect of bacteriocin production on the composition of the intestinal lactobacilli flora was 
probably negligible, although a slight increase in isolation frequency of L. reuteri strains 
occurred in the faeces of group C animals. However, as mentioned above, a definite 
Enterococcus-effect was noted which did influence the composition of the lactobacilli 
microflora. This study therefore, gives new insight on the effect of a probiotic on the 
composition of the gastrointestinal microflora. Furthermore, the study supplied detail on the 
predominant bacterial groups occurring in rat faeces, and the composition of the rat lactic acid 
bacterial microflora. To date, only very limited information is available on the lactic acid 
bacteria species that predominate in this ecosystem. This study clearly showed that in the rat 
faeces L. salivarius L. reuteri, L. johnsonii and L. gasseri strains predominate, with L. 
salivarius being most ferequently isolated. For the enterococci, E. faecalis strain 
predominated, together with enterococci which in this study could not be identified and which 
may either consist of presently undescribed enterococci species, or may belong to E. ratti, E. 
moraviensis or E. haemoperoxidus. Further studies would be need to identify these strains 
further. The effects of the bacteriocin-producing probiotic noted in this study using a rat 
model probably can not be directly interpolated for the human situation, as a result of 
differences in physiology, as well as composition of the host autochthonous microflora. 
However, it support the idea also in the human environment a bacteriocin-producing probiotic 
could potentially alter the autochthonous microflora.  
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